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PRQLQgUE
This thesis concerns two investigations into the opioid 
analgesic fentanyl. The first is a clinical investigation into 
the safety and efficacy of fentanyl administered by inhalation. 
The second is a theoretical assessment of the feasibility and 
merits of applying an alternative form of pharmacokinetic model 
to the drug. The second project is linked chronologically and 
conceptually to the first in that it grew out of a general 
interest in the pharmacology of fentanyl developed during the 
first study and in that it provides a useful theoretical 
framework for considering the comparative pharmacokinetics of 
drug delivered intravenously and drug delivered for absorbtion 
from other sites.
The thesis is in two related but essentially self-contained 
parts preceded by a brief review of fentanyl pharmacology.
v
CHAPTER 1
Introduction: Relevant Fentanyl Pharmacology
chapter 1
Fentanyl (figure 1.1) is a potent synthetic opioid which was 
introduced into clinical practice in the early I960's. It is the 
chemical congener of the reversed ester of pethidine, and is the 
prototype of the 4 -anilinopiperidine series of narcotic 
analgesics which include alfentanil, sufentanil, lofentanil and 
carfentanil. Until recently it has mainly been used by 
intravenous administration either as an adjuvant or main agent 
during anaesthesia where it has advantages of extreme 
antinociceptive potency (probably through agonist action at the 
mu opioid receptor), relative lack of cardiovascular side 
effects compared to older opioids and of not causing histamine 
release [35, 37]. These properties in addition to its high lipid 
solubility, which should enable it to equilibrate quickly across 
biological membranes, and lack of local tissue toxicity
suggested to us that it might be a suitable drug for 
administration by nasal or pulmonary deposition. Other current, 
though not yet common, uses for the drug include the provision 
of post-operative pain relief by intravenous administration from 
patient controlled analgesia machines or by percutaneous 
absorption from specially prepared skin patches and the
production of profound analgesia by administration into the 
subarachnoid and epidural spaces.
This chapter presents some relevant aspects of fentanyl 
pharmacology.
The pharmacology of fentanyl has been reviewed by Mather 
(pharmacokinetics only) [1], Bovill (pharmacodynamics only)
[37], Andrews and Prys-Roberts [35] and Hug [36].
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Figure 1. 1
CH2-CH2-N
n- c- ch2- ch3
M.W. : 336.60
Fentanyl: N - (1-phenethyl-4-piperidyl) propionanilide
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PHARMACOKINETICS 
Oral Absorption
The bioavailability of oral Fentanyl is about one third that of 
intravenous Fentanyl reflecting its relatively high hepatic 
clearance [2],
Distribution in the Blood 
This is discussed in more detail in chapter 13. At pH 7.4 
fentanyl is about 80% bound to plasma proteins and this 
proportion is unaffected by plasma fentanyl concentrations 
within the clinical range [34, 155]. The blood : plasma
concentration ratio is approximately 1 and is independent of pH 
and haematocrit [34, 157, 158]. Protein binding is decreased and 
comparative partitioning into red cells increased at low plasma 
protein concentrations [21, 34, 155, 158].
Distribution in the Body 
Fentanyl is extremely lipid soluble, although there is 
considerable disagreement as to the exact value of standard 
solubility coefficients (see table 13.2 for comparison with 
morphine and methadone) . On account of its high lipid 
solubility it equilibrates rapidly across biological membranes 
and across the blood brain barrier [26] and has a large volume 
of distribution (table 13.3) reflecting the relatively large 
mass of drug taken up by the tissues. More than 90% of an 
intravenous dose is lost from the blood within 2 minutes [38, 
180] .
The distribution of fentanyl in the body at any time will 
reflect both the relative blood flow to the various organs and
4
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the avidity with which they take up fentanyl. There are no 
detailed studies in man. Matejczyk [43] reports fentanyl 
concentrations in liver and kidney tissue were 2.4 and 2.1 times 
the plasma concentration respectively at postmortem examination 
of a corpse following a fatal fentanyl overdose. The 
distribution of fentanyl to tissues and organs has been 
examined in rats and rabbits.
In the rabbit Hess and his colleagues [23] describe three groups 
of tissues. In the "central" group of tissues, containing lung, 
heart, brain, kidney and spleen, the maximum concentration of 
fentanyl occurred within half a minute of intravenous injection 
and then declined in parallel with the plasma concentration. In 
the second group; skeletal muscle, intestinal wall and liver, 
the maximum concentration of fentanyl occurred five minutes 
after injection. Finally,in fat the maximum concentration of 
fentanyl occurred half an hour after an intravenous bolus. (See 
figure 15.10). All tissue concentrations were greater than the 
plasma concentration after the first few minutes. The highest 
concentration of fentanyl at any time was in the lungs (100 
times plasma concentration during the first h o u r ) . Brain 
concentration was approximately ten times plasma concentration. 
In the rat Hug and Murphy [33] found a slightly different 
relative distribution although maximum drug concentrations 
occurred in the three tissue groups at the same times as the 
rabbit. Concentration maxima in kidney and liver occurred at 5 
and 15 minutes respectively but this was ascribed to the 
artifactual measurement of metabolites as unchanged fentanyl and 
both organs should probably be grouped with the "central" group 
of tissues along with lung etc. Initially the highest
chapter 1
concentration was in lung but after the first 30 minutes or so 
the highest concentration was to be found in fat. Concentration 
in brain was 2 to 3 times plasma concentration, lung 10 times 
plasma concentration and fat 35 times plasma concentration.
Lung Sequestration 
Of particular relevance to the present investigation is the 
observation that most of an intravenous injection of fentanyl is 
sequestered in the lungs after the first pulmonary pass. This 
fentanyl diffuses back into the circulation over the next few 
minutes (There is no evidence for any significant pulmonary 
metabolism of fentanyl). The phenomenon has been investigated in 
rabbits [23] and man [24, 25]. Roerig suggests that the
mechanism of uptake by the lung is likely to be diffusion into 
non specific sites. The phenomenon will increase the 
concentration differences between arterial and mixed venous 
blood in the first few minutes after fentanyl injection and also 
smooth out the sharp high peak that would otherwise occur in the 
concentration of fentanyl in blood entering the brain 
immediately after intravenous injection. The subject is 
discussed at greater length in chapter 15.
Pharmacokinetic Constants 
There are several published pharmacokinetic studies of 
intravenously administered fentanyl in healthy volunteers and in 
assorted patients undergoing surgery and anaesthesia. Most 
investigators have described the kinetics in terms of standard 
two or three compartment models. Experimental values of the 
pharmacokinetic constants for fentanyl are given in table 13.3. 
There is considerable inconsistency between the values reported
6
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in different studies. The reasons for this are not clear. 
Similar studies on newer derivatives such as alfentanil have 
apparently [1] produced much more consistent results which 
suggests a particular problem with fentanyl rather than a 
general problem with study design. Mather [1] has suggested that 
the difficulty may be caused by inaccuracies or lack of 
specificity in fentanyl analysis at the low concentrations 
involved but this seems unlikely to be the sole cause. The 
subject is discussed further in relation to plasma clearance in 
chapter 13.
When fentanyl was first used clinically it was thought to have a 
short duration of action and this is indeed the case with single 
small (up to say 300 pg per adult man) doses of fentanyl. 
However when tissue distribution (see above) and pharmacokinetic 
studies became available it was clear that the initial fall in 
plasma concentration and consequent termination of 
pharmacological effect was due to redistribution of drug to the 
tissues. When fentanyl is administered by large dose, repeated 
doses or continuously, the plasma concentration may still be in 
the effective range after redistribution and further decrease is 
dependent on the slower process of metabolic clearance. This 
pharmacokinetic profile makes intuitively judging the 
consequences of a given dose regimen difficult and unfortunately 
the lack of agreement on the values of standard pharmacokinetic 
parameters diminishes the predictive power of pharmacokinetic 
models. Reilly and colleagues [20] say in this context "The best 
that pharmacokinetics can do ...is to say that following a 500 
pg bolus the patient's plasma fentanyl concentration will fall 
below analgesic concentrations somewhere between 13 minutes and
7
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6 hours later."
Secondary Peaks
After the administration of a large dose of fentanyl, during the 
period of falling plasma concentrations, the plasma 
concentration may spontaneously rise again before continuing to 
fall [16, 21, 27]. The cause of this fluctuation is not known. 
Release of fentanyl from muscle, stomach or lungs have been 
suggested as possible causes. These secondary rises can be 
associated with respiratory depression appropriate to the higher 
concentrations of fentanyl [16].
Clearance and Elimination 
Clearance is mainly by metabolism in the liver to hydrophilic 
metabolites which are excreted by the kidney. Small amounts of 
fentanyl are excreted unchanged in the urine.
Man: McClain and Hug [21] used tritiated fentanyl to study
fentanyl kinetics in normal male volunteers. They recovered 
6.4% of the total dose unchanged in the urine over 72 h and a 
further 70% of the dose in the urine as metabolites. 1.2% of the 
total dose was excreted unchanged in the faeces with a further 
8% present as metabolites (total recovery 85%).
There are few other studies which specifically examine the 
urinary excretion of fentanyl. In five patients with severe 
cardiovascular disease undergoing cardiac surgery on by-pass 
Bovill and Sebel [38] found only 2.1% of a large dose of 
fentanyl administered at the start of the anaesthetic was 
excreted unchanged in the urine by 24 hours. Fentanyl excretion 
increased and decreased with the rate of urine production. Large 
volumes of urine were produced by these patients but kidney
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function may well have been abnormal as a result of the invasive 
procedures. Schleimer and his colleagues [179] found about 17% 
of a fentanyl dose excreted unchanged in the urine of three non­
cardiac surgical patients by 50 h. However they used an early
fentanyl radioimmunoassay (see p 163) which might well have had
cross sensitivity to metabolites. Hess and colleagues [40] 
estimated unchanged fentanyl as a proportion of unchanged 
fentanyl plus metabolites in samples of urine from three 
subjects at various times after an intravenous dose (all samples 
less than 10% unchanged fentanyl in two subjects, 12 to 25% in 
the third) but they made no cumulative measurements. Corall and 
colleagues [39] studied plasma fentanyl concentrations in ten 
patients with end stage renal disease. Plasma levels of fentanyl 
decreased faster in the renal patients than normal controls in 
the first 4 h after an intravenous bolus dose suggesting that 
renal function is not necessary for clearance. There are no 
studies which examine the effect of urine pH on urinary fentanyl 
excretion.
Animals; In the dog Murphy and colleagues [22] using tritiated 
fentanyl, found 4% of an intravenous dose unchanged in the urine 
after 6 h compared with 32% as metabolites. The clearance of
fentanyl in hepatectomised dogs was markedly reduced [41] but
small amounts of metabolites were still excreted in the urine 
suggesting an extrahepatic site for biotransformation.
In the rabbit [23] the appearance of metabolites in the plasma 
within minutes after injection is prevented by evisceration 
(functional hepatectomy).
Bullinghara and colleagues [42] studied fentanyl clearance 
directly in the chronically cannulated cow and found the hepatic
9
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extraction ratio to be 1 (i.e. clearance equal to liver blood
flow) at fentanyl concentrations in portal vein plasma above 
about 7 ng ml'1 although oddly it decreased with concentration 
at concentrations less than this.
PHARMACODYNAMICS
Anti-Nociception
The distinction sometimes drawn between analgesic and 
anaesthetic effects of opioids is rather arbitrary and vague 
depending on the context of the study and the parameters chosen 
for measurement as much as the underlying phenomena. The 
concepts of analgesia and anaesthesia themselves are difficult 
to define in objective physiological terms. Strictly, analgesia 
might refer to a diminution of pain in the absence of other 
cognitive effects. There are difficulties with this however when 
the complexities of pain perception and the relations of 
associated phenomena such as autonomic or hormonal responses are 
considered. In practice opioids, including fentanyl, manifest a 
range of effects from , at low doses, euphoria, perceptual 
detachment, and diminished pain awareness in conscious patients 
to, at high doses, a profound "anaesthetic" unresponsiveness and 
amnesia. The terra analgesia is used below with its everyday 
meaning of pain reduction in a conscious patient.
Studies During Anaesthesia: Fentanyl is widely used during
anaesthesia, usually with other drugs but sometimes alone. Doses
- 1 1vary from under 1 pg kg to over 150 pg kg . However, despite
many studies, there is not enough information available to draw
a clear pharmacodynamic picture. One problem in interpreting the
10
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data is the fact that plasma concentrations are often rapidly 
changing during the investigations. Thus plasma concentrations 
do not have time to equilibrate with concentrations at receptor 
sites in the central nervous system. Scott and colleagues [31] 
suggested a mean half-time of 6.4 minutes for equilibration 
between plasma and an effect compartment when effect was 
measured by_ EEG changes. There are no systematic studies where 
plasma concentrations .have been held steady above about 
30 ng ml"1.
Another problem is the difficulty, worsened by the poorly 
characterised pharmacokinetics, of devising dosage regimens which 
will produce a given plasma concentration. There is a wide 
scatter of plasma fentanyl concentrations within each dose group 
in most studies. This compounds a situation in which 
stimulation is variable and unquantifiable, subjects have 
usually received several drugs and there may be other 
physiological perturbations such as those introduced by 
cardiopulmonary by-pass. Drug effects and study events are 
sometimes poorly defined in physiological terms.
Despite this, there is evidence for various effects occurring in 
a concentration-related manner over a range of plasma fentanyl 
concentrations from about 5 ng ml-1 to over 20 ng ml"1. Thus, 
"awakening" after anaesthesia is reported at mean concentrations 
of 6.4 ng ml"1 [6] and 8.6 ng ml"1 [32]. (In another study [3] 
onset of unconsciousness occurred at a mean concentration of 34 
ng ml"1 but plasma concentration had been rising rapidly at this 
time). Several investigations are consistent with better 
cardiovascular stability during surgery (i.e. with better 
"anaesthesia") as plasma fentanyl concentrations rise from below
11
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10 ng m l -1 to over 20 ng m l ”1 [e.g. 4, 28, 29 ]. Hug and
Moldenhauer [5] reported eye opening and movement during surgery
in all of their 18 patients whose plasma fentanyl concentrations
- 1fell below 10 ng ml A during coronary artery by-pass surgery,
- 1whereas concentrations above 17ng ml A suppressed responsiveness 
in all patients.
It is not clear whether the antinociceptive or cognitive effects 
of fentanyl increase at plasma concentrations much above 20 
ng ml”1 or whether indeed there is a concentration which will 
completely prevent the effects of noxious stimulation in all 
patients. Cardiovascular responses to skin incision and 
tracheal intubation are seen in some patients at plasma
_ i
concentrations of over 30 ng ml A [4, 28]. There is evidence in 
dogs that fentanyl receptors become saturated at plasma 
concentrations of about 30 ng ml”1 [7, 8]. It is tempting to
speculate that a similar thing happens in man but there is no 
clear evidence for this.
Analgesia: Difficulties of establishing an "analgesic blood 
concentration" of fentanyl or any other drug in a clinical 
setting include the variability of the pain stimulus, the 
variability of the pain response to that stimulus and the 
virtual impossibility of measuring either. Nevertheless attempts 
have been made to relate plasma concentrations of fentanyl to 
the extent of post-operative pain relief.
One approach is give the fentanyl according to fixed dosage 
regimens and to estimate the analgesia obtained either from 
additional opiate requirement or by subjective scoring systems 
or both [9, 10, 11]. Fairly constant plasma fentanyl
concentrations of between 1 and 3 ng ml”1 were associated with a
12
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reduction in expected morphine requirements in the first 24 
hours following major orthopaedic, upper abdominal, prolonged or 
cardiac surgery (45 patients) [10]. Similarly, a mean 
concentration of 1.79 ng ml-1 (s.d. 0.67) in 8 post hysterectomy 
patients was associated with a diminished requirement for 
morphine and lower subjective pain ratings than a control group. 
A lower dose giving a mean fentanyl concentration of 0.56 ng ml" 
1 (s.d. 0.25) had a lesser but still demonstrable effect [11].
A second, perhaps more elegant, approach is to measure the 
concentrations obtained when the subject uses an intravenous 
patient controlled analgesia system. These allow, within certain 
preset limits, each patient to self-administer a small 
intravenous bolus of drug whenever they wish, thereby 
continually adjusting drug effect to the required level [12, 13, 
14). The limitations of this approach reflect the intrinsic 
limitations of the patient controlled analgesia systems. Thus, 
for instance, some changes in pain stimulus intensity, as during 
coughing or movement, may be too rapid to follow, or the end 
point of drug titration may represent a balance between 
analgesia and unwanted effects such as nausea, dysphoria or 
sleepiness. Minimal analgesic concentrations (the plasma 
concentration at the time the subject feels it necessary to 
command another bolus) have been reported as: median 1.2 ng ml"1 
(range 0.2 to 8 ng ml"1 ) [13], range 0.44 to 3.44ng ml"1 [14]) 
and mean 0.63ng ml”1 (range 0.23 to 1.18ng ml"1) [12]. There is
considerable variation between these values in different 
patients but much less variation between the values obtained at 
different times in any one patient.
In a variation of this approach, Cartwright and his colleagues
13
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[15] titrated intravenous fentanyl into patients immediately 
they had woken from a fentanyl and nitrous oxide anaesthetic. 
Mean plasma concentrations from 2.3ng ml"* to 3.2ng ml"* were 
obtained for four small groups of patients but a description of 
the precise endpoint used to determine satisfactory analgesia 
was not given.
Respiratory Depression:
The ventilatory depressant effect of fentanyl is related to the 
plasma concentration [15, 16, 17, 18]. Slight respiratory
depression, demonstrable by changes in the ventilation-carbon 
dioxide response curve, occurs in volunteers at plasma 
concentrations below 1 ng m l " 1 [16], well within the range 
required for post-operative analgesia. A 50% decrease in the 
slope of the carbon dioxide response curve has been reported at 
plasma concentrations of 4.6 ng ml"1 in volunteers [17] and
_ i
between 2.0 and 3.1 ng ml in post operative patients [15]. 
Arterial carbon dioxide tension and minute ventilation can be 
expected to remain normal until the gradient of the carbon 
dioxide response curve has decreased by more than 50% [9, 15].
The presence of additional drugs may decrease respiratory drive 
still further as may other factors such as previous 
hyperventilation during anaesthesia [15]. The phenomenon of 
recurrent respiratory depression following apparent recovery 
from the effects of a single bolus of fentanyl may be associated 
with an increase in plasma concentrations of fentanyl occurring 
at the time [16].
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PART 1 
FENTANYL BY INHALATION
CHAPTER 2
Rationale and Aims
chapter 2
The body may be regarded as an organised mass of tissues bounded 
by various surfaces, including the invaginated or "internal" 
surfaces such as the alveolar membranes or intestinal mucosa. 
With the exceptions of injection and implantation all drug 
access to the body must take place by absorption across these 
surfaces, usually by concentration-driven passive diffusion. 
Problems of drug administration concern the relationship between 
the drug (lipid solubility, concentration etc.) and the local 
environment (pH, mucous barrier, epithelial type, blood supply, 
local metabolism etc.) Drug must be delivered to the absorptive 
surface and remain in contact with it long enough for the 
required absorption to take place.
Historically means of getting drugs into the body have grown 
from tradition and usage. Cultural and psychological ties have 
often bound a particular drug preparation to a method of 
delivery as strongly as considerations of efficacy. However, 
with the rise of modern pharmacology a more rational approach to 
the manipulation of drug administration has emerged.
Alongside interest in improved methods of drug delivery through 
the gut mucosa such as slow release preparations, pro-drugs etc. 
and the utilisation of the skin as a route of absorption for 
systemic drugs, there is growing interest in the respiratory 
tract, although of course the idea of using this region for drug 
delivery is not new. There are several considerations favourable 
to the idea of drug administration by this route. The local 
environment in the respiratory tract is biochemically less 
hostile towards drugs than that in the gut. Confounding factors 
such as the presence of food or drink and variations in gut 
motility are avoided. There is no first pass liver metabolism.
17
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The blood supply to the lower respiratory tract comprises the 
whole cardiac output and is separated from the vast external 
surface by a fine barrier in an anatomical arrangement 
specialised for the transfer of small molecules. The mucosa of 
the upper respiratory tract (mouth, nose and pharynx) has a rich 
and reliable blood supply from the systemic circulation. 
Together these points suggest the possibility of rapid and 
predictable entry of drugs.
The upper membranes of the respiratory tract, those of the nose, 
mouth and pharynx, are readily accessible but have a relatively 
small area and it may be difficult to maintain drug in contact 
with the mucosa to provide a gradient for absorption, especially 
in the mouth. Several modern and traditional drug preparations 
are designed for absorption via the buccal or nasal routes. The 
popularity of the nasal route is growing rapidly [122]. Drugs 
targeted on the respiratory epithelium will also be partly 
deposited on and absorbed from the upper respiratory tract 
because of imperfections in present delivery techniques.
One of the main difficulties in using the epithelium of the 
lower respiratory tract is delivery of drug to the terminal 
airways. This is easiest for volatile substances and gas es. The 
method of quantifiable, controlled administration of sytemically 
active gas es and vapours has been highly refined in the 
practice of modern anaesthesia. Delivery is more difficult for 
non volatile drugs. The traditional answer has been to heat or 
burn them and breath the resultant smoke as in the smoking of 
tobacco, opium or cannabis. This method has been ignored by 
mainstream medicine in modern times, although it has been 
applied by social drug users to highly refined pharmacological
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products such as cocaine base and diacetyl morphine. The drug 
smoke contains an aerosol of the active ingredients and the 
pharmacokinetic effects of its inhalation may resemble 
intravenous injection [120, 123]. A second method is mechanical 
aerosolisation, usually of a drug-containing solution but 
sometimes of a dry powder. This technique was originally 
developed for the local application of respiratory drugs but has 
recently been applied as a means of systemic administration 
[e.g. 121].
The Present Investigation 
Intravenous administration remains the "gold standard” for the 
systemic administration of opioid analgesic drugs in that there 
is 100% bioavailability of the administered dose and almost 
instant control over the direction in which plasma 
concentrations are changing. Many patients dislike injections 
but the main practical disadvantage is the expertise which is 
required either for each separate administration or for the 
insertion of an indwelling cannula. Patient controlled analgesia 
devices allow patients to administer their own intravenous 
analgesia. These are becoming more portable but must 
nevertheless be linked to the patient by an indwelling 
intravenous catheter.
The respiratory route may possibly permit some of these 
problems to be overcome in that respiratory administration might 
approximate the pharmacokinetic advantages of intravenous 
administration while being potentially pleasant and having no 
requirement for technical expertise or for an invasive physical 
connection to the patient. A patient controlled analgesia device 
based on an inhaler for example would not have to accompany a
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post-operative patient to the bathroom or could be carried in a 
handbag to allow a mobile patient with cancer pain instant 
analgesia for breakthrough pain.
There has been recent interest in the absorption of opioids from 
the upper respiratory tract [e.g. 107, 108] but very few studies 
on the clinical administration of opioid analgesic drugs by 
absorption from the lungs: Chrubashick and colleagues [121, 124] 
have investigated the effects and bioavailability of inhaled 
nebulised morphine.
We wanted to further investigate the use of the pulmonary route 
for the clinical administration of opioid analgesics.
As outlined in chapter ^ we chose fentanyl as it is very potent 
(and therefore needs only a small mass of drug to be delivered), 
it is rapidly acting in that there is only a small lag between 
the time course between changes in plasma concentration and 
effect (compared with morphine for example), it does not cause 
histamine release, there is no evidence it causes local tissue 
irritation and it is relatively free of cardiovascular side 
effects. Nebulisation of an aqueous solution was chosen as the 
method of delivery as it is at present the only available method 
of targeting the respiratory epithelium in a clinical setting. 
The work described in part one of this thesis thus concerns an 
investigation into the safety and efficacy of inhaled nebulised 
fentanyl solution.' The following two chapter review some 
theoretical aspects of aerosol formation and deposition and of 
pain measurement. The remainder is a report of the clinical 
study.
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Aspects of Nebulisation and Aerosol Deposition
chapter 3
Therapeutics aerosols are primarily used to deliver drug to the 
respiratory tract. They are the only practical means of 
delivering some drugs to the distal airways but also provide an 
effective and convenient means of distributing drug over the 
surface of the upper respiratory tract, particularly the nasal 
membranes. The physical characteristics of the aerosol in 
combination with structure and physiology of the respiratory 
tract will determine where the drug is deposited. This chapter 
comprises a review of aspects of aerosol characterisation, 
formation by nebulisation of solutions and deposition, with a 
particular emphasis on the functioning of jet nebulisers.
CHARACTERISATION AND DEPOSITION OF AEROSOLS
Definition:
An aerosol is an airborne dispersion of particles.
Characterisation
The following account has been taken largely from the reviews by 
Brain and Valberg [59], Morrow [66] and Lipmann [62].
One convenient way to characterise an aerosol is by the 
frequency distribution of the aerodynamic diameters of its 
particles. The aerodynamic diameter is the diameter of a unit 
density sphere having the same settling velocity as the particle 
in question. It is a device to allow easy description of the 
behaviour of particles of different shapes. Many therapeutic 
aerosols are made up of spherical liquid droplets so the actual 
diameters of their particles bear a simple relationship to the 
aerodynamic diameters. Other variables such as mass can be 
described in terms of aerodynamic diameter. For instance, the 
mass median aerodynamic diameter is that aerodynamic diameter
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for which half the mass of the aerosol lies in smaller 
particles.
Depending on the variation of particle size and shape, aerosols 
may be described as monodisperse or heterodisperse. Strictly 
speaking the particles of a monodisperse aerosol should all be 
of the same size and shape but in fact the difference is one of 
degree and monodisperse aerosols are defined to arbitrary 
tolerance [e.g. 61].
Aerosols of biological interest, including therapeutic aerosols 
are almost always heterodisperse and often show a log-normal 
distribution of their aerodynamic diameters. That is a plot of 
the number of particles of given size interval versus the 
logarithm of size is a bell-shaped normal distribution curve. A 
given example of such a distribution can be described by two 
numbers, the count median diameter and the geometric standard 
deviation (which corresponds to the standard deviation of a 
normal distribution) .
Other properties, such as mass, which are a function of particle 
aerodynamic diameter will also be log normally distributed and 
will have the same geometric standard deviation. The median 
diameters for these variables will be related to the count 
median diameter in a predictable way for example:
(3.1) ln(MMD) = ln(CMD) + 3(lnGSD)2
where MMD is the mass median diameter, CMD is the count median 
diameter, In is the natural logarithm and GSD is the geometric 
standard deviation. (Notice the mass median diameter is larger 
than the count median diameter).
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Deposition
There is a large body of work, experimental and theoretical, on 
the deposition of inhaled aerosols [see 59, 62, 66, 122].
Particles are deposited when their motion brings them into 
contact with a surface. Any forces on a particle which give it a 
velocity relative to the gas stream in which it is suspended may 
do this. Brain and Valberg [59] describe four effects of 
importance in respiratory deposition: inertial impaction which
occurs when there is a sudden change in direction or speed of 
the gas stream , sedimentation owing to gravity, diffusion or 
Brownian motion, and electrical attraction. In addition 
particles with the same velocity as the surrounding gas stream 
may be deposited should it happen that this gas becomes adjacent 
to a surface (interception) . This last effect is small in the
of any surface is small (140 ml) compared with the total lung 
volume (5 1). The role of electrical attraction may be to cause 
deposition of particles that are brought very close to a 
surface.
The main factor determining whether and where particles will be 
deposited is aerodynamic diameter. Because of differences in 
airflow in its different parts the respiratory system acts as a 
filter with larger particles being deposited more proximally.
In the nasopharynx airflow velocities are high, there are 
frequent changes of airstream direction and larger particles are 
deposited by inertial impaction. Small particles are less 
susceptible to inertial impaction. In the distal airways flow 
velocities are progressively smaller and deposition occurs 
because of sedimentation or for very small particles diffusion.
lungs since the volume of gas within a small
24
chapter 3
Most particles bigger than 5 ji/are deposited in the nasopharynx. (_/ 
Particles of less than 0.1 j^are mainly deposited in the ^ 
terminal airways and alveoli. About half the deposition of 
particles around 1 to 2 n/occurs in the respiratory bronchi and ^ 
alveoli. Total deposition of particles (i.e. the ratio particles 
deposited:particles inhaled) is almost 100% for particles larger 
than 10 p^ reaches a minimum of 20 to 40 % for particles of 0.5  ^
p|^and increases markedly for particles less than 0.1 p^ / The 
minimum occurs because particles with an aerodynamic diameter of 
around 0.5 p^are too small to be greatly affected by inertial /. 
impaction and sedimentation but too large for Brownian motion to 
be important.
Breathing pattern has a marked effect on deposition [see 59] and 
accounts for an important amount of inter-subject variation. 
Mouth breathing increases the penetration of larger particles 
distally. Deposition of 3 ^ p a r t i c l e s  in the alveoli and 
respiratory bronchioles may reach 50% of the inhaled load during 
quiet mouthbreathing [62).
Much of the basic work on the deposition of aerosols in the 
human respiratory tract has been carried out using non- 
hygroscopic aerosols in relation to toxicity studies and the 
methods and results extended to cover therapeutic aerosols. Non- 
hygroscopic aerosols are easier to work with than hygroscopic 
aerosols as once produced the particles do not normally change 
size. Therapeutic aerosols however, being aqueous solutions or 
water soluble solids, are hygroscopic and the particles will 
change size by the absorption or evaporation of water depending 
on the relative humidity [60, 66]. This means that, in addition 
to the initial aerodynamic diameter, the osmotic composition of
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the particles will affect the pattern of deposition since it is 
a major determinant of how particles change size in the 
respiratory tract. Despite work addressing these problems [e.g. 
63, 66, 111], there are still difficulties in describing how a 
given aerosol will behave, for instance, the exact relative 
humidities of the different regions of the respiratory tract are 
not known [66]. The size profile of a hygroscopic aerosol will 
change between generation and inhalation making specification 
difficult. There is a relative lack of the kind of careful 
quantitative experimental studies that have been performed with 
nonhygroscopic aerosols. The general principles of aerosol 
deposition still apply however and other things being equal 
smaller particles will be deposited more distally in the 
respiratory tract [e.g. 64].
NEBULISERS
Definitions
A nebuliser is a device for converting a liquid into an aerosol. 
There are two types of nebuliser in clinical use, ultrasonic 
nebulisers, and jet nebulisers.
Strictly speaking, metered-dose inhalers are also nebulisers 
(although they sometimes aerosolise a dry powder) but in every 
day usage they are usually called "inhalers”.
Another term occasionally encountered is "atomiser". An atomiser 
is a simple spray device distinguished from a nebuliser by the 
large size (>10 p) of the particles it produces.
Small plastic disposable jet nebulisers are the most commonly 
used nebulisers in the United Kingdom and are freely available 
in most hospitals. Jet nebulisers are discussed in detail below.
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Ultrasonic nebulisers are less commonly used, mainly because of 
the difficulties they pose with regard to cleaning and 
sterilisation. The mechanism of aerosol production and the 
factors governing output differ from those operating in jet 
nebulisers. For the purposes of the present study ultrasound 
nebulisers do not offer any clear advantages in terms of aerosol 
output or character that would justify overcoming the practical 
difficulties associated with their use [49, 52] and they will
not be discussed further.
Jet Nebulisers
Jet nebulisers employ the Bernoulli effect whereby a flow of 
gas through a nozzle creates a region of subatraospheric 
pressure. This causes liquid to flow along a capillary tube 
from a reservoir into the gas stream. Shearing forces at the 
interface between the gas and the liquid break the liquid into 
droplets. The turbulence of the gas flow disperses the droplets 
throughout the gas stream. A small amount of energy is required 
for the processes of deforming the liquid and forming new 
surface, (overcoming surface tension and viscous forces). A 
larger amount is required to accelerate the particles to the 
velocity of the gas. Energy is supplied from the kinetic energy 
of the gas. The diameter of a droplet of average mass in such an 
aerosol is proportional to
Dl .(2T/(Pa. V 2 . Dl ))4 *5
where DL is the diameter of the liquid flow tube, V is the 
relative velocity of the gas and the liquid, T is the liquid 
surface tension, Pa is the density of the gas [54].
Droplet size decreases as the gas velocity increases up to sonic
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velocity where the Venturi effect fails. Droplet size increases 
with increasing viscosity or surface tension.
The main resistance to gas flow through the nebuliser occurs at 
the gas nozzle so the diameter of the nozzle largely determines 
the pressure difference that must be applied across the 
nebuliser to produce a given gas flow through it. For a given 
gas flow the smaller the nozzle the greater the velocity of the 
gas flow through it and the smaller the droplet size [53, 55]. 
This process produces an aerosol with droplets of relatively 
large average size compared to that of the final aerosol emitted 
from the nebuliser, however a baffle (see figure 3.1) is sited 
in the gas stream close to the nozzle, and larger droplets (most 
of the primary aerosol) deposit on this because of inertial 
impaction, coagulate and run back into the reservoir. Smaller 
droplets are carried out of the nebuliser without impacting. 
Nebulisers are usually made of glass or plastic and may be 
sterilisable or disposable. Some models have an adjustable vent 
drawing in room air by venturi effect to dilute the aerosol 
output. In practice aerosol production by jet nebulisers is 
affected by the following:
Make: The design of the nozzle, baffle, capillary tube and 
outflow path are important in determining the amount and size 
distribution of the output. There are differences between models 
[44, 46, 49] and between examples of the same model [49]
Filling Volume: A typical disposable nebuliser reservoir
capacity is 10 ml, however, during nebulisation, when the volume 
of liquid falls to a certain low amount, which varies with the 
model but may be 2 ml or more, the reservoir end of the
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Figure 3.1 
Stylised Diagram of a Jet Nebuliser
exit p o r t -  -
baffle
•gas nozzle
fluid feed _ _ _
capillary tube
drug solution 
reservoi r
driving gas
In many common models, including the Lifecare Micro-Neb, the 
driving gas tube and fluid feed tube are concentric.
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capillary tube is no longer continuously submerged but 
alternately exposed and submerged as large coagulated droplets 
from the baffle and inner surfaces run back into the bottom of 
the reservoir. The tube thus intermittently entrains gas rather 
than liquid and nebulisation becomes increasingly sporadic as 
time goes on. With some models the onset of this effect may 
occur at a higher residual volume if the nebuliser is not 
completely vertical. The efficiency of nebulisation during this 
stage may be improved by agitating or tapping the device in 
order to hasten the run back of drops to the reservoir [45], 
Nebulisation of a given dose of drug is ended arbitrarily at a 
point when the process has become too inefficient to be worth 
continuing [44, 45]. At this point there will still be some
liquid remaining in the nebuliser mostly clinging as large drops 
to the inside surface. This may be almost as much as 2 ml [44].
Driving Gas Flow: When there are several ml of fluid in the 
nebuliser nebulisation occurs continuously at a rate which 
increases with driving gas flow [44, 49]. Increasing the driving 
gas flow decreases the mass median diameter of the aerosol, a 
typical figure being a reduction in mass median diameter of 50% 
for a doubling of flow from 4 to 8 1 min”1 [46]. Aerosols 
produced at these higher flows may not have a log normal 
distribution owing to droplet disintegration and coagulation. 
However they still have a larger proportion of smaller particles 
than aerosols produced at lower flows. Because they may not be 
strictly log normal therapeutic aerosols are sometimes described 
in terms of the proportion of particles below 5 p rather than by 
log normal parameters [46]. Using a high flow may result in a 
smaller mass of solute (see below) being left in the nebuliser
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at the end of nebulisation [52].
As flow increases above about 10 1 rain"1, which is the upper end 
of the range for most studies and for present clinical use, the 
graph of aerosol output against driving gas flow rate appears to 
flatten [110]. The phenomenon has not been studied in detail but 
it implies.that as gas flows increase above (roughly) this value 
the aerosol output becomes less concentrated (total aerosol mass 
production rate is still increased) . This in turn has 
implications for therapeutic aerosol delivery since 10 1 min"1 
is less than normal peak inspiratory flow and mixing of aerosol 
with room air will occur during inhalation. There will be an 
interrelationship between respiratory pattern, aerosol flow rate 
and inhaled aerosol concentration which will determine how much 
aerosol is taken in by the subject. Despite work on the optimal 
respiratory pattern for pulmonary deposition this particular 
aspect seems not to have been examined.
Variable orifice rotameters are often used to measure and 
control flow through nebulisers, especially in clinical work. 
Errors in flow measurement occur when non pressure-compensated 
rotameters (i.e. those with the needle valve upstream of the 
flow measuring chamber) are used in conjunction with high 
resistance devices like nebulisers since the pressure in the 
rotameter chamber is raised to a value which depends on the size 
of the down stream resistance [55, 56]. If the space around the 
bobbin behaves like an orifice indicated flow (Fi) may be 
corrected to actual flow at atmospheric pressure (Fa) by:
(3.2) Fa = Fi. J(Pf/Pa)
where Pf is the pressure at the rotameter bobbin and Pa is
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atmospheric pressure [57].
Unfortunately one cannot make this assumption when the bobbin is 
at the lower end of the tube [56, 58], To give accurate flows 
throughout its range the rotameter scale must be individually 
calibrated to the working pressure.
Many published studies on the effects of gas flow through 
nebulisers fail to specify the exact method used to measure flow 
[e.g. 44, 46, 48].
Driving gas Pressure: The size of the internal nozzle varies 
between models and sometimes between nebulisers of the same 
model [53, 65]. This is reflected in the driving pressure
required to produce a given gas flow and in droplet size.
In one study [49] driving pressures of 47 kPa and 75.5 kPa were 
required to provide a flow of 6 1 min"1 through two different 
nebulisers. These were associated with aerosol volume mean 
aerodynamic diameters of 3.7 p in the low pressure nebuliser and 
2.6 p in the higher.
The nature of the Solution: Different solutions may have 
different surface tensions and viscosities which may contribute 
to measurable differences in aerosol output. For instance 
changing the concentration of histamine acid phosphate from 0.5 
to 32.0 mg ml-1 resulted in a fall in estimated primary (i.e. at 
the moment of formation) volume median aerodynamic diameter from 
3.8 to 2.3 p [50]. The differences between most commonly used 
clinical solutions are slight [46, 110], but relatively viscous 
solutions such as antibiotics may differ markedly from the rest 
[48].
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•Rvaporation Effants; Gas leaving the nebuliser is saturated with 
water (or other solvent) vapour derived partly from the 
nebulised particles but mainly from the large area of liquid 
spread as films and droplets over the inner surface. Water 
therefore leaves the nebuliser both in the aerosolised particles 
and as vapour. Since solute only leaves in the nebules this 
means the concentration of the residual solution is continually 
increasing [50, 51, 52, 65). Output of solution as determined by 
weighing the nebuliser or measuring residual volume is thus not 
equivalent to solute output and the rate of solute output 
changes as nebulisation progresses. The discrepancy between 
solute and solvent output increases as nebulisation goes on [51, 
52] because evaporation continues unabated when aerosol output 
becomes intermittent. This is reflected in the data from studies 
designed to quantify the phenomenon. One group [50] found an 
increase in saline concentration in the residuum of a 4 ml fill
_ i
from 8.8 to 9.2 mg 1 A after 2 min nebulisation at a gas flow of 
8 1 min"1. Another group [52] using a different nebuliser found 
an increase in saline concentration from 70 mg ml"1 to 185 
mg ml"1 when 4 ml of solution were nebulised over a much longer 
period to a residual volume of less than 1 ml by a gas flow of 6
_ i
1 min A.
The proportional increase in concentration (concentration at 
time t / initial concentration) after a given time of 
nebulisation will depend on the filling volume, other things 
being equal. It is greater for low filling volumes [51] because 
the amount of water vapour leaving the nebuliser per unit time 
is independent of filling volume, being dependent only on the 
flow rate and saturation of the incoming gas.
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Humidifying the driving gas lessens the effects of evaporation 
[51].
Nebulisers cool down over the first few minutes of use until an 
equilibrium is reached whereby heat entering the device down the 
temperature gradient from the surroundings is equal to the 
latent heat of vaporisation of the evaporating solvent. There is 
an initial fall in aerosol output corresponding to this cooling 
phase. This has been attributed to a temperature dependent 
increase in surface tension [44, 53].
Extension devices; Any extension device added to the nebuliser 
outlet will collect some droplets depending on its shape and 
size. These will mainly be larger droplets deposited by 
inertial impaction or sedimentation. This will shift the size 
distribution of the escaping aerosol towards the smaller end of 
the scale. The total mass of aerosol will be reduced. The longer 
the extension the more aerosol deposited [49].
In conclusion it must be said that interpretation of published 
work on the effects of such interrelated factors is often 
difficult because of varying experimental design and because the 
complete set of relevant information is often not given. For 
experimental work such as drug dose comparisons the problems of 
intermittent nebulisation can be avoided and the inaccuracies 
owing to evaporation lessened if nebulisers are filled with 
several ml of liquid and the last two ml not used.
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A Digression on the Measurement of Pain by 
Linear Visual Analogue
chapter 4
Pain like any other subjective psychological process may be 
regarded as a cognitive behaviour, that is a process of 
information transformation firmly dependent on underlying 
patterns of neuronal activity. As such it is perfectly objective 
and, in theory, as open to investigation, modelling and 
quantification as any other physical process. In practice lack 
of knowledge makes the difficulties immense.
The demonstration of an analgesic response in this project 
relies heavily on the use of Linear Visual Analogue (LVA) scores 
to measure pain changes. The apparent extreme simplicity of this 
method conceals some conceptual complexity and it is worth 
discussing the subject in detail.
Description
LVA scores are a method of allowing quantification of internal 
states such as feelings and emotions on a continuous scale. [74, 
75, 76 ]. They are finding an increasing role in pain
measurement. The ends of the scale are defined by verbal 
descriptions of states such as "no pain at all" and "the worst 
pain I could imagine". The rest of the scale is represented by 
an unmarked line of standard length assumed to represent a 
continuum between these two extremes. Subjects must decide where 
on this continuum their own pain lies and make a corresponding 
mark on the line. The score is converted into a number by 
measuring the distance between the mark and the "zero" end of 
the line.
The Concept of Measurement: Levels of Measurement 
To begin examining the properties of LVAs in particular it is 
helpful to consider the concept of measurement more generally.
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Measurement was defined by a committee of the British 
Association for the Advancement of Science in 1946 as "the 
assignment of numerals to things so as to represent facts and 
conventions about them" [67]. The numbers form symbolic systems 
or scales whose mathematical structures model these "facts and 
conventions". Stevens [67] classifies scales into a hierarchy of 
four types: Nominal, Ordinal, Interval, and Ratio. Each higher 
type of scale uses additional types of mathematical operation to 
model information. The scales thus have a progressively higher 
information content. The type of scale formed by a given 
measuring operation (i.e. the level of measurement) will depend 
on the rules used to assign numbers to the property being 
measured i.e. on the physical nature of the measurement process. 
For instance an ordinal scale of hardness for rock samples might 
be constructed by breaking different combinations of sample 
pairs against each other. A ratio scale could be constructed by 
ascertaining the height of drop required to shatter each sample 
against a standard surface. In the physical sciences the nature 
of the measurement process is usually apparent. In the 
behavioural sciences the measurement process often involves 
psychological mechanisms whose physical basis is not known. This 
may make it difficult to know what level of measurement one has 
achieved. However, psychological processes are simply a way of 
describing physical interactions between neurones. It is 
important to stress that the level of measurement remains an 
objective consequence of these interactions and is open to 
experimental verification even though we remain ignorant of the 
neuronal interactions themselves.
The level of measurement is important since it determines what
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the numbers mean. One must know this in order to know how to 
interpret and manipulate the data since statistical tests and 
mathematical manipulations appropriate to ratio or interval 
scales of measurement may rely for their validity on information 
not contained in ordinal scales where the corresponding 
mathematical relationships are "empty".
Effects of Data Processing 
After making a measurement, during any subsequent processing of 
data, it is possible to loose information and degrade data to a 
lower level. When the data refer to psychological measurements 
which have been made by a subject on his own mental state this 
may occur as a result of mental processes which occur before the 
subject reports the data (i.e. during the process of 
transforming the data into an output signal). For instance 
answering the question "Is your pain greater or lesser than 
before?" may involve processes which generate data at an 
interval or ratio level. The final output however is only 
ordinal.
Other systematic distortions may occur during the transformation 
of data to an output signal. For instance ratio level data may 
be subjected to a non linear transformation which renders the 
final numerical scale on which it is expressed logarithmic.
The difficulty of designing experimental techniques to measure 
pain or other such variables is thus twofold. Firstly there is 
the problem of getting the nervous system to measure an aspect 
of its own function as accurately, as precisely, and on as high 
a level of measurement as possible. Secondly there is the 
problem of making the resultant information available without 
loss or distortion.
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Level of LVA Measurement 
There is debate as to the level of measurement achieved with LVA 
scores i.e. whether they give ordinal or ratio information. If 
they represent an ordinal level measurement they can be used to
show the direction but not the magnitude of pain changes within
a given subject. Apparent information as to the magnitude of 
pain differences must be regarded as spurious and only very 
limited types of comparisons are possible between subjects. If 
on the other hand they represent a ratio level measurement they 
are a much more useful and flexible tool, particularly for 
making comparisons between subjects.
Stevens's categories are of ideal scales which reflect the ideal 
properties of the number system. All actual measurement systems 
are imperfect to some degree. (Since it is impossible to
abstract pure reference attributes from the generality of
material interactions this will be so even in the measurement of 
fundamental properties in physics). It is important to 
distinguish between a measurement technique which is inherently 
ordinal and one that is imprecise and inaccurate but still 
contains, albeit distorted, interval or ratio information.
It would seem intuitively that one can judge pain on a 
continuous scale and make judgements as to the relative size of 
pain differences (to comprehend, for instance, that a pain is a 
lot worse rather than just worse) . The scale has an absolute 
zero (which distinguishes a ratio from an interval scale) . Since 
there seems no reason to doubt the apparent ability of people to 
use this process to generate an output signal it seems likely 
that an LVA pain measurement is an inaccurate ratio measurement. 
The question then becomes how accurate and reliable a ratio
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scale it is. The technique may be so invalid as to be useless. 
On the other hand there may be systematic distortions in parts 
of the scale either present always or appearing under certain 
circumstances which can be identified and to an extent 
corrected. There may be large variation in the measurement of 
similar pain within and between subjects. In measurement 
generally, random differences can be cancelled by repeated 
measurements of the same quantity so the mean value of many 
measurements may be very accurate even though individual 
measurements are unreliable. Although one cannot cancel the 
effect of interindividual variation in the measurement of a 
given pain such a technique may distinguish accurately between 
the average pain of different populations. The size of the 
intersubject variation will determine the discrimination which 
can be obtained with a given number of subjects.
Accuracy and Reproducibility of LVAs: Validation 
LVAs are not accurate or reproducible enough between subjects 
for absolute individual measurements to be of value (see for 
instance [90]). That is one cannot measure an individual's pain 
as one can measure his blood pressure. Accuracy, reproducibility 
and practicality of LVA pain measurement have been investigated 
by various workers. In the absence of an accepted standard 
method of pain measurement most of this work has involved the 
following techniques.
1) Comparison with other methods of measuring pain such as
rating scales, or pain behaviour.
2) Evaluation as a measure of experimental pain where it is
assumed that the intensity of the pain experience is
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related to the (measurable) stimulus intensity. This method 
allows fairly sophisticated investigation of their 
sensitivity and variability within and between individuals.
3) Use to detect known changes in clinical or experimental 
pain such as those induced by analgesics.
4) Evaluation of their consistency in repeated measurements of 
the same clinical or experimental pain.
Comparison with other methods: A number of studies [79, 82, 84, 
85, 86, 87, 88, 100, 101, 102, 103] directly compare LVA scores 
with other methods of pain measurement, particularly with 
categorical descriptive scales in the measurement of clinical 
pain. A problem with this work is that results are often given 
as correlation coefficients between the various methods of pain 
measurement. Unfortunately the meaning of correlation 
coefficients in this context is not clear. Coefficients 
calculated by different methods may give different results. They 
may be influenced by factors such as the suitability of the 
numbers chosen to represent a categorical scale or the greater 
resolution (and hence variation) of a ratio scale. Depending on 
what is being compared, other analyses may be more informative. 
For instance where the pain can be measured in the same units, 
as in a comparison between an LVA and a numerical categorical 
scale, measures of the bias and the spread of the differences 
should be given throughout the length of the scales [80]. When a 
ratio scale is compared with a categorical scale a useful 
presentation is the average ratio value along with the 
distribution of individual ratio values associated with each 
category [see e.g.84].
Other important difficulties are that both the names and number
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of the rating categories and the anchor phrases of the LVA may 
differ between studies, and finally, when there is a poor 
agreement between two or more methods there is no way of knowing 
which method is closer to the true value.
LVAs however are clearly used with enough consistency by 
different individuals to demonstrate at least rough agreement 
with other methods of pain measurement using groups of around 15 
to 100 subjects. Thus, when LVA measurements are compared with 
simple verbal categorical scales, average LVA values rise with 
words denoting increasing pain severity. There is a marked 
overlap in the distribution of individual LVA values associated 
with each word (figure 4.1). Unfortunately there ©r-e not enough 
comparable data available to examine usefully the association 
between average numerical scores and specific words for 
different groups of subjects. (Wallenstein and colleagues [100] 
make an interesting attempt for two populations).
Experimental pain: Price and colleagues [72] conducted a
detailed investigation of pain scores as a measure of heat 
induced experimental pain and concluded that they behaved as 
ratio scales. The relationship between pain score and stimulus 
intensity could be described by a power function. This function 
was then predictive of the temperature required to produce a 
doubling of pain intensity or of the proportional increase in 
pain associated with a given temperature increase. In chronic 
pain patients there was good agreement between measurement of 
pain by LVA and by matching to heat stimulus. Conclusions were 
drawn from pooled data of between 20 and 60 observations. 
Unfortunately the investigators did not provide an analysis of
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Relationship between Linear Visual Analogue Score and Verbal
Rating of Pain
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ii. Reproduced from [82]. The extremes of the analogue scale 
were marked "no pain" and "the worst pain imaginable".
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the data from individual subjects as opposed to pooled results 
or of the variability between subjects. The related question of 
what resolution could be obtained in discriminating between 
stimuli was not addressed.
Detection of expected pain changes; Various workers [81# 84, 91, 
92, 93, 94, 95, 96, 97, 100, 102] have successfully demonstrated 
the ability of LVA measurements to reveal expected drug effects 
such as superior analgesia from an active drug compared with a 
placebo or dose response relationships. These studies provide 
strong circumstantial evidence that LVAs measure pain on a ratio 
scale since interval or ratio information from the data is often 
implicitly used in the analysis of the results. With crossover 
designs to minimise the effects of inter-subject measurement 
variation and very carefully controlled experimental conditions 
it is possible to detect slight drug effects with a surprisingly 
low number (6 to 12) of subjects [81, 93, 97]. Clinical studies 
which used different subjects for each treatment [84, 94, 95,
96] used larger numbers (10 to 20 subjects per treatment) and 
results were not always as unequivocal. Different experimental 
designs and data analysis techniques were used in each case.
Six of the above studies have compared LVAs with simple 
categorical scales (a widely used alternative). In four of these 
[84, 95, 97, 100] LVAs are the more sensitive method, achieving 
higher probability values for expected changes. One study [94] 
is equivocal with the performance of the two methods depending 
on how the results are analysed. One small study of six patients 
[102] (cross-over design) failed to show any significant 
differences with either method but the expected trends were more 
pronounced (higher F-ratio values) using the categorical scale.
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Repeatability; The repeatability of LVA measurement was 
addressed by Revill and colleagues [77] who found the LVA very 
consistent in repeated measurements of a clinical pain that had 
occurred weeks or months in the past. They found an average 
absolute difference of 2.5% between ratings 24 hours apart 
compared with 4.8% in duplicating from memory a randomly placed 
mark. Scott and Huskisson [70] found a high correlation between 
successive pain measurements of ongoing pain which they 
interpreted as an indication of consistency of measurement. 
Ekblom and Hansson [85] found good agreement in the pain scores 
for an ongoing pain that was reported as unchanged.
Output Distortion and Data Processing;
LVAs may be particularly susceptible to output distortion into a 
non linear scale because the total range of the scale is fixed. 
Thus a subject who indicates near maximum pain on a pain scale 
but then finds his pain markedly increased can only increase his 
score by a small amount. This might make the scale approximately 
logarithmic particularly towards the upper end. This would only 
happen during increasing pain when the subject was caused to 
revise his conception of maximum possible pain and the 
occurrence of the effect would thus be influenced by previous 
pain experience (see below). Such distortions should be amenable 
to experimental analysis. For example during decreasing pain it 
might be possible to assess* non linearity of a pain LVA by 
comparing pain score differences with pain relief scores marked 
"no pain relief" / "complete pain relief", assuming, of course, 
that the fundamental measuring process is the same in both cases 
and the only difference is in the data output (see below) .
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Practical Aspects 
Serial measurements: Should previous scores be available for
comparison when new measurements are being made during serial 
measurements of ongoing pain? It seems that using previous 
readings for comparison does influence the values obtained, 
particularly when making readings over a long period (weeks) 
[68, 69, 70] . It is not clear in which situation readings are 
more likely to be most accurate. The case against allowing 
comparison with previous scores is that it may introduce a bias. 
(This constraint applies to all measurements where there is a 
necessity to exercise observer judgement and there is a danger 
of bias towards an expected value created by knowledge of the 
previous reading. When measurements are truly independent this 
systematic error is removed). The argument for allowing direct 
comparison is that it decreases the error due to inaccuracy in 
memory. The scale becomes calibrated at more fixed reference 
points and any tendency to a "calibration drift" is opposed.
The premise that pain score readings can be completely 
independent is false because the measuring device (neuronal 
circuitry) remembers, i.e. is changed by, successive pain 
states. Moreover, it is possible that adjustment and 
recalibration of the scale in the light of experience is a 
beneficial process leading to greater accuracy. Maxwell [71] 
showed that when LVAs were used to measure the loudness of a 
series of sounds a more evenly distributed set of corresponding 
LVA values was obtained when the same sounds were presented on a 
second occasion 2 days later. (Unfortunately the elegance of the 
experiment was diminished by a lack of sophistication in the 
production and objective measurement of the sounds).
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Essentially however, the arguments on both sides are speculative 
and there is no conclusive evidence. It is important to be 
consistent whichever method is chosen.
Pain relief scores It has been suggested [73], that pain relief 
scores rather than the subtraction of pain scores should be 
used to measure analgesic effect. This has three proposed 
advantages. Firstly, patients most naturally express the 
efficacy of a treatment in terms of pain relief. Secondly the 
problem of possible non-linearity of pain scales is apparently 
circumvented. Thirdly the phenomenon is avoided whereby pain 
score decrement tends to be related to the initial pain score. 
This phenomenon has two causes. Firstly, people may calibrate 
their scales differently such that some subjects give a similar 
degree of pain a higher rating. Since the magnitude of any 
changes will also be exaggerated there is a tendency for the 
size of the pain relief to be related to the initial pain. 
Secondly smaller initial pains have less scope for decrease 
(figure 4.2).
There are several good arguments against reliance on analgesia 
scores. Analgesia scores by themselves give no indication as to 
the initial distribution of pain between groups and may thus 
disguise an inadequacy of trial structure. Pain scores should 
show up a difference in initial pain between groups and 
(correctly measured) differences in pain decrease between groups 
could then be rightly attributed to the differing ability of the 
groups to respond rather than the relative efficacies of the 
treatments. Analgesia scores (or calculated fractional pain 
score changes) abolish real differences of absolute magnitude
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and pain score decrease: all treatments must lie 
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perfect analgesic. Adapted from [73].
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between subjects. A small decrease in a small pain is made
equivalent to a large decrease in a large pain. This again may
lead to erroneous conclusions when groups are not perfectly
matched in terms of initial pain. Analgesia scores are unable to
show increases in pain. In some circumstances this will result
in a waste of useful information, for instance an analgesic
treatment may prevent or attenuate a pain increase that would
otherwise occur. Some investigators [83, 85, 90] have attempted
to avoid this last problem by using a pain change scale with the
midpoint labelled "initial pain" or "present pain" and the ends
variously anchored to indicate increasing pain in one direction,
decreasing pain in the other. This introduces further
difficulties of interpretation which will vary with the
individual scales. For instance it is possible for the scaling 
to b c.
on both arms^very different depending on the magnitude of the 
initial pain.
The assumption that the problems of non-linearity are avoided by 
using an analgesia scale, although plausible, may be unsound. If 
pain scores are not linear, numerically equal differences 
derived from different parts of the scale will not represent
equal differences in pain. With analgesia scores the difficulty 
should not arise since all differences on an analgesia scale are 
measured from the same starting point of "no analgesia". The
analgesia scale is anyway more likely to be linear since there 
it is no possibility of resetting its extremities. (By the same 
token interindividual differences in scaling may be minimised). 
However, if analgesia scores are not linear the pattern of non-
linearity may differ with the absolute amount of pain. For
instance the position of the mark may be unduly influenced by
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the absolute amount of residual pain rather than corresponding 
strictly to the proportional decrement and this influence may be 
more or less pronounced depending on the size of this residual 
pain. Thus numerically equal analgesia scores would represent 
different proportional pain decreases, an exactly analogous 
difficulty to that with pain score differences.
It is not clear whether the use of pain and analgesia scores 
represent different outputs from the same psychological process 
(i.e. that analgesia is measured by manipulating estimates of 
pain generated in the same way as the estimates used to give 
pain scores) or whether a different psychological process is 
involved.
Line length, orientation and visiosoacial factors To determine 
the error involved in marking an LVA in a given place Reville 
and colleagues [77] asked subjects to make several attempts at 
placing a mark one fifth of the way along the line. The 95% 
confidence limits for the error were ± 7% for an individual mark 
and ± 2% for the group mean (20 subjects 10 marks each) . This 
visio-spacial judgement error may vary depending on the position 
along the line [78]. The length of the analogue line [77, 82]
and its orientation [98, 99] may influence the results obtained 
with LVA scales. These effects are probably small compared with 
other sources of inter-subject variation. LVAs should be 10cm or 
more long and should be presented consistently in the same 
orientation.
End Phrases In the present study LVAs have been used to make a 
single compound measure of pain magnitude. However pain is 
better characterised as a multidimensional phenomenon whose
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aspects can be quantified separately. LVAs can be used to 
measure any aspect of pain by means of careful instructions and 
choice of end phrases. Most commonly a distinction has been made 
between unpleasantness and intensity [e.g. 81, 92]. Within a
given dimension the choice of end phrases will influence the 
magnitude and distribution of the measurements [82].
Statistical treatment of LVA data Investigators have employed a 
wide variety of statistical methods in the treatment of LVA 
data. In considering the broad question of whether to use 
parametric or non parametric methods the arguments from 
principle centre around the measurement level and the 
distribution of the data. I have argued here that LVAs represent 
inaccurate ratio level data. The distribution of scores is 
variable [73, 74, 82]. This is as one would expect since it will 
depend both on the real distribution of the pain and the 
distribution of any measuring error. One should not assume the 
scores will be normally distributed and there is no 
transformation that can be reliably applied to make them so. On 
these grounds operations like the subtraction of scores or the 
calculation of areas under painscore/time curves are justified 
(providing any conclusions are based on a large enough number of 
subjects) but it is logical to use non parametric tests of 
significance. In practice [71, 96], as with the present study, 
parametric and non parametric significance tests are unlikely to 
lead to very different conclusions.
Conclusion
LVAs are probably an inaccurate ratio measure. In addition to 
random error they may be subject to systematic distortions.
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These distortions may vary with the circumstances of use. 
Despite this they can be used to distinguish clinically useful 
differences in pain between groups of subjects and they are 
probably more sensitive than simple categorical scales for this 
purpose. Unfortunately despite a reasonable body of published 
experimental work there is still much that is unclear about 
their behaviour in common situations. In particular, firstly, it 
would be useful to have a better qualitative and quantitative 
understanding of inter-subject measurement variation. This might 
allow trials to be designed so that such variation was minimised 
but it would also allow better estimation of the power of 
various sizes of trial to demonstrate given pain differences. 
Secondly, (and this is different from the application of 
transformations for statistical analysis) it would be useful to 
have information on the feasibility of applying corrections to 
the raw scores in various conditions.
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Route
The purpose of the study was to investigate the effectiveness 
and safety of fentanyl delivery by the pulmonary route. We 
wanted to deliver drug to the terminal airways for absorption 
into the pulmonary circulation as we expected absorption here 
would be more rapidly complete than absorption across the upper 
respiratory tract i.e. more likely to mimic intravenous 
administration. Streisland and his colleagues have administered 
fentanyl by buccal absorption to good effect [107] but with 
apparently slower absorption than would be achieved 
intravenously (Time to peak sedation between 25 and 45 minutes). 
This may have reflected a slow release effect from their 
fentanyl lollipops. Another group of investigators [108] 
demonstrated the onset of effects within 10 minutes of nasally 
administered sufentanil but they used a comparatively large dose 
and the timing of the full response was masked by induction of 
anaesthesia and institution of controlled ventilation.
Nebuliser and Delivery System 
Currently the only practical way of delivering fentanyl to the 
respiratory epithelium is by nebulising fentanyl solution. We 
chose the simplest possible way of doing this using a 
commercially available disposable jet nebuliser, driven by the 
hospital piped oxygen supply and attached directly to a 
disposable plastic face mask. This simple arrangement is 
effective for other drugs such as salbutamol and is commonly 
used in clinical practice. It is not an efficient way of 
delivering drug however. Drug nebulised outwith inspiration is 
wasted. Furthermore the nebuliser flow rate is unlikely to 
approximate the maximum inspiratory flow of even a quietly
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respiring patient. During part of each inspiration therefore the 
aerosol will be diluted with room air, decreasing the rate of 
drug administration from its potential maximum. Various, 
improvements to this basic system have been proposed such as the 
addition of chambers and valves [e.g. 109]. However such devices 
are not yet in widespread clinical use and their effects on 
aerosol delivery and deposition have not been clearly evaluated. 
The results of a given modification to a nebuliser breathing 
system are difficult to predict because of the many factors 
involved.
The nebuliser used in the study was the model used routinely in 
the study hospital; the Lifecare Micro-Neb. This has good output 
characteristics in terms of percentage of nebulised droplets 
below 5 p. (about 75% at a driving gas flow of 8 1 min"1) and 
rate of aerosolisation [110]. (The relationship between initial 
particle size and pulmonary deposition is more complex for 
therapeutic than nonhygroscopic aerosols. Nevertheless, aerosols 
of smaller particles tend to deposit more peripherally in the 
respiratory tract than aerosols of larger particles (chapter 3)J. 
Preliminary tests showed that nebulisation was continuous down 
to residual volumes of about 1.5 ml. The design of the supplied 
facemask connector allows the nebuliser to remain upright when 
the subject is lying on he.r side. This is an important 
consideration in the present study as it is difficult to sit 
some patients upright immediately after their operation. 
Experiments showed that, when the nebuliser was filled to 5 ml, 
it would nebulise 3 ml of normal saline (determined by weighing 
the nebuliser before and after nebulisation) in 9 minutes using
_ 4
a driving gas flow rate of of 8 1 min A (measured uncorrected on
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the oxygen pipeline system wall rotameters upstream of the 
nebuliser: the actual oxygen flow at atmospheric pressure would 
be greater than this.^bee page 31). The flow rate, which fell at 
the upper end of the manufacturer's recommended range, was 
chosen to maximise the rate of aerosol delivery and minimise 
particle size. The effects of using higher flows than this are 
unpredictable since they are outwith the range for which
performance data cure available. At higher flow rates connecting 
tubing tended to blow off at the nebuliser or at the wall 
rotameter. The filling volume was chosen to minimise the effects 
of evaporation and intermittent nebulisation thereby increasing 
the standardisation of the drug dose.
There was variation in the rate of nebulisation on different 
occasions even when a standardised regimeswas attempted. Some of 
this was no doubt due to differences between the nebulisers 
themselves and some to factors such as differences in 
calibration between different oxygen flow meters (see chapter 
3) . In order to know what amount of solution had been nebulised 
we decided to weigh the nebulisers in the study before and after 
each aerosolisation.
It is possible that delivering the aerosol by a mouthpiece 
rather than a face mask increases pulmonary deposition by 
avoiding nasal filtration of particles [59]. However, a face 
mask was chosen for this study as it does not require any
t
special co-ordination or co-operation from the subjects at a 
time when they are likely to be still influenced by residual 
anaesthetic.
Persons and her colleagues [111] suggest that slow deep 
continuous breathing maximises the amount of pulmonary
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deposition during a given period of aerosol exposure.
The Fentanvl Solution 
Prior to the present study a pilot study [117] was carried out 
by Worsley and colleagues using standard commercial fentanyl 
citrate solution (50 jig ml"1 fentanyl base) in a maximum dose of 
6 ml nebulised "to dryness" over 12 to 17 minutes. This would 
correspond to a nebulised dose of about 200 to 250 jig fentanyl 
base. The results of this study were interesting in that they 
suggested fentanyl by this route was providing substantially 
greater analgesia than would be expected from the estimated 
absorbed dose or the plasma concentrations. Unfortunately early 
attempts to replicate these promising results were unsuccessful. 
We concluded the doses nebulised had been too small and the 
pilot results had been largely artifactual.
A longer period of nebulisation using a larger volume of 
fentanyl solution would result in a larger total dose of 
fentanyl. However the slow rate of drug delivery would not be 
increased. For a very lipid soluble drug like fentanyl with a 
short redistribution half life it is unlikely that we would 
achieve a substantial increase in plasma concentration with even 
quite a marked increase in aerosol exposure time. Furthermore 
this would be unacceptable for two other reasons; firstly 
patients become increasingly intolerant of longer periods of 
nebuliser therapy and secondly, pain relief has to be achieved 
within a time at least comparable to that for standard 
intramuscular analgesia. For patients who failed to get pain 
relief from the nebulised fentanyl this time must include an 
allowance for the assessment of analgesic adequacy and the 
administration of intravenous escape therapy. For these reasons
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we considered nebulisation time should be limited to a maximum 
of ten minutes. In order to increase the dose without prolonging 
the nebulisation time it is necessary to use a more concentrated 
solution. For the present study therefore fentanyl citrate 
crystals were obtained and made up to order in the hospital 
pharmacy.
Fentanyl doses were chosen on the basis that about 10 to 20 % of 
the nebulised dose would enter the patient [118, 119]. A maximum 
strength solution of 318 pg ml"1 fentanyl base (500 pg fentanyl 
citrate ml"1) was prepared to provide a nebulised dose of 954 pg 
(3ml), corresponding to an estimated delivered dose of between 
100 and 200 pg fentanyl base, to be given over 9 minutes. One 
would expect to detect the analgesic effect of an intravenous 
dose of 100 to 200 pg given over the same time period. Larger 
doses than this given intravenously would be expected to produce 
clinical respiratory depression in increasing numbers of 
patients. Two lower doses, one corresponding to the dose used in 
the pilot study and one intermediate betwen that and the high 
dose were also administered. These were 477 pg fentanyl base
_ i
(given as 3 ml of 159 pg ml . solution) corresponding to a 
delivered dose of between 50 and 100 pg, and 192 pg (given as 3 
ml of 64 pg ml"1 solution) corresponding to a delivered dose of 
between 20 and 40 pg. A saline placebo was not necessary since 
the dose groups could be compared against each other.
Persons and her colleagues [111] have considered the effects of 
solution tonicity on pulmonary deposition of hygroscopic 
aerosols. They suggest that better peripheral deposition can be 
obtained by using a hypertonic saline solution. However 
hypertonic saline is more likely to cause bronchospasm or
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coughing than normal saline and we felt that normal saline was 
more appropriate as a vehicle in this trial. Hence the three 
strengths of fentanyl citrate solution were made up with normal 
saline and sealed in coded glass ampoules of 5 ml each.
General Design. Study Population and Environment 
The method of drug administration as it stood was untried and 
relatively cumbersome. It would have been difficult to 
incorporate it in a repetitive-dose analgesic regimen. As with 
the pilot study we thus designed a trial to examine the 
effectiveness of a single dose of nebulised fentanyl in 
immediately-postoperative patients. The advantages of this were: 
Firstly, the study took place in the operating theatre recovery 
rooms where the patients were constantly under the observation 
of trained nursing staff and full resuscitation facilities were 
to hand. This was particularly important in planning to deal 
with dangerous respiratory depression or bronchospasm, both of 
which were possible, though unlikely, effects of the treatment. 
Secondly, the timing of subjects' need for analgesia was 
relatively predictable. Thirdly, we were able to avoid 
confounding effects resulting from variable amounts of 
previously administered intra muscular opiates. Fourthly, we 
avoided confounding effects resulting from the subjects 
undertaking different degrees of activity (sitting out of bed, 
washing etc.) which might change the pattern of their pain.
The main disadvantage of this situation was the residual effect 
of anaesthesia which would be expected to interfere with the 
ability to carry out the assessment tasks and might affect the 
patients' experience of and reaction to their pain.
Approval for the trial was obtained from the local ethical
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committee. Potential subjects were selected from patients 
undergoing a broad range of elective general surgical and 
gynaecological procedures. Suitable candidates were in good 
general health and about to undergo what was expected to be 
uncomplicated surgery. They were all patients who would have 
normally been offered opioids for postoperative pain relief. 
Specific reasons for exclusion are detailed in the summary 
below. Eligible patients from the lists of two operating 
theatres (general surgical, and gynaecological) were interviewed 
the day before surgery. They were told to request analgesia as 
soon after waking up as they felt the need for it. It was 
emphasised that this was normal procedure and that inclusion in 
the study should have no influence on whether or not, or when 
they requested pain relief. Formal written consent was sought. 
For logistic reasons not all suitable patients were actually 
included in the study. Decisions as to which patients to include 
were made on the grounds of convenience. Subjects entered the 
study when they spontaneously requested analgesia in the 
recovery room. Patients who were too distressed by pain at this 
stage to be rational and co-operative were automatically 
excluded. We intended that the selection procedure would thus 
impose a degree of standardisation on the initial pain levels. 
In retrospect not choosing patients undergoing a single standard 
operation was a design fault (chapter 7).
Randomisation and Drug Accounting 
The trial was double blind. This is o f ’ paramount importance 
since the important measurements in the trial such as pain 
scores and time to escape analgesia are highly susceptible to 
subconscious bias and manipulation. Eligible subjects were
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randomised to one of three groups at the time they made their 
first request for postoperative analgesia. Each group received a ' 
different dose of fentanyl. The solutions were made up in 
advance in ampoules labelled only with the group code. 
Accounting was in a special drug book.
Anaesthetic Standardisation 
All patients were given a routine balanced anaesthetic, i.e. 
they were premedicated, anaesthesia was introduced with an 
intravenous agent and maintained with nitrous oxide, a volatile 
agent and morphine.
Intraoperative analgesia is a normal part of balanced 
anaesthesia. It allows the use of lower doses of the other 
anaesthetic agents and prevents the patient waking in agony at 
the end of the operation. Morphine was chosen because it is 
commonly used by the anaesthetists in the study hospital and 
because it does not interfere with estimations of plasma 
fentanyl concentration. All patients were given intravenous 
morphine approximately 0.07 mg kg’* at induction followed by 
increments of 2 mg as required. We chose this flexible dose 
regimenbecause there is no predictable relationship between dose 
of opioid and the effect it will have in a given individual and 
because subjects were undergoing a range of different 
operations.
Premedication was with an oral benzodiazepine. No patient 
received intramuscular drugs, thereby avoiding the possibility 
of rising plasma opioid concentrations in the postoperative 
period as a result of previously administered opioids.
We did not think it was desirable to further standardise the 
anaesthetic technique in view of the range of operations. Choice
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of ventilatory method, induction agent, muscle relaxant (if any) 
and volatile agent were left to the individual anaesthetist (see 
chapter 7).
The Measurements
Respiratory Rate: Fentanyl causes a decrease in respiratory rate 
when the dose is high enough. It is a relatively crude sign of 
opiate action in that there may be a varying degree of central 
respiratory depression before any changes in respiratory pattern 
are evident (chapter 1). Many other factors apart from opioids 
also change respiratory pattern. Deep breathing during nebuliser 
therapy could cause a lowering of blood carbon dioxide tension 
leading to a slower respiratory rate afterwards. In some post 
operative patients the pattern of respiration is irregular and 
the rate is difficult to determine. Nevertheless a more marked 
decrease in respiratory rate in the group receiving high dose 
fentanyl would be confirmatory evidence of an opiate effect. 
Monitoring the respiratory rate is also an important safety 
precaution against the onset of dangerous respiratory 
depression. Respiratory rate was measured by inspection and 
palpation.
Pulse and Blood pressure: Blood pressure was measured manually 
using a mercury sphygmomanometer. Pressures corresponding to the 
first and fourth Korotkoff sounds were recorded. Pulse was 
recorded by palpation.
Arterial Oxygen Saturation: It was possible that subjects' 
oxygenation might be compromised after nebulised fentanyl should 
either central respiratory depression or bronchospasm occur. In 
either case it would be important to detect it quickly so that
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relevant treatment could be instituted. Arterial oxygen
saturation was measured with a BTI BIOX III pulse oximeter.
Pulse oximetry gives moment to moment information on the 
percentage saturation of the subjects haemoglobin. It is rapidly 
becoming a routine anaesthetic monitoring technique. The Biox 
III has a digital display of the current arterial oxygen
saturation and is equipped with an alarm which will alert the 
observers attention should it fall below a preset value.
Saturation is measured by probes which attach either to a 
subject's finger or his earlobe. If the subject has marked
peripheral vasoconstriction the pulse signal may be too weak for 
the machine to make a reliable measurement. This occasionally 
happens with otherwise "normal" postoperative patients and is 
indicated on the display . The situation can usually be 
rectified by either repositioning the probe or increasing local 
blood flow by gentle rubbing. Pulse oximetry is not of any use 
for following changes in arterial oxygen tension around and 
above the normal range because the shape of the oxygen 
dissociation curve is such that changes here are not reflected 
in changes of haemoglobin saturation.
Airway Resistance: Bronchospasm is a possible hazard of inhaling 
any foreign substance. We felt that our fentanyl preparation was 
unlikely to cause bronchospasm as the solution was isotonic, the 
molecular concentration of fentanyl was relatively low and 
fentanyl is not known to be irritant to tissue. Fentanyl does 
not cause tissue histamine release [114]. (Histamine release is 
one mechanism whereby drugs may cause bronchospasm). Morphine 
causes tissue histamine release and is thus more likely to cause 
bronchospasm than fentanyl. Inhaled morphine causes a slight
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transient increase in respiratory resistance in normal subjects 
[115] but this effect does not appear to be marked enough to be 
clinically important [121]. Despite its unlikelihood we felt it 
was important to look for any change in airway resistance caused 
by fentanyl inhalation. We measured the ratio Forced Expiratory 
Volume in One Second to Forced Vital Capacity (FEV1/FVC) in each 
subject before and after aerosol therapy using a Micro Medical 
Spirometer. The FEV1/FVC is widely used as a measure of small 
airways resistance. A decrease in the ratio is a measure of 
bronchoconstriction. We expected this would both allow us to 
diagnose bronchoconstriction in individual patients and, by 
looking at the inter group differences, to discover any tendency 
for the fentanyl preparation to cause small airways obstruction. 
We also expected that anaesthesia and surgery themselves would 
change the ratios from their preoperative control values. In 
fact the effects of anaesthesia and surgery were so marked that 
further interpretation was difficult (chapter 7) . The Micro 
Medical Spirometer is a small hand-held battery-operated 
spirometer. Its performance has been favourably evaluated in 
this department.
Fentanyl Concentrations in Plasma: In four patients peripheral 
venous blood samples were taken for fentanyl assay. The samples 
were centrifuged and the plasma separated within four hours of 
collection. The plasma was frozen to await analysis. Fentanyl 
analysis was carried out using a commercially available 
radioimmunoassay kit (Medgenix FEN - RIA - 100) (chapter 7).
Pain and analgesia Pain relief was mainly assessed by changes in 
linear visual analogue (LVA) pain scores. We chose LVAs to
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measure pain because of their simplicity and speed of use. The 
subject is discussed in some detail in chapter 4. The LVAs were 
constructed as horizontal 10cm. lines marked "no pain" and 
"agonising pain". The ends of the lines were marked clearly with 
vertical bars. The text was separated from the ends of the 
lines by a 1cm space and was typed in thin clear script so that 
it was unlikely to be mistaken for a continuation of the line 
(figure 5.1). Subjects who normally wore reading glasses had 
their glasses available in the recovery room. The LVAs were 
arranged serially on a separate single sheet of paper for each 
patient so that at each assessment the patient has his previous 
scores for comparison. This was to maximise the accuracy of the 
scores as a record of the change of each patient's pain with 
time.
In addition to the LVA pain scores we also used a simple 
categorical analgesia score although we expected LVA scores
to be a more sensitive indicator of drug effect:
no pain relief (0). 
a little pain relief (1).
moderate pain relief (2).
almost complete pain relief (3). 
complete pain relief (4).
There were no numbers on the scale as presented to the subjects.
It would have been interesting to design the analgesia score as
a LVA. Direct comparisons could then have been made between the 
pain score changes and the analgesia scores. However we felt 
there was a danger of confusing the subjects between two such 
•similar scales.
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Figure 5.1
Linear Visual Analogue Scales
NO PA IN
AGONISING PAIN
AGONISING PAIN
Five scales were arranged on each sheet of A 4 .
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We carried out a preliminary experiment to test subjects' 
ability to use pain scores on waking after anaesthesia. Ten 
patients were given, double blind, a small intravenous dose (100 
pg) of fentanyl or saline placebo when they first asked for 
analgesia in the recovery room (followed if necessary by 
intravenous morphine after assessment of analgesia). They 
completed pain scores and analgesia scores. Other observations 
were made as in the main study. Lack of physical co-ordination, 
a residual effect of anaesthesia, proved to be an obstacle to 
the completion of pain scores. Subjects appeared to know where 
they wanted to mark the line but were unable to manipulate a 
pen. Other workers have designed mechanical or computer 
controlled analogues to overcome this problem (85, 105, 106). We 
adopted a simpler solution whereby subjects pointed to where 
they wished the mark to be. The mark was then made by the 
observer after he had checked the pen was correctly positioned. 
It is likely that some precision in the placing of the marks was 
lost by this method. Any errors should have been randomly 
distributed. Patterns in the pain score results showed wide 
inter subject variation. It was not possible to predict from the 
pain scores which individuals had received fentanyl and which 
had received placebo. There was however a trend for pain score 
decreases to be greater in the fentanyl group than the placebo 
group (p = 0.1 Mann Whitney U test). We accepted this as
evidence that the pain scores could be used to distinguish an 
analgesic effect of similar magnitude between groups in the main 
study using a larger number of subjects.
Analgesia scores only showed a slight tendency to be be greater 
in the treatment group.
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Sedation: This was scored by one observer according to the
following scale
0. No obvious sedation. Patient interested in surroundings. 
Eyes open most of the time.
1. Slight sedation. Eyes closed most of the time. Responds to 
speech alone.
2. Moderate sedation. Requires gentle shaking and speech to 
rouse.
3. Difficult to rouse. Requires vigorous shaking or painful 
stimulus. Falls immediately back to sleep.
4. Unconscious. No response beyond localisation of or 
incoherent vocalisation in response to painful stimulus.
Follow-up Questionnaire: We did not expect that, even if it 
proved to be effective, this particular method of administering 
fentanyl from a nebuliser over nine minutes would be useful 
without further development. The purpose of the study was to 
investigate the feasibility of the respiratory route. However we 
were interested to discover the impressions of the subjects as 
to its acceptability or otherwise and to find out any unforeseen 
subjective effects. We therefore administered the following 
short questionnaire the next day:
~W '
Do you remember your treatment with the nebuliser in the 
recovery room after your operation yesterday?
Analgesia score as above.
Was there anything about the treatment or its effects that 
you found unpleasant?
Was their anything about the treatment or its effects that 
you particularly liked?
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Would you like to have this form of pain relief again if 
you had another operation?
Side effects: Signs were noted by the observer as and when they 
occurred. Symptoms, if not volunteered, were sought at the end 
of the session by first of all a general and then specific 
questions.
Collection and Recording of Data 
Data were recorded manually on a standard form.
Number of Patients 
Thirty patients were studied, ten in each group.
Data Analysis
Initial comparisons between groups were made for each variable 
using the Kruskal-Wallis Test (nul hypothesis: no difference
between the three groups). If this showed the groups differed 
significantly (p < 0.05) the groups were compared in pairs using 
the Mann-Whitney U test. Pulse and blood pressure were compared 
within each group before and after drug administration using the 
Wilcoxon matched pairs test.
Pain score changes, time to further analgesia, respiratory rate 
change and possibly analgesia score can be regarded as separate 
measures of drug effect. To give an overall measure of response 
the variables were put on a common scale by ranking, and the 
arithmetic mean of each subject's four rank values used as a 
single combined index of relative drug effect. The groups were 
then compared using the Kruskal-Wallis and Mann-Whitney U tests 
on these averaged ranks. Demonstration of a dose response 
relationship was to be regarded as an indication of efficacy.
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Summary of Method 
Eligible patients were between the ages of 18 and 65 years of 
age and ASA grade I or II. The following patients were excluded:
1 Patients with liver disease, renal disease, severe 
hypertension, symptomatic ischaemic heart disease, 
bronchial asthma or severe respiratory disease of any sort.
2 Patients who are allergic to opiates.
3. Patients with a history of opiate addiction
4 Patients taking drugs known to interfere with the action or
metabolism of opiates.
Potential subjects were interviewed the night before theatre and 
invited to sign the consent form. The relevant tests were 
explained and demonstrated and pre-operative values obtained as 
part of the familiarisation process. All patients received 
routine balanced anaesthesia. An oral benzodiazepine was used 
for premedication and intravenous morphine was the only
analgesic used pre or intra operatively. This was given in a 
dose of 0.07rag per kg at the beginning of anaesthesia with 
further incremental doses of 2mg as required for anaesthetic 
stability. In three patients an intravenous cannula was inserted 
and heparinised for post operative blood sampling.
After the operation the patients were returned to the recovery 
room where they breathed 28 per cent oxygen from a Ventimask 
and had regular heart rate, blood pressure and respiratory rate 
measurements according to normal practice.
Subjects were assessed as normal at 5 minute intervals to 
determine their level of consciousness. When each subject was 
awake and asked for pain relief the following procedures were 
undertaken:
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1 Each patient was allocated to a dosage group 1,2 or3.
2 Patients were invited to perform an FEV/FVC manoeuvre using 
the pocket Spirometer. A pulse oximeter was used to assess 
oxygen saturation. Sedation scores were noted.
3 Patients were asked to indicate the extent of their pain 
using a 10cm linear visual analogue scale (LVA) .
4 In four patients, including one from each group, a 
peripheral intravenous sample was taken for baseline 
fentanyl analysis. The samples were centrifuged and 
separated soon after collection and the serum frozen for 
storage.
5 Each patient was positioned on his side with his head at
the edge of a pillow. A nebulised solution containing 
64 jig ml"1 fentanyl base (group 1), 159 jig ml"1 (group 2)
or 318 jig ml"1 fentanyl base (group 3) was administered. In 
each case the drug was dissolved in normal saline. Subjects 
were asked to breath slowly and deeply during nebulisation. 
The drug was nebulised such that 3 ml of solution were 
administered. (Nebulisation over 9 minutes by an oxygen 
flow of 8 1 min"1) . The nebulisers were filled with 5 ml of 
solution. The filled nebulisers were weighed before and 
after nebulisation. To prevent evaporation whilst awaiting 
weighing they were sealed in small airtight polythene bags.
6 In the four patients from whom samples had been taken
previously, peripheral intravenous blood samples were taken 
at the following times from the start of nebulisation: 1, 
3, 5, 7, 9, 11, 13, 15, 17, 19, 24, 29, 39, 49, 59, 69,
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129, and 189 minutes. The samples were centrifuged and 
separated soon after collection and the serum frozen for 
later fentanyl analysis.
7 At five minutes after nebulisation was complete 
measurements were taken of pain (using the LVA), FEV/PVC, 
respiratory rate, pulse and blood pressure. Analgesia was 
assessed by the patient on a five point rating scale.
8 If pain relief was inadequate at this point or at any point 
thereafter, the patient was offered the escape therapy. The 
escape therapy consisted of intravenous morphine titrated 
until the patient was comfortable. After receiving escape 
therapy the patient was considered to have left the trial.
9 Measurements of pain, sedation score FEV/FVC, respiratory 
rate, pulse and blood pressure were made at 15 minutes, 30 
minutes, 45 minutes, 60 minutes and thereafter at 30 
minute intervals until three hours after nebulisation or 
until the patient received escape analgesia, whichever was 
the sooner. The time to escape analgesia was noted.
10 In addition the following were noted if they occurred at
any time: cough, bronchospasm, laryngospasm, flush/rash,
headache, nausea, vomiting, euphoria, dysphoria, 
confusion, restlessness, taste in mouth, rhinorrhea, itch.
After the three hour study period or after their escape 
analgesia patients received routine analgesia as prescribed by 
the anaesthetist who gave their anaesthetic.
The next day the patients were invited to complete a brief 
questionnaire about side effects and acceptability.
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Results
Table 6.1: Concentration of Solution: jig ml-1 Fentanyl Base
Group 1 Group 2 Group 3
64 159 318
Table 6.2: Mass of Fentanyl Solution Delivered (g): mean (s.d.)
Group 1 Group 2 Group 3
3.01 (0.31) 3.10 (0.23) 2.99 (0.42) *
* Groups not significantly different at p = 0.05 Kruskal-Wallis 
test (null hypothesis: no difference between the three groups)
Tables 6.1 and 6.2
TABLE 6.3: Patient Data
Group 1 2 3
Age years 
mean (s.d.)
42.3 (14.6) 35.8 (7.2) 35.1 (11.9) *
Sex m 3m lm lm *
f 7f 9f 9f
Height cm 
mean (s.d.)
167 (8) 154 (7) 160 (7) **
Weight Kg 
mean (s.d.)
66.9 (11.7) 64.7 (12.4) 62.4 (8.3) *
Operation Laparoscopy 2 Laparoscopy 3 Laparoscopy 8
(Sterilisation 1) 
(Diagnostic 1)
(Sterilisation 3) (Sterilisation 7) 
(Diagnostic 1)
Hysterectomy 3 Hysterectomy 6 Hysterectomy 1
Herniorrhaphy 2 
Other 3
Herniorrhaphy 1 Herniorrhaphy 1
* Groups not significantly different at p = 0.05
** Groups significantly different (p < 0.01)
Kruskal-Wallis test (null hypothesis: no difference between the 
three groups)
Table 6.3
Table 6.4: Times to Escape Analgesia in Minutes
Group 1 Group 2 Group 3
Subject no. 1 80 180 + 90
2 15 5 24
3 5 5 80
4 10 5 5
5 5 12 180 +
6 5 5 5
7 5 120 10
8 5 5 180 +
9 5 5 30
10 30 5 180 +
Groups significantly different at p = 0.05 Kruskal-Wallis test 
(null hypothesis: no difference between the three groups)
Comparison between pairs of groups. Mann-Whitney U test (null 
hypothesis: no difference between groups):
1 and 2 p = 0.91
3 and 2 p = 0.08
3 and 1 p = 0.04
Table 6.4
Table 6.5: Analgesia Scores at Five Minutes after the End of 
Nebulisation
Group 1 Group 2 Group 3
Subject no. 1 3 1 3
2 2 1 2
3 1 1 2
4 1 0 0
5 1 2 2
6 1 0 1
7 0 2 2
8 1 2 2
9 0 0 3
10 3 0 2
Groups not significantly different at p = 0.05 Kruskal-Wallis 
test (null hypothesis: no difference between the three groups)
Table 6.5
TABLE 6.6: Pain Scores before Start of Nebulisation and Change 
by Five Minutes after End of Nebulisation (Maximum Pain Score = 
10)
Group 1 Group 2 Group 3
Subject no. 1 7.5 (-4.5) 5.8 (-0.7) 6.9 (-5.4)
2 6.4 (-3.3) 6.0 (-1.5) 7.7 (-2.0)
3 2.9 (-2.1) 7.3 (0.0) 4.7 (-2.1)
4 3.8 (-1.0) 8.2 (-1.3)
oorH (0.0)
5 8.9 (-2.7) 3.6 (-0.2) 5.0 (-4.0)
6 8.2 (-0.8) 7.0 (+1.3) 10.0 (-2.4
7 8.9 (+0.2) 7.7 (-4.4) 6.4 (-3.7)
8 5.3 (0.0) 8.2 (-1.5) 5.9 (-5.5)
9 8.7 (+0.2) 7.3 (0.0) 7.2 (-5.4)
10 3.9 (-3.0) 8.7 (+0.6) 6.1 (-3.6)
Kruskal-Wallis test (null hypothesis: no difference between the 
three groups):
Initial pain scores: Groups not significantly different
(p = 0.95)
Pain score changes: Groups significantly different at p = 0. 05
Comparison of pain score changes between pairs of groups. Mann- 
Whitney U test (null hypothesis: no difference between groups):
1 and 2 p = 0.28
3 and 2 p = 0.004
3 and 1 p = 0.05
Table 6.6
TABLE 6.7: Respiratory Rates (Breaths per Minute) before Start 
of Nebulisation and Change by Five Minutes After End of 
Nebulisation
Group 1 Group 2 Group 3
Subject no. 1 12 (+ 1) 16 ( + 1) 16 (-4)
2 26 (+ 2) 31 (-9) 18 (-8)
3 22 (-2) 22 (0) 26 (-12
4 16 (0) 26 (-2) 24 (-4)
5 16 (-6) 28 (-12) 16 (-4)
6 24 (+ 2) 20 (0) 24 (-8)
7 28 (-8) 14 (+2) 30 (-4)
8 26 (-2) 24 (-4) 16 (0)
9 20 (-2) 17 (-1) 26 (-6)
10 13 (+3) 28 (-4) 16 (+ 2)
Kruskal-Wallis test (null hypothesis: no difference between the 
three groups):
Initial respiratory rates: groups not significantly different
(p = 0.62)
Respiratory rate changes: groups not significantly different at 
p = 0.05
Table 6.7
TABLE 6.8: Spirometry Average (s.d.) Before Surgery, Before
Nebulisation, and Five Minutes after Nebulisation
Before
Surgery
Before
Nebulisation
After
Nebulisation
FEV1.
group 1 2.72 (0.52) 0.94 (0.48) 1.17 (0.67)
group 2 2.36 (0.64) 0.88 (0.28) 1.15 (0.19)
group 3 2.48 (0.43) 1.18 (0.59) 1.55 (0.67)
FVC Li
group 1 2.95 (0.61) 1.13 (0.55) 1.44 (0.84)
group 2 2.58 (0.74) 1.07 (0.33) 1.28 (0.26)
group 3 2.71 (0.58) 1.41 (0.56) 1.82 (0.52)
FEV/FVC
group 1 0.92 (0.06) 0.83 (0.18) 0.85 (0.11)
group 2 0.92 (0.05) 0.83 (0.14) 0.91 (0.09)
group 3 0.93 (0.07) 0.82 (0.14) 0.82 (0.19)
Table 6.8
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Combined Analysis of Drug Effect 
Each subject was ranked separately in terms of the analgesia 
scores, the pain score decreases, the respiratory rate changes 
and the time to further analgesia. A combined score then was 
calculated for each subject by taking the arithmetic mean of 
these four rank values (see page 69). The groups differed 
significantly in terms of these combined scores (p = 0.003
Kruskal-Wallis test). Using the combined scores to compare the 
groups against each other with the Mann-Whitney U test showed no 
significant difference between the two lower dose groups 1 and 2 
(p > 0.5) but a significant (p < 0.01) difference between group
_ i
3 (318 pg ml A) and each of the other two groups. It could be 
argued that the analgesia scores and the pain score changes 
should not both be included in the combined score calculation on 
the grounds that they carry the same information. However the 
analysis is essentially unchanged when it is repeated using 
combined scores calculated without analgesia scores.
Sedation Scores
All patients had a sedation score of 1 (Slight sedation responds 
to speech alone. Eyes closed most of the time) at the time they 
first requested analgesia. No subjects increased their sedation 
score after fentanyl.
PLasma Fentanvl Concentrations 
Plasma samples from four subjects were analysed for fentanyl 
concentration. Two of the subjects were in group 3 (318 pg ml"1) 
and one in each of the two lower dose groups. The results are 
shown in figures 6.1 to 6.4. Unfortunately (see chapter 7) these 
assay results are not felt to be reliable.
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Side Effects
There were no serious side effects. In particular there was no 
clinically important respiratory depression (arterial oxygen 
saturation < 90% or respiratory rate < 10) . No patient suffered 
a fall in arterial oxygen saturation as a result of treatment. 
No patient became wheezy or complained of difficulty breathing. 
The results obtained from micro-spirometry are difficult to 
interpret since all the early post operative values around the 
time of aerosol therapy are markedly reduced compared to the 
preoperative values (see table 6.8). Major factors contributing 
to this were a lack of co-ordination and motivation owing to the 
residual effects of anaesthesia. Both FEV and FVC values showed 
a gradual increase back towards pre operative values whilst the 
subjects were in the recovery room. Most of the changes in 
FEV/FVC ratios about nebulisation occurred as a result of 
disproportionate increases in either FEV or FVC values. In this 
situation changes in the FEV/FVC ratio are probably not a valid 
measure of changes in airway resistance.
None of the groups showed significant (p < 0.05 Wilcoxon
matched pairs) changes in pulse rate or systolic blood pressure 
five minutes after fentanyl compared with immediately before.
Two subjects had a slight dry cough intermittently during 
inhalation, one in group 1, one in group 2. The subject in group 
1 had been coughing before aerosol therapy.
Eight subjects complained of nausea during the study period, 
Four in group 3, two in group 1, and two in group 2. All except 
three of these (all in group three) had also been nauseated 
before fentanyl. No subjects complained of unpleasant taste.
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Questionnaires
There was generally poor recall of the treatment the next day. 
Six patients (four in group one, and two in group three) were 
either completely i unable to remember having the
treatment or remembered virtually nothing about it. In addition 
many of the remainder who did complete the questionnaire stated 
that their memories were vague or hazy. Some were clearly mixing 
up the nebuliser therapy with the spirometer measurements or the 
effect of the injected escape therapy. No new side effects were 
discovered but four patients commented that the process of 
nebulisation (noise, wetness, mask on face etc.) was unpleasant. 
Two found it soothing. The most common favourable comment was on 
the absence of injections (five patients).
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Efficacy of the Fentanvl 
Group 3, receiving the highest concentration of fentanyl (318 
jig ml”1 fentanyl base), produced larger decreases in pain score 
and respiratory rates, higher analgesia scores and longer times 
to further analgesia than both the lower dose groups (tables 6.4 
to 6.7, figures 6.5 and 6.6). The differences in analgesia 
scores and respiratory rate changes between the groups were not 
significant statistically but there were significant differences 
between group 3 and the lower dose groups in terms of the pain 
score changes, times to further analgesia and in particular, 
the combined rank scores (p 69) which were intended to give an 
overall measure of effectiveness.
None of the differences between the two lower dose groups 
approached statistical significance and it was not possible to 
distinguish between the efficacy of the two lower concentrations 
or to demonstrate a dose response relationship across the three 
groups. The 64 pg ml"1 solution produced greater pain score 
decreases and analgesia scores than the 159 pg ml”1 solution but
_ i
the 159 pg ml A solution gave longer times to further analgesia 
and caused greater slowing of respiratory rate (none of these 
changes statistically significant).
Thus patients receiving the highest fentanyl dose (group 3) 
showed greater evidence of opioid effect than patients in the 
two lower dose groups which were indistinguishable.
Unlike Worsley and colleagues' pilot study [117] which 
suggested that fentanyl might be efficacious at surprisingly low 
doses there was no evidence on this occasion that the effects 
were greater than might be expected from the plasma 
concentrations. Indeed it is hard to see any reason why the
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pharmacodynamics of fentanyl absorbed from the lung should 
differ from those of intravenously administered fentanyl which 
enters the lungs at first circulation [24, 25]. There is,
however, some evidence that drugs absorbed through the nasal 
mucosa are able to gain direct entry to the brain and
cerebrospinal fluid via the olfactory mucosa and via
communications between the subarachnoid space and nasal cavities 
[122]. It seems unlikely that this could have a significant 
effect on dynamics in the case of a rapidly equilibrating drug 
like fentanyl but the possibility is intriguing and could be 
tested with an experiment that simultaneously made a precise
examination of pharmacodynamics and pharmacokinetics (as for 
example in the work of Scott, Poganis and Stanski [31] who 
related opioid-induced EEG changes to plasma concentrations in 
the study of intravenous fentanyl and alfentanil).
In a given patient the plasma concentration range, and hence 
usually the dose range, over which fentanyl causes useful 
analgesia without marked respiratory depression is quite small 
(chapter 1) . This will be particularly so in the immediate 
postoperative period in the presence of other respiratory 
depressants. If, as appears, the strongest solution here was 
giving measurable analgesia without marked respiratory 
depression it is likely that both the weaker solutions were 
resulting in doses that were only marginally or not at all 
effective. The trial was unlikely to show up a marginal 
difference in effectiveness between solutions because of the 
many sources of variability. The present experiment was 
designed with three groups to cover a wide range of doses since 
we had little idea of what fentanyl concentration would give
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doses in the correct range. Given this knowledge, efficacy might 
have been more elegantly demonstrated using two dose groups 
only.
Pain and Analgesia Scores 
The agreement between pain score decreases and analgesia scores 
is shown in figure 6.7. There is a large scatter in the 
individual matching of pain score decreases to analgesia scores 
but the agreement between analgesia scores and average pain 
score changes is surprisingly good. Intergroup differences in 
pain score decreases and analgesia scores are in the same 
direction (tables 6.5 and 6.6) but the pain scores are a more 
sensitive measure in that the p values are lower. This is in 
agreement with the findings of other investigators (chapter 4) 
and it increases confidence in the validity of pain scores in 
this difficult situation where cognitive and motor functions are 
impaired by residual anaesthetic drugs. Interestingly, there was 
nothing to choose on this occasion between using absolute and 
proportional changes in pain score (chapter 4) since pain score 
changes and proportional pain score changes were roughly 
linearly related (figure 6.8). Neither was there an obvious 
relationship between initial pain scores and pain score 
decreases (figure 6.9).
Subject Characteristics 
Subjects were not limited to those undergoing a standardised 
procedure. We thought it preferable to have a range of common 
postoperative patients in each dose group thereby making the 
findings more widely applicable. Unfortunately the trial was not 
large enough for the distribution of operations to even out and 
the groups are not matched in terms of surgery. In particular
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there is a marked preponderance of laparoscopies in the high 
dose group as opposed to the other groups. The severity and 
natural history of postoperative pain will depend to some extent 
on the nature of the surgery so this chance imbalance is 
unfortunate since it weakens the argument for attributing the 
apparently better analgesia in the high dose group to fentanyl. 
However, the pre-analgesia pain scores in all three groups are 
well matched. Furthermore even in the high dose group all but 
three subjects requested further opiate analgesia within three 
hours of receiving fentanyl. This would indicate that the 
analgesia attributed to fentanyl was not purely an artefact of 
post laparoscopy pain being mild or fleeting. The effect (trend) 
on respiratory rates is unlikely to be influenced by the nature 
of the surgical procedures.
Blinding
The blinding of the experiment can be criticised as all the 
ampoules of the same concentration were marked with the same 
code. This arrangement was made in order that the collection of 
blood samples could be arranged efficiently to include the 
various dose groups in equal proportion. At the time the trial 
was started it was hoped that it would be possible to assay the 
blood from more patients than proved the case. With hindsight it 
would have been a better arrangement to have made the blinding 
watertight and to have used separate additional subjects for the 
few analyses we were able to carry out.
Measurement of Respiratory Rates 
Changes in respiratory rate are a useful objective sign of 
opioid effect, particularly in a controlled comparative trial
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(although only a suggestive trend was seen on this occasion). It 
was surprisingly difficult to measure respiratory rates without 
disturbing the patients, a combination of listening, inspection 
and sometimes palpation being required. Measurement often took 
over a minute. The patients consequent awareness of the process 
may have altered respiratory pattern. An automated method of 
measuring respiratory rate unobtrusively, for instance by 
sensing exhaled carbon dioxide and movement of the chest and 
abdomen [116] would be of great benefit in a similar trial.
Plasma Concentrations 
The fentanyl radioimmunoassay proved disappointingly inaccurate 
in my hands to the extent that the results cannot be regarded as 
reliable. The procedure is very susceptible to laboratory 
technique [112] and is therefore best performed by someone who 
has practice in its use. Unfortunately this was not possible. 
The assay was performed in duplicate and the overall
coefficient of variation between the paired samples was high at 
16.3%. The instruction booklet gives typical examples around 5%. 
(Woestenborghs and colleagues [113] however found a coefficient 
of variation of 14.2% at a fentanyl concentration of 0.25 ng ml"1 
though it was around 5% at higher concentrations). Furthermore 
for all four patients there was a difference between the counts 
obtained from the standard blank (no fentanyl) and the first 
patient samples (which were drawn before the start of analgesia 
and should also have been free of fentanyl). The effect of this 
was to indicate a small amount of fentanyl in these base line
_ i
samples (around 0.1 ng ml A where the claimed detection 
threshold of 0.02 ng per tube corresponds to 0.04 ng ml"1). 
Although in theory this effect could have been caused by cross
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reaction between antibody and another constituent in the plasma 
samples it most likely reflects unknown technical errors. One 
specific error should be noted. In the preparation of the 
standard samples for the calibration curve an incorrect amount 
of buffer solution was pipetted into the tubes. This was noticed 
and corrected at a later stage but meant that the fentanyl / 
tritiated fentanyl / antibody reaction took place in a smaller 
absolute volume in the standards compared with the samples 
although relative concentrations of the three reactants were not 
altered. For financial and logistic reasons it was not possible 
to repeat the assay.
Because of the uncertain accuracy of the plasma concentrations 
detailed analysis is not justifiable although the following 
general points may be noted.
Peak plasma concentrations of around 1 ng ml"1 were found in the 
two patients who received the 318 ng ml"1 fentanyl solution. 
Concentrations in the other two subjects were lower. Such 
concentrations are just compatible with a clinical picture of 
analgesia with slight respiratory depression especially since 
arterial concentrations would have almost certainly been higher, 
and the subjects had also received morphine and anaesthetic 
drugs (see chapter 2) . The plasma concentration rose sharply 
within a minute or so of starting the nebulisation and fell 
again as soon as nebulisation ceased but, in the case of two 
subjects, remain at around a third and a half of peak value for 
the three hours of the study.
The Method of Delivery: Jet nebulisation, as expected, is a very 
inefficient way to deliver fentanyl. A comparatively 
concentrated (and commercially unavailable) solution is
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required. On this occasion in order to maximise the efficiency 
of the nebulisation the last 2 ml (636 pg in group 3) were 
discarded. Even if the solutions were nebulised to the point 
where aerosol production ceased there would still be a 
considerable wasted residual volume (chapter 3). Of the 
nebulised 3 ml (954 pg in group 3) it is likely that only a 
relatively small proportion, perhaps in the region of 200 pg or 
so, is absorbed by the patient. The actual dose received will 
vary greatly between patients depending on the pattern of 
respiration.
The method is also awkward. Constant supervision was required to 
keep the mask in position, the nebuliser upright and the tubing 
attached. Drug administration is relatively slow. Several 
patients disliked the experience. In order to exploit the 
benefits of the respiratory route a more efficient, and 
convenient means of delivery is required. We are hoping that the 
continuation of this work will involve the design and testing of 
a suitable hand-held pressurised fentanyl aerosol dispenser.
Summary
The trial would have been improved if only two groups had been 
used corresponding to the highest and the lowest dose groups in 
the present trial,if the blinding had been unimpeachable and if 
one class of patients had been chosen, all undergoing the same 
operation with a completely standardised anaesthetic. 
Nevertheless the evidence suggests that it is possible to 
deliver fentanyl effectively and safely via the respiratory 
route. In order to do this with a standard jet nebuliser a high 
concentration of fentanyl citrate solution (around 318 pg ml 
fentanyl base) is required. The method tested is very
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inefficient and awkward but these problems could be overcome 
with better techniques of delivery such as the use of 
pressurised inhalers.
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Summary and Conclusions
1
1) The study! examines j the efficacy of nebulised
inhaled fentanyl for post-operative pain relief.
2) There were no major side effects following administration 
to 30 patients.
3) The particular regimen we employed has major disadvantages 
and would not be suitable for general use. It might be 
profitable to develop and evaluate more convenient methods 
of delivering intrapulmonary fentanyl such as small 
pressurised inhalers.
4) Improvements in trial design were discussed.
5) Within the limits of the trial design the study suggests 
possible efficacy of nebulised inhaled fentanyl for 
postoperative pain relief.
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A PHYSIOLOGICAL MODEL OF FENTANYL PHARMACOKINETICS
CHAPTER 9
Rationale and Aims
chapter 9
In conventional pharmacokinetics drug concentration changes in 
plasma are usually described in terms of empirical corapartraental 
models. The models correspond to reality in that the physical 
processes responsible for these changes, redistribution of drug 
from the plasma to the rest of the body and elimination of drug 
from the body, have explicit mathematical representation. 
However the models have no representation of the mechanisms 
whereby elimination, distribution or relevant physiological 
processes occur and the model compartments between which drug 
moves are mathematical devices with no direct relation to 
physical entities. Empirical compartmental models cannot 
therefore predict the effect of alterations in the real 
structure and function of the system.
Once a model has been fitted to a set of plasma concentration 
data and the appropriate constants determined the model can be 
used to calculate the plasma concentration at any time during or 
after any pattern of drug administration providing the rate of 
entry of drug into the plasma can be constantly specified and 
providing the physical system under study (i.e. the subject(s) 
and their physiological state) remains the same a^ the one in 
which the model was originally determined. In real life the 
quantitative predictive abilities of such models are much 
diminished by biological variation and constantly changing 
physiological conditions. Even so they provide a powerful 
conceptual framework for the qualitative understanding of some 
common pharmacokinetic phenomena such as the marked prolongation 
of effect that may emerge with large or repeated doses.
The predictive ability of these models is best for intravenous 
administration where entry of drug into the plasma can be
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directly measured. For other routes e.g. intramuscular, oral or 
nasal an empirical relationship must be determined between the 
pattern of drug administration and the entry of drug into the 
plasma. Where data do not exist to determine this 
relationship, as for instance in the intranasal or 
intrapulmonary administration of fentanyl, conventional models 
are of little help either quantitatively or conceptually.
Whilst developing the theoretical background to the clinical 
trial of inhaled fentanyl I became aware of alternative 
pharmacokinetic approaches and in particular the work of 
Mapleson [127] in developing realistic physiological models of 
drug kinetics. In this approach explicit representation is made 
of the mechanisms (diffusional equilibration, mass transport, 
metabolism and excretion) that determine drug entry into, 
disposition within and exit from the body. This type of model 
has the theoretical advantage that if it were fully valid and 
provided it were possible to measure all the relevant anatomical 
and physiological variables, it would be possible not only to 
adjust the model to any individual but to incorporate the 
effects of ongoing physiological changes. In these terras the
models remain at an early stage of development. Nevertheless
<
they are extremely useful for exploring the interrelations of 
factors governing drug concentrations in different parts of the 
body (including locations where concentrations could normally 
not be measured) . The basic elements of which the models are 
built can be rearranged or extended to make predictions about 
new situations such as new routes of absorption.
A physiological model of fentanyl kinetics able to encompass all 
methods of administration would thus be particularly useful
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during the development of new routes. For instance it might help 
answer the questions of the possible mechanisms and likely rate 
of absorption following deposition on the nasal mucosa. Again, 
there have been some tantalising suggestions that administering 
drug through the respiratory tract might produce greater effect 
than one would expect at the same plasma concentrations 
following intravenous injection [117, 120, 121]. A suitable
physiological model could be used to explore possible 
differences between intrapulmonary and intravenous 
administration in terms of initial drug concentration changes in 
arterial plasma and brain tissue. Similarly, a comparison 
between methods of the time course of arterio-venous 
concentration differences and the role played by tissue binding 
in lung would be of interest. In addition there are particular 
problems with the conventional approach to fentanyl 
pharmacokinetics. The inconsistency between different 
estimations of pharmacokinetic constants and the consequent poor 
predictive power of conventional kinetic models has been 
discussed in chapter 1. Conventional pharmacokinetic models are 
not able to throw any light on phenomena such as the occurrence 
of secondary peaks in fentanyl concentration as a result of 
changes in drug distribution.
Ideally one would be able to use a physiological model to make 
accurate predictions of specific measurements. However an 
equally valid, and probably at the moment more realistic, role 
is in the qualitative exploration of alternative situations. At 
the very least such a model should provide a single conceptual 
framework within which to address disparate ^uesbibnsl 
Mapleson's models [127, 128] were originally developed for
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inhaled volatile anaesthetic agents, however Davis [125, 126,
129] has extended Model P to encompass injected pethidine. As a 
step towards developing a comprehensive physiological model for 
use as described, I felt it would be worthwhile to attempt the 
adaptation of Davis's pethidine version to cover the respiratory 
administration of fentanyl.
The remainder of part 2 concerns this project. The next chapter, 
chapter 10, describes Davis's existing model for injected 
pethidine. Chapter 11 summarises the method of the present 
project and discusses rewriting the original pethidine program. 
Chapters 12 and 13 describe adding a nasal compartment and 
quantifying the model for fentanyl. A summary of the new 
fentanyl program is presented in chapter 14 and evaluation is 
discussed and conclusions presented in chapters 15 and 16. The 
complete fully commented listing of the fentanyl program is 
given as appendix 1 to this thesis and compiled versions of both 
programs are enclosed in the back cover on a 5.25" floppy disk.
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Davis's Physiological Model of Pethidine 
Pharmacokinetics
chapter 10
Davis's physiological model of injected (intramuscular or 
intravenous), pethidine kinetics exists in the form of a Fortran 
computer program suitable for running on a mainframe computer. 
Both the program and detailed descriptions of the model, its 
derivation and quantification have been published [125, 126,
129], However a brief outline of the structure of the model is 
necessary in order make the following chapters intelligible. 
Some of the mathematical symbols below differ from those used 
by Davis but otherwise this chapter summarises the account given 
in his thesis [125].
General Description 
The model is based on an ideal man. Its central features 
(figure 10.1) are a division of the bloodless body mass into 
various discrete blocks and a representation of the blood 
circulation (including the hepatic portal circulation) which 
simulates both the rates of blood volume flow and the mean 
transit time (i.e. volume of blood between two points divided by 
flow) through these blocks. This allows a realistic 
representation of the distribution of drug (given as the local 
concentrations) between the tissues and different regions of the 
circulation at any time.
The gut and spleen, kidney, liver, and lung blocks correspond 
to their anatomical counterparts, the rest of the body mass is 
divided between four blocks; unperfused tissue, other viscera, 
lean and fat on the basis of relative blood flow. There are, in 
addition, (see below) two other blocks; sample brain and 
intramuscular injection site which have been given almost 
negligible mass.
The total volume of the circulation is realistic. The volume
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Figure 10.1 
The Physiological Model
1 LUNGS (0.464 kg)
INJECTION 
POOL 
(0.674 1)
MIXED
VENOUS
POOL
(0.674 1)
PERIPHERAL SHUNT-f-
ARTERIAL
POOL
(0.674 I)
e xcre t io n f- - - - - - - ^
PORTAL
POOL
4 GUT AND SPLEEN (1.391 kg)
5 LIVER (1.721 kg)
3 KIDNEYS (0.284 kg)
metabol i s m ^ -------- 1
UNPERFUSED TISSUE (8.358 kg)
9 SAMPLE BRAIN (0.007 kg)
10 IM INJECTION SITE (0.01 kg)
6 OTHER VISCERA (1.880 kg)
7 MUSCLE (LEAN) (36.713 kg)
MUSCLE
POOL
FAT
POOL
11 NASAL MUCOSAL SITE (0.0083 kg ^ -1+ 0.0004 kg mucus) V.
The numbers on the tissue blocks are the labels used in the computer program. The 
mass of each tissue block and the resting volumes (between calculation cycles) of 
the blood pools are given in brackets. Density of blood = 1.06 kg 1 . Total mass
of model man (excluding blocks 9 to 11) = 70.001 Kg.
Adapted from Davis [125]
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distribution of the circulation and hence the blood transit 
times, are modelled by placing blood pools in series with and 
downstream of each tissue block.
Blood is circulated in discrete aliquots or "stroke volumes". 
The size of each "stroke volume" is given by:
_ i
(10.1) cardiac output (litres s i) x cycle time (s)
where cycle time is the elapsed time represented by each 
calculation cycle. Divergent blood flow from the arterial pool 
to the tissues is achieved by splitting the stroke volume into 
fractional stroke volumes in proportion to the cardiac output to 
each tissue block. The sum of the fractional stroke volumes is 
equal to one stroke volume.
At the start of a calculation cycle all the blood is in the
pools. One calculation cycle involves computing the local
concentration changes consequent on the simultaneous removal of
a stroke volume or fractional stroke volume of blood from each 
of the pools followed by its addition to and instantaneous
mixing with the next pool downstream. If a tissue block 
separates the two pools, drug is distributed between the blood 
and the tissue block as described below before the blood is 
mixed with the downstream pool. The two fractional stroke 
volumes which converge on the liver from the portal pool and 
from the arterial pool are added together before drug is 
distributed between the combined blood and the liver tissue.
Drug may be added directly into the blood (venous injection 
pool) or into the tissues (intramuscular injection block). Drug 
leaves the system by excretion from blood entering the renal 
block or metabolism from the blood entering the liver block
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after mixing of the arterial and portal fractions. Otherwise the 
total mass of drug in the system is conserved.
If the mass of drug which moves from each (fractional) stroke 
volume into the corresponding tissue block (or vice versa) at 
each cycle is known, together with the amounts of drug 
administered and eliminated then the concentration changes 
which result from the circulation of the blood can be calculated 
by keeping a tally of drug movement. For example to calculate
the change in drug concentration over one cycle in the
injection pool:
(10.2) babiold = apiold / wpi
(10.3) afiout = aPiold x (svw / wpi)
(10.4) afvout = apvold x (svw / wpv)
(10.5) afiin = afvout
(10.6) apinew = apiold + afiin - afiout + dose
(10.7) babinew = apinew / wpi 
where
babiol£ = concentration drug injection pool: start of cycle
babinew = concentration drug injection pool: end of cycle
afiou-t- = mass drug in blood leaving injection pool
afvQut = mass drug in blood leaving mixed venous pool
afiin = mass drug in blood entering injection pool 
apv0id - mass drug mixed venous pool: start of cycle 
api0id = mass drug injection pool: start of cycle 
apinew = mass drug injection pool: end of cycle 
dose = mass drug administered in that cycle
wpi = mass blood in injection pool
wpv = mass blood in mixed venous pool
svw = mass blood in stroke volume
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Drug Distribution Within and Between Blood and Tissue 
Each tissue block is characterised in terms of the proportion of 
cells and extracellular fluid (ecf) it contains. Each of these 
subdivisions is further characterised in terms of the proportion 
of its mass made up of water, fat and protein. The four non- 
anatomical blocks are given the average characteristics of their 
constituents. Blood also is divided into cells and plasma which 
are in turn divided into water, fat and protein.
In life, as blood passes through the tissues, drug will diffuse
from plasma in the capillaries into the ecf and cells of the
tissues (or vice versa if plasma drug concentration is low 
compared to tissue concentration). As the concentration of drug 
in plasma changes there will be a simultaneous redistribution of 
drug between red cells and plasma. The lipid membranes of the 
tissue cells, red cells and capillaries act as diffusion 
barriers which slow the passage of drug. However, providing the 
drug is lipid soluble enough, diffusion equilibrium is reached 
during the blood's passage through the tissue and drug 
distribution is said to be perfusion as opposed to diffusion 
limited. This is the case assumed in the model.
In aqueous solution drugs such as pethidine or fentanyl are
present in two forms, ionised and unionised whose relative
proportions depend on the pH. The model contains equations which 
give the pH in each compartment from the plasma pH.
Drug distribution between each tissue block and its 
corresponding fractional stroke volume (or whole stroke volume 
in the case of the lungs) of blood is thus modelled by 
calculating the equilibrium distribution of both drug species 
(ionised and unionised) between the three constituents
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(water,fat and protein) of each of the four compartments (tissue 
cells, blood cells, plasma and ecf).
Derivation of equilibrium calculation: Equation 10.8 relates the 
total amount of drug present in a compartment to the 
concentrations of each species in the different constituents.
(10.8) Aax = Wtx .(Cbx .gpx + Clx .flx + Csx .fwx + Cix .fwx ) 
where
Aax = Total amount drug (mmol) in compartment x
Ci = aqueous concentration ionised drug (mmol drug / g water)
Cs = aqueous concentration unionised drug (mmol drug / g water)
Cl = concentration of drug in lipid (mmol drug / g lipid)
Cb = ratio (mmol bound drug / mmol protein)
gp = concentration protein (mmol protein / g compartment mass) 
fl = concentration lipid (g lipid / g compartment mass)
fw = concentration water (g water / g compartment mass)
Wt = Mass of compartment (g)
At equilibrium the aqueous concentration of unionised drug is 
assumed to be the same in all four compartments since unionised 
drug, unlike the ionised species, diffuses freely across
membranous lipid barriers. The other concentrations in each 
compartment may be related to the unionised aqueous 
concentration as follows:
The aqueous concentration of ionised drug will reach an
equilibrium with the aqueous concentration of unionised drug 
according to the Henderson-Haselbach equation (shown here for a 
basic drug and rearranged conveniently).
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(10.9) Ci = Cs.lo(pKa " pH) 
where
pKa = negative logarithm of the acid dissociation constant 
pH = pH in the compartment concerned
The unionised drug equilibrates between aqueous and lipid phases 
according to an appropriate solubility coefficient. The ionised 
form is lipid insoluble.
(10.10) Cl = Cs.lambda 
where
lambda = lipid solubility coefficient
Finally, binding to protein is characterised according to the 
Scatchard equation which is derived directly from the law of 
mass action [164, 165] and describes the relationship between
the equilibrium concentrations of free drug, bound drug and 
protein in aqueous solution. Two situations are considered (see 
chapter 13) in alternative forms of the model: one in which only 
unionised drug binds to protein and one in which both unionised 
and ionised forms bind with equal avidity. The Scatchard 
equation for binding of unionised drug only is shown here.
(10.11) Cb = n.k.Cs
(1 + k.Cs)
where
n = a constant (number of binding sites per protein molecule) 
k = binding constant
The total amount of drug present in a tissue block and its 
associated (fractional) stroke volume of blood is simply given 
by the sum of the amounts in the constituent compartments:
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(10.12) Aabt = Aap + Aar + Aac + Aae 
where
bt = tissue block and (fractional) stroke volume of blood 
c = tissue cells 
p = plasma
e = eof
r = red blood cells
Equations 10.9 to 10.11 may be substituted in equations 10.8 and 
10.12 to give equation 10.13 which relates the total amount of 
drug present in the blood and tissue mass (Aabb) to the (same in 
all compartments) unionised aqueous concentration at equilibrium 
(Cs) .
(10.13) Aabt =
Wtp .
wtr.
np.kp.Cs.gpp + Cs.lambda.flp + Cs.fwp + Cs.l0^pKa " .fwp
1 + k.Cs
nr .kr .Cs.gpr + Cs .lambda.flr + Cs.fwr + C s . l 0 ^ Ka ” PHr) .fwr
1 + k.Cs
wtc. nc .kc .Cs.gpc + Cs.lambda.flc + Cs.fwc + Cs.l0^pKa ” PHc).fw(
1 + k.Cs
wte. ne .ke .Cs.gpe + Cs.lambda.fle + Cs.fwe + C s . l 0 ^ Ka " PHe) .fwe
1 + k.Cs
Aabt is known from tally keeping. Equation 10.13 is solved by an
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iterative method to give Cs and thence the total drug 
concentrations and amounts in each of the four compartments.
Note on sample brain and injection compartments: The sample
brain tissue has the estimated characteristics of real brain 
including blood content and perfusion per unit mass but has a 
mass (7 g) only a small fraction the mass of the complete brain 
(which is included in the "other visceral" tissue block). The 
device of giving sampling compartments very small mass allows 
additional sampling compartments to be added to and removed 
from the model at will without having to consider the effect on 
the overall distribution of blood, tissue and drug. The 
concentrations of drug in the tissue calculated by equilibrium 
with arterial blood will be unaltered by the absolute size of 
the tissue block providing perfusion is correctly scaled. The 
intramuscular compartment and in the new version the nasal 
compartment are also so small as to have negligible effect on 
the overall performance of the model.
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Method.
Replication of the Existing Model
chapter 11
The immediate aim of the project was to quantify Davis's 
pethidine model [125] for fentanyl and extend it for the 
administration of drug into the respiratory tract. The model 
already has a lung compartment perfused by the pulmonary 
circulation and drug may be simply added into the lung tissue 
at the end of a relevant calculation cycle and distributed 
between the lung and the perfusing blood at the next cycle. This 
takes no account of the processes of drug inhalation, deposition 
and absorption. The model would lend itself to such extension 
but the task is too large for the present occasion. A first step 
in the construction of such a comprehensive model would probably 
be to incorporate an existing model of aerosol deposition [e.g. 
63]. For each administered dose the prevalent breathing 
pattern, and the size distribution, chemical composition, 
inhaled particle density and method of administration of the 
aerosol would have to be specified.
The simpler arrangement of adding drug directly into the lung 
tissue is useful in that it represents an idealised "best case" 
for comparison with intravenous administration.
During aerosol inhalation an important proportion of the inhaled 
drug may be deposited in the upper respiratory tract which is 
perfused by the systemic circulation. Drug deposited in the 
mouth and pharynx is probably rapidly washed away by saliva and 
swallowed but there is likely to be significant absorption from 
the nasal mucosa. The nasal mucosa is increasingly often 
targeted as an area for drug administration in its own right. A 
nasal compartment would thus be a useful addition to the basic 
model.
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Method
The following method was used:
1) The original program was rewritten in a form convenient 
for use by people with minimal computer expertise on a 
microcomputer of the kind available in this department.
2) A nasal compartment was added and the program modified to 
allow drug administration directly into the lung tissue.
3) A version of the program was quantified for fentanyl.
4) The model was evaluated with particular regard to the 
purposes suggested in chapter 9*
Rewriting the Original Model 
In the following sections there are necessarily references to 
subroutines and variable names from the original program. For
further details see Davis [125]. Rewriting was carried out using
the quantifying data and detailed model description given by 
Davis [125]. The exercise had two main purposes. Firstly to 
familiarise myself with the model and to gain programming 
expertise. Secondly to allow the model to be checked for 
correctness at this intermediate stage against the published 
simulation data from the original. It would also result in a
useful working version of the pethidine model.
Agreement with the original model: I was unable to get the
simulation output to match that published by Davis [125]. A 
careful comparative scrutiny of the old and new programs in 
collaboration with Davis who provided a full list of input data, 
the listing of a working version of the program and detailed 
simulation results lead to the discovery of previously unnoticed 
faults but also to several errors in his original program. The
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original program exists in several versions of which two are
given in Davis's thesis [125]. Not all the errors are present in
all versions.
The errors are:
1) In the subroutine lamset the variable rkar is used in the 
place of rkap in the calculation of mp.
2) In the subroutines pend and lamset in the common block 
statement pdlt the arrays phe(15) and phc(15) are 
transposed compared with the common block statement in the 
main program resulting in the transposition of their 
values.
3) In the subroutine tbrat in the calculation of baer an 
erratic + sign occurs so that 10.0** becomes 1+0.0** and 
the value of the calculation is changed.
4) In the subroutine blconc both in the calculation of bap and 
bar the sign for exponentiation ** is used in place of the 
sign for multiplication * changing the values of the 
calculations (not in the main listing given in the thesis)
5) In the main program in the calling routine for subroutine 
tbrat the variable bpratio is translocated from the end to 
the middle of the calling statement resulting in a complex 
transposition of variable values (not in the main listing 
given in the thesis).
6) In the main program time is incremented inbetween calling 
N the subroutines blconc and tbrat which each calculate part
of the results set. Thus results from the same calculation 
cycle are attributed to different simulation times (and 
vice versa).
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In addition the value of 6n£ variable, /s . incorrectly given in 
Davis's thesis [125]:
thesis correct
rkar 0.12287 0.012287
Kg tissue / kg total mass
tissue 4 0.1990 0.0199
Once these discrepancies had been taken into account the new and 
the old versions of the program agreed exactly and later 
versions of the program incorporating slight modifications could 
be compared against this correct "standard". The existence of 
these errors may have implications for the published 
quantitative evaluation of the pethidine model and the choice of 
best alternative parameter values. (The version enclosed with 
this thesis although "correct" has not yet been re-evaluated).
Final version of pethidine program The final version of the 
pethidine program written for this project differed from the 
original in the presence of a nasal compartment, input routines 
to accept drug dose information and variable changes from a 
keyboard, and the program output (see note page 179). In 
addition two small changes were made to the mathematics:
1) The sum of the fractional stroke volumes was made equal to 
exactly unity. As previously written there was a slight tendency 
for drug to accumulate in the arterial pool since the combined 
stroke volume entering from the lungs was slightly larger than 
the sum of the fractional stroke volumes leaving for the 
tissues. Similarly there was a tendency for drug to be 
excessively removed from the mixed venous pool. (The weights of 
'the tissue blocks jas a proportion of total body mass were also
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specified more precisely to give absolute weights which were 
correct to the nearest gram).
2) Originally two different iterative methods were used to 
solve the equation for equilibration of drug between blood and 
tissue in subroutine equil and the equation for equilibration 
between red cells and plasma in the subroutine blconc. The 
method used in equil (which uses the differential to provide 
estimates of the dependent variable) was adapted for blconc 
since it is superior in that it solves the equation to a given 
tolerance in much fewer iterations.
Note On the Programming Language 
Both the new version of the pethidine program and the adaptation 
to fentanyl were written in Turbo Basic. Turbo Basic is a 
compiled language marketed by Borland International Inc. and is 
a development of Basic. It is relatively easy language for a 
programming novice. It lends itself to making programs which are 
"friendly" at the time of use, for instance it is easy to devise 
keyboard input routines which incorporate simple error checks 
and allow re-input of correct information if necessary. Turbo 
basic was already in use in this department when the project was 
undertaken.
Unfortunately, the language has a serious drawback which only 
became apparent once the project was well underway and which 
cost many hours of programming time. There is no obligation to 
declare variables in the start of the main program. New 
variables if not allocated a value are given the default value 
zero the first time they are used. Similarly the declaration of 
variables in subroutines is optional. If variables are not 
declared "common" to a subroutine and main program they are
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given the default type "static" (i.e. recognised by that 
subroutine only but keep their value between callings of the 
subroutine) and if necessary given a default value of zero. This 
means that not only may accidental failure to declare a variable 
to a subroutine go unnoticed, with the result that a value is 
not passed, but misspellings of variables, either in the main 
program or in subroutines, may also go unremarked with 
consequent distortion of the calculations. As there is a large 
number of variables in these programs such errors were fairly 
common and time consuming to weed out. Furthermore it was 
difficult to recognise their presence unless they occasioned 
final numerical results which were obviously incongruous. In the 
case of the the fentanyl program there was no standard against 
which its output could be checked and the only solution was 
careful checking of the program listing. Thus a design 
presumably intended to simplify programming in fact detracts 
from the safety of the language and adds difficulty. I would not 
recommend Turbo Basic for future similar applications.
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Addition of a Nasal Compartment
chapter 12
To allow nasal administration of drug I had to add a nasal 
compartment to the model. The compartment consists of a mass of 
nasal mucosa, its associated mucus and perfusing blood. Its 
quantitative features were based on the following anatomy and 
physiology.
Anatomy and Physiology 
Gross Anatomy; The paired nasal cavities are irregular,
high, narrow slits separated by the nasal septum and extending 
from the nares anteriorly to the posterior choanae where they 
open into the naso-pharynx. Several large air-filled cavities 
lined with respiratory mucosa, the paranasal sinuses, open off 
the nasal cavities by small apertures. The distance from the 
nares to the posterior wall is around 12 to 14 cm. The combined 
surface area of both cavities excluding the paranasal sinuses is 
about 150 cm2 and the combined volume about 15 cm3 [136].
The nasal cavities are lined throughout by mucus membrane which 
is continuous with the periosteum and perichondrium of the bone 
and cartilage walls.
The mucus membrane: The mucus membrane consists of an epithelium 
separated from a lamina propria by a basement membrane [136). 
The lamina propria merges with the underlying perichondrium or 
periosteum. Most of the epithelium consists of ciliated 
pseudostratified columnar epithelium, but anteriorly a mixture 
of types are found and the epithelium becomes squamous towards 
the nares. The olfactory epithelium is a patch of specialised
o
epithelium of about 10 cur each side on the upper posterior 
aspect of the cavities. The lamina propria may be divided into 
four indistinct layers (figure 12.1).
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Redrawn from Myngind [136].
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Mucosal blood supply: Immediately below the epithelial membrane 
is a layer rich in large capillaries. The capillaries are 
fenestrated and have (in common with the arterioles and venules 
of the mucus membrane) an unusually porous basement membrane. 
The fenestrations are described as openings in the epithelial 
lining where the endothelial cell consists of only a single 
membrane, this membrane along with the basement membrane 
constituting the barrier between blood plasma and tissue fluid. 
[135, 136]. This arrangement will obviously speed the
equilibration of lipid soluble molecules. The implications for 
large ionised molecules (such as ionised fentanyl) are not 
clear.
Deeper in the mucosa is found the cavernous plexus of venous 
sinusoids. When the sinusoids are engorged the blood content and 
thickness of the mucosa are considerably increased. The 
sinusoids receive blood from capillaries draining the surface 
layer and surrounding -glands but also direct by arteriovenous 
anastomoses. The filling of the sinusoids is probably regulated 
by a combination of functional sphincters controlling input from 
the anastomoses and sphincters controlling the outflow 
resistance [135]. In the cat Anggard [137] estimated 60% of the 
nasal mucosal blood flow went through the arteriovenous 
anastomoses. Capillary flow was 0.5 ml min"1 g mucosal tissue"1. 
Capillary flow was less variable than shunt flow in response to 
sympathetic nervous stimulation.
In man, total nasal mucosal blood flow has repeatedly been
-1 -1estimated as about 0.4 ml A g in the mucosa of the nasal 
passage by a technique based on the clearance of injected 
radioactive Xenon [138, 139, 140, 141].
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Blood flow in the mucosa of the human maxillary paranasal sinus 
has been estimated as 1.25 ml min”* cm”  ^ and 0.88 ml min“* cnT^ 
by a plethysmographic technique and 0.93 ml m i n ”* cm'** by 
clearance of xenon [142, 143]. However these estimates of sinus 
mucosal blood flow were calculated using an estimated mucosal 
thickness of 125 p^which is at the lower range of the likely Jrr\ 
values (see below). If the mucosa were thicker the blood flow 
per unit volume tissue would be reduced proportionately. The 
mucosa in the paranasal sinuses is very similar to that in the 
nasal cavity but there is no cavernous plexus [135].
Mucosal thickness: The thickness of the mucosa varies in
different parts of the nose, mainly because of variation in the 
the amount of cavernous tissue present. In the nasal cavity 
proper it ranges from several hundred \ij to about 5 mm [135, m) 
144]. Drettner [145] gives the thickness of the mucosa in the 
paranasal sinuses as between 100 and 500 p^ There are no venous w  
sinusoids or glands in the mucosa of the paranasal sinuses. In 
one of the micrographs of the mucosa of the nasal cavity 
presented by Cauna [135], the sinusoids of the cavernous plexus 
begin 200 to 400 pi below the epithelial surface. The IRCP report 
on reference man [151] estimates nasal mucosal thickness as 
2 mm.
Nasal mucous: The ciliated epithelium of the nasal cavity is 
covered with a continuous layer of mucous. Widdicombe and Wells 
have reviewed the composition and physiology of nasal mucous 
[147]. Mucous is a mixture of secretions from various cells, 
(some of which are collected into glands) and plasma 
transudate. On the epithelium the mucus is in two layers, a 
watery layer surrounding the epithelial cilia and a superficial
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viscous layer which is moved along by the beating cilia in the 
manner of a conveyer belt. The thick layer may be completely 
continuous or may exist in.confluent plaques.
The viscous properties of mucous derive from its high content of 
glycoproteins which account for 70 to 80% of its dry weight. 
Glycoproteins consist of polypeptide chains linked by sugar side 
chains. The resulting polymers aggregate to form a continuous 
network. Mucus glycoproteins contain 50 to 80% carbohydrate (as 
opposed to the glycoproteins found in plasma which contain less 
than 25% and are associated with different sugar residues) . In 
addition to glycoproteins and inorganic salts many other 
proteins are present, some of which, for example albumin, are 
also found in plasma. The total protein content of mucus has
_ i
been measured as 6.36 mg ml ■L [146] which if mucus water content 
were 94% [122] would be an aqueous concentration of 6.77 mg ml'1. 
(This figure refers to "whole mucus": mucus can be separated in 
the laboratory by centrifugation into watery gel and viscous sol
layers which may or may not correspond to their in vivo
counterparts). Techniques for estimating total protein content 
in mucus are likely to measure the polypeptide chains in the 
glycoproteins but exclude the associated carbohydrate residues 
[147].
Mucus from the lower airways contains some lipid, partly as a 
consequence of the presence of cellular debris. Lipid content of 
nasal secretions is unknown [147].
The pH of nasal secretions in health is between 5.5 and 6.5
[122] .
Thickness of the mucus layer: The watery layer of mucus extends 
to the tips of the epithelial cilia which are 4 to 6 \ij long ryv
130
chapter 12
[136]. The depth of this layer appears to be closely regulated 
by absorption of fluid into the epithelial cells. I could find 
no estimates of the average thickness of the viscous layer in 
humans although the cilia are capable of moving very large loads 
[150]. The IRCP report on reference man [151] uses an estimate 
of 0.5 mm for the total thickness of the mucous layer but this 
seems a little large. No justification or reference is given. In 
a variety of unspecified laboratory animals Graziadei [149] 
gives the thickness of the mucous layer over the olfactory 
mucosa as 20 to 50 p thick (presumably measured by direct 
microscopic observation though this is not stated).
Mucosal Clearance: As a result of the beating action of the
epithelial there is a continuous conveyer belt-like flow of 
mucous over the nasal mucosa though the watery mucus surrounding 
the cilia and the superficial viscous layer may not flow 
together [150]. Most clearance is backwards into the pharynx 
where mucous and deposited particles are swallowed. The mucus 
from some small areas of mucosa flows anteriorly whence 
accumulated matter is removed by sneezing or grooming. Proctor 
[150] suggests that there is large interindividual variation in
the flow rate of nasal mucus with 80% of individuals falling in
-1 -1 the range of 2.3 to 23.6 mm rain A (Av, 8.4 mm min A) and a group
of slower clearers having rates less than this. Hardy and
colleagues [148] discovered a half time of 6 to 9 min for the
clearance of radioactive tracer from ciliated epithelium.
Nasal deposition: Material may be introduced into the nose in 
many different ways including the simple instillation of fluid 
or powder, the use of sprays and atomisers and the generation
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and inhalation of aerosols.
Inhaled aerosols comprising particles larger than 5 p are almost
completely deposited in the nose. Most inhaled particles less
than 1 to 2 ji will pass through the nose into the lower airways
[122]. The paranasal sinuses can probably be safely ignored as
there is very little bulk flow of air between them and the nasal
cavity on account of their small openings [145].
The location of substances on the nasal mucosa and the area of
the.
mucosa over which deposition occurs will depend both on, nature
A,
of the material and the manner of its introduction. The area 
covered may range from a few square millimetres in the case of 
badly instilled drops [see 136] to most of the nasal mucosa 
[e.g. 148]. After deposition the distribution of substances will 
be changed by mucus clearance currents.
The Nasal Compartment 
In life drug-containing solution will be deposited on the nasal 
mucosa and drug will diffuse from the administered solution into 
the nasal mucous, the tissue of the mucosa and the perfusing 
blood, drug presumably penetrating more deeply into the tissue 
with time. There is evidence in rats [152] that absorption is 
pH dependent, absorption being faster for unionised species and 
that substances which are more lipid soluble are absorbed more 
rapidly. However this work also suggested that there may be 
considerable absorption of lipid insoluble species. Furthermore, 
dissolution in nasal lymph and direct diffusion into nerve 
cells through the olfactory mucosa or into the subarachnoid 
space may be relevant [122]. For the model I have assumed a 
simpler situation in which drug is deposited into the nasal 
mucus and an immediate concentration equilibrium, based on equal
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aqueous unionised fentanyl concentration, is reached with the 
more superficial part of the underlying mucosa and its perfusing 
blood.
Assuming that a large proportion of fentanyl absorption would 
take place into the superficial capillary plexus I have given 
the absorbing tissue a thickness of 1 mm. This should exclude 
most of the cavernous sinusoids. The absorptive area was set at 
80 cm-2. This is probably generous for most applications but the
continuous inhalation of a heterodisperse aerosol, as in the
nebulised inhaled fentanyl study, is likely to result in 
deposition of particles over a wide area of mucosa. This sort of 
coverage can probably also be achieved with properly applied 
nose drops [148].
The mass of the nasal tissue block assuming a tissue density of
1.04 gm ml"* is thus 8.3 x 10”3 kg
The mucus layer was given a total thickness of 50 p.
The mass of mucous associated with the tissue block is thus 
approximately 4.0 x 10"4 kg
In the absence of specific data on nasal mucosa the tissue block 
was given the same density, proportional division into ceils and 
ecf, and proportional content of water, fat and protein as 
intestine, a tissue which contains a large amount of mucosa. 
Mucosal perfusion was set at 0.5 ml min"1 g"1 and the tissue was 
given the fastest mean transit time of 18.7 s along with brain 
other viscera and peripheral shunt. (This might be inappropriate 
if there were a relatively large amount of blood stored in the 
sinusoids).
Mucus was given a protein content of 6.77 x 10 "3 kg kg"1 and the 
proteins were assumed to have the same binding characteristics
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and molecular weight as plasma proteins. (The device of giving 
these and other tissue proteins the same average molecular 
weight as plasma proteins, even when it is clearly not the case, 
is simply a convenient way of giving these proteins the same 
drug-binding ability gram for gram as plasma proteins. An 
alternative would be to express the binding constants in terras 
of g or kg rather than jimol of protein). No account was taken of 
any contribution to binding by the carbohydrate groups of the 
glycoproteins and mucus was supposed to be lipid free.
Mucus pH was set = 6.0.
Other assumptions were that absorption would be complete before 
drug was removed by mucus clearance and that the volume of water 
in which the drug was administered would be negligible. The 
justification for this last assumption is that the volume of the 
watery mucus phase appears to be regulated and any excess water 
added to the mucous layer would be rapidly removed by a mixture 
of absorption into the epithelial surface and evaporation into 
the nasal airstream.
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Adaptation of the Model to Fentanyl
chapter 13
Protein Binding oKa and Lipid Solubility 
To quantify the original pethidine model Davis [125] performed 
in vitro binding experiments with three different groups of 
proteins, those from blood plasma, muscle cells and 
erythrocytes.
He considered two interpretations of the resulting data, firstly 
that only unionised pethidine bound to protein and secondly that 
binding of both ionised and unionised forms occurred. The data 
was fitted to alternative forms of the mass action or 
Scatchard binding equation. (Strictly the term Scatchard 
equation refers only to one particular arrangement of this 
equation but it is convenient to use it as a general label for 
equation 13.1 no matter how it is arranged [see 164, 165]).
(13.1) Cp = n.k.Cfree
1 + k * C free
where Cp is moles drug bound per mol protein, Cfree is 
the aqueous molar concentration of free drug and
a ) cfree =
or b) cfree = Cs + Ci
where Cs is the aqueous molar concentration of free
unionised drug and Ci is the aqueous molar
concentration of free ionised drug.
Rather than resolving these alternatives with in vitro 
experiment Davis included the two forms of the equation with 
their corresponding values of n and k in a set of alternative 
parameter values. He then examined these in the completed model 
to determine which gave the best fit between simulation results
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and published experimental pharmacokinetic data.
Protein binding of fentanyl. Available information; A 
comprehensive search yielded several investigations of binding 
to human plasma proteins, but no information on binding to other 
types of protein. I thus had to extrapolate plasma binding data 
to characterise all protein binding (except for binding to blood 
cell proteins, see below) in the fentanyl version of the model. 
The two most detailed studies are those of Bower [155] and of 
Meuldermans and colleagues [34] both of whom investigate the 
effects of pH, drug and protein concentration and other 
variables on binding. Holt and Teschemacher [153] carried out a 
detailed study but used rabbit plasma or albumin solution for 
several of the experiments. Hargrave [154] reports briefly on 
the effects of pH, as do Maclean and Hug [21] who also report on 
binding at two different protein concentrations though at an 
unphysiological pH. Lehman and colleagues [157] measured binding 
at pH 7.4 and 37*C. Schaer and Jenny ([163] quoted in [155]) 
performed binding experiments at 2 5 #C but as binding is 
increased by temperature [155, 34] their results are not
comparable with the other studies.
Estimates of binding to whole human plasma at various pH values 
are shown in figure 13.1 and the results of the investigations 
of Bower and of Meuldermans and colleagues into the effects of 
plasma dilution are shown in figure 13.2.
If [3 is the proportion of the total fentanyl concentration which 
is bound to protein, Holt and Teschemacher [153] and Lehmann and 
colleagues [157] report a smaller {3 under normal physiological 
conditions than other investigators. Apart from these two groups 
there is good agreement between laboratories on {3 in whole
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Figure 13.1
Binding of Fentanyl to Plasma Protein Showing Changes with
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Figure 13.2
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undiluted plasma at pH 7.3 and above, but wide disagreement at 
the other end of the pH range. Lehmann and colleagues [157] 
found a very much greater variation in {3 between plasma from 
different individuals than did Meuldermans and colleagues [34] 
or Bower [ 155].
Four additional conclusions may be drawn from the available 
work.
i) Albumin probably accounts for about half plasma fentanyl 
binding with a number of different proteins responsible for 
the remainder.
ii) {3 is independent of fentanyl concentration, probably up to 
concentrations as high as about 6 mg ml-1 in undiluted 
plasma.
iii) |3 is dependent on pH increasing with higher pH
iv) p is dependent on protein concentration increasing with 
higher protein concentration.
Fitting the data to a model: Alternative (b) of the Scatchard 
equation 13.1 (above) is precluded as it does not account for 
the pH dependence of fentanyl binding. Since the ratio of 
ionised to unionised free drug changes with pH according to the 
Henderson Hasselbach equation (13.12), the pH dependence of 
binding may be explained by assuming that proportionately more 
unionised fentanyl binds than ionised fentanyl. i.e. n.k is 
larger for unionised than ionised fentanyl. Alternative (a) 
represents an extreme form of this situation where the value of 
n.k for ionised drug is 0. However n.k for ionised fentanyl may 
well be > 0.
Independence of p from drug concentration (conclusion ii above) 
is predicted by the Scatchard equation when drug concentration
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is low compared with the concentration of available binding 
sites.
Thus:
(13.2) Cp = CfrQund
P
where
P = aqueous molar concentration of protein 
cbound = aqueous molar concentration of bound drug
Substituting equation 13.2 for Cp, the Scatchard equation (13.1) 
may be rearranged to give {3
(13.3) J3 = 1
1 + cfree + 1
n.P n.k.P
where
(13.4) {3 = cbound
^bound + cfree
When the concentration of binding sites in the system is high 
compared with the concentration of unbound drug the term 
Cfree/n.P approximates to zero and equation 2 simplifies to:
(13.5) {3 = n.k.P
1 + n.k.P
In this situation (3 approaches a maximum which depends only on 
the concentrationA of binding sites and not on the concentration 
of drug. Note that n and k cannot be determined separately. 
Substituting for ]3 from equation 13.4, equation 13.5 may be
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rewritten:
(13.6) ^bound ~ n * ^  ree
P
or, substituting from equation 13.2
(13.7) Cp = n.k.Cfree
This simplified .Scatchard equation can be expanded to 
accommodate different binding constants for the ionised and 
unionised forms. Thus, from equation 13.6:
(13.8) Cboundi = P.Ci.ki
(13.9) cbounds = P-Cs.ks
where ks = n.k for the ionised species
ki = n.k for the unionised species 
Cboundi = a(Jueous concentration of unionised 
bound drug
Cbounds = aqueous concentration of ionised 
bound drug
but
(13.10) cbound = cboundi + cbounds
substituting f°r cfc>oundi cbounds from equations 13.8 and 13.9
(13.11) cbound = (Ci.ki + Cs.ks)
but from the Henderson Hasselbach equation
(13.12) Ci = Cs.lO(pKa ' pH)
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substituting in equation 13.11 for Cfree± from equation 13.12 
and rearranging gives
(13.13) Cbound = Cs.(10<PKa ' PH >.ki + ks)
P
which substituting from equation 13.2 may be written:
(13.14) Cp = Cs.(10(PKa " pH).ki + ks)
In order to calculate ks and ki from the available data equation 
13.13 must be rearranged to give p. Thus:
(13.15) cfree = Ci + Cs 
substituting for Ci from equation 13.12
(13.16) Cfree = Cs.(1 + 1 0 <PKa '
substituting equation 13.16 and equation 13.13 in equation 13.4 
Cs cancels to give:
(13.17) p = ki.P.10(pKa ' pH> + ks.P
1 0 (PKa " PH).(ki.P + 1) + 1 + ks.P
The Scatchard equation is the simplest of many possible
mathematical models of protein binding. It is derived directly 
from the law of mass action [see 164, 165] assuming:
i ~
a) 'There is only one class of binding site all members of
which have equal affinity for the ligand.
b) All protein molecules have an equal number of binding sites
c) There is no cooperativity between binding sites i.e. that
binding at one site does not affect the affinity of 
adjacent sites on the same molecule.
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In addition, to apply the model to fentanyl as equation 13.12 
(a) must be rewritten as:
d) Each species has only one class of binding site all members
of which have equal affinity for their respective ligand.
and...
e) A logical consequence of (d), the ionised and unionised 
forms bind to separate sites with no cross binding.
f) The concentrations of both species of unbound drug are low
compared to the concentration of available binding sites
When assumptions (a) to (c) are met a plot of Cb/Cfree against
Cfree wil1 yield a straight line with n and n.k as the
intercepts on the abscissa and ordinate respectively. When in 
addition assumption (f) is met, i.e. when the value of 
Cfree/n.P is negligible, the line will be parallel to the
abscissa intercepting the ordinate at n.k. When all the above 
assumptions are met for two separate species the line will 
intercept at an apparent n.k which is the concentration-weighted 
mean of the individual n.k values.
It might seem unlikely that these rigorous conditions will be 
met in life when binding occurs to a heterogeneous mix of
plasma proteins. Meyer and Guttman [164] caution against 
attempting to apply Scatchard plots to whole plasma and a 
Scatchard plot for a ligand obeying equation 13.1 at several 
sites of different affinity is curved. If binding at all the 
sites obeys equation 13.7 however the plot is a straight line
■t
irrespective of how many different sites there are. Bower's 
experimental Scatchard plot of fentanyl binding to whole plasma 
approximates well to a straight line parallel to the abscissa 
[159].
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Furthermore equation 13.7 is of the same form as an equation 
describing partition of a solute between two solvent phases 
(e.g. equation 13.19 below) where n.k is the partition 
coefficient. If the process of binding by unionised species 
involved non-specific partitioning into hydrophobic regions on 
the protein molecule it would not be necessary to postulate a 
large number of separate individual binding sites on each 
protein molecule in order that binding should obey this equation 
up to relatively high molar concentrations of free drug, n.k in 
this case could be conceptualised as a mean partition 
coefficient, weighted according to the relative concentrations 
of sites with different affinity, between the aqueous phase and 
available hydrophobic areas in the protein molecules.
Binding of ionised fentanyl accounts, with this model, for only 
a small proportion of the total binding at physiological pH. 
Thus though it may also obey the low-free-drug-concentration 
approximation it would be difficult to confirm or refute this 
from its proportionately small effect on the shape of a 
Scatchard plot at pH 7.4.
In order to determine ki and ks from equation 13.17 the pKa of 
fentanyl must be supplied. Meuldermans and colleagues [34] quote 
8.43 determined by electrometric titration in the laboratories 
of the original manufacturers Jansen Pharmaceuticals Ltd. There 
are no experimental details. Apart from this I was able to 
discover only two other estimates both derived from the effects 
of pH on lipid / aqueous phase apparent partition coefficients. 
Bower [159] gives 6.9, Holt and Teschemacher [153] give 7.7 (see 
lipid solubility below).
The aqueous concentration of protein is also required. This
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should be the concentration of the protein to which binding 
occurs. Since binding occurs to a range of plasma proteins but 
the precise pattern is unknown I have followed Davis's procedure 
for pethidine and used, for whole plasma, his estimate of total 
molar concentration of plasma proteins.
P = 7.47 10‘2 pmol Kg"1 plasma = 8.16 10"2 pmol Kg’1 plasma 
water
The protein concentration in diluted plasma has been calculated 
accordingly. (In the published studies relevant plasma protein 
concentrations are mostly expressed on an arbitrary scale of 
plasma dilution. An absolute value of plasma protein 
concentration is required for determining values of n.k which 
can be applied to tissue cell proteins whose concentration is 
expressed in the same units but note that it has no influence on 
the fit of the experimental data to equation 13.17).
The data of Meuldermans and colleagues [34], Bower [155] and 
McLean and Hug [21] were fitted separately to equation 13.17 
using a computer curve-fitting program based on the Levenberg- 
Marquardt routine [166] to give ki and ks. The results are shown 
in figs 13.3 to 13.5.
When the pKa is fixed at 8.43 (not shown for McLean and Hug's 
data) there is not a great deal to choose between the data sets. 
Meuldermans and colleagues' data are possibly a marginally better 
fit than that of Bower. Including the pKa as an unknown variable 
in the fitting process gives pKa = 9.59 (Bower), pKa = 7.85
(Meuldermans) , and pKa = 8.18 (Mclean) . There is only marginal
improvement in the overall fit of Bowers' data but a noticeable 
improvement in that of Meuldermans which is now better than both 
others, (note Meuldermans' investigation spans a larger range of
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Figure 13.4
Change with pH in Binding of Fentanyl by Plasma Proteins.
Experimental and Predicted Values
Bower [155]
percent drug free
70
60
pKa = 8.43
50
40
30
20
76 985
PH
fitted values +  experimental values
percent drug free
70
60
pKa = 9.59
50
40
30
20
98765
PH
fitted values +  experimental values
See text for details
Figure 13.5
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pH than Bower's). 7.85 is within the range of possible pKa 
values suggested above though it is not possible to estimate how 
likely this really is compared with the manufacturer's value. 
Experimental values of p may deviate from predicted values 
because of inadequacy of the binding model (binding is more 
complex/ for example cooperative binding is involved, or the 
nature/number of binding sites is directly altered by changes in 
pH) or because of experimental error. In the present case it is 
not possible to say which of these factors are involved. No 
doubt better fitting of individual data sets could be obtained 
with more complex models but there is insufficient agreement 
between^the results from different laboratories to justify this. 
Further experimental exploration of the problem would involve 
confirmation of the apparent pKa and studies of binding at 
different protein concentrations over a range of pH.
It seems reasonable then to accepted the model as quantified by 
the data which fits it best. This, from /Heulderman& data, 
gives:
pKa = 7 . 8 5
ki = 1.246 x 10"3
ks = 1.9121 x 10"2
Fig 13.6 compares Meuldermans and colleagues' experimental 
results for the variation in binding with plasma protein 
concentration at pH = 7.35 with values calculated using the
values above in equation 13.17. Some of the disparity here 
between model and experiment is the consequence of an 
inconsistency in the experimental data: the proportion of bound 
drug in undiluted plasma reported in the plasma dilution
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Figure 13.6
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experiment, apparently performed at pH 7.35 is different from 
that reported at pH 7.35 in the separate experiment to examine 
the effects of pH on binding to undiluted plasma. This is 
reflected in a larger difference between calculated and 
experimental values at ph 7.35 in undiluted plasma in fig 13.6 
compared with fig 13.3.
Note: As pKa and the binding constants are mutually dependent in 
equation 13.17, should the pKa used in the model be changed for 
any reason, ki and ks must also be recalculated from the in 
vitro data using the new pKa.
Lioid in plasma and ecf: The experimental studies of fentanyl 
plasma protein binding discussed above make the assumption that 
all plasma binding of drug is due to protein binding. No 
allowance is made for dissolution in plasma lipids such as the 
triglycerides present in chylomicra after fat absorption from 
the intestine. Bower found no increase in plasma fentanyl 
binding after a fatty meal associated with increased plasma 
triglyceride concentration [156] and no change in binding to 
artificially defatted plasma [155]. In contrast to the original 
pethidine program therefore no term was included in the fentanyl 
version for plasma lipid. Similarly no term was included for 
lipid in the extracellular fluid.
Lipid solubility
Ideally a set of solubility coefficients for the major types of 
lipid present in each tissue would be available. Failing that 
the average solubility of fentanyl in representative human or 
animal triglycerides (which comprise the largest proportion by 
mass of body fats) would be useful. In fact, as for pethidine,
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neither of these levels of information are available and only 
solubilities in the industrial solvents heptane and octenol can 
be found. Even here the available data is not consistent. Table 
13.1 shows the data I was able to find. Lambda has beenC
calculated in each case from the measured apparent coefficient 
lambdax at pH x
\
(13.18) lambdax = Cl/Cw
where Cl = concentration of drug in lipid phase
Cw = total concentration of drug in aqueous phase
The true partition coefficient, lambda is given by
(13.19) lambda = Cl/Cs
where Cs is the concentration of unionised drug in the aqueous 
phase and it is assumed that only the unionised form is soluble 
in lipid.
lambda was calculated using
(13.20) lambda = lambdax .(l + iO^PKa " )
which is derived by combining the Henderson Hasselbach equation 
with equations 13.18 and 13.19.
There is an obvious difficulty in choosing which value of pKa 
to use. Internal consistency within the model would suggest 7.85 
but this value is not the best fit to all the data. Bower [159] 
investigated the variation in lamkc/a^ with pH and her results 
give a very good fit to the dissociation curve of a base of pKa 
6.9. Holt and Teschamacher [153] calculate a pKa of about 7.7 
from their investigation of partitioning into heptane. 
Meuldermans and colleagues [34] quote the official pKa of 8.43
153
Table 13.1: Fentanyl Solubility in Heptane and Octenol
Heptane Octenol Study
L l 8 .64 L7 .4 L L9 .8 L 8 .34 L7 .4
*** 9957 9550 [34]
§
539 * 520 [159]
M
11220 [162]
M M
49 '** 43 878 ** 
2928 ***
250 [153]
M
68 ** 
227 ***
19.35 [160]
M§
11.8 * 
105 ***
9.0 [161]
M
L = true oil / aqueous phase partition coefficient for
unionised species (lambda)
L„ = apparent oil / aqueous phase partition coefficient at pH x 
(iambdax )
measured values are bold underlined
* calculated assuming pka_= 6.9
** calculated assuming pKa= 7.8
*** calculated assuming pK<^= 8.43
# temperature not given, "double extraction" method
M  37*C . tritiated fentanyl
### room temperature. Beckman spectrophotometer 
M M  no experimental details
Table 13.1
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in their paper but solving equation 13.20 for pKa using the two 
values they give for lambdax results in pKa = 6.46. In addition 
to this problem there are considerable differences in absolute 
measured values of lambdax . All in all the lack of agreement is 
remarkable for what appears at face value a fairly 
straightforward piece of physical chemistry.
The data in table 13.1 may be used as a pointer to the
solubility of fentanyl in triglyceride in the form of olive oil 
(plant triglyceride) by following the same interpolation 
procedure Davis employed for pethidine. Table 13.2 shows the
opioids fentanyl, morphine and methadone ordered in terms of 
their solubility in various solvents. The lambda for fentanyl in 
octenol is probably close to that for methadone, lambda for
fentanyl in heptane lies in a fairly intermediate position 
between that for methadone and morphine. On the other hand 
lambda for methadone in olive oil is less than in both octenol 
and heptane, lambda for morphine in olive oil is less than in 
octenol but perhaps greater than in heptane though both values 
are small. On these grounds lambda for fentanyl in olive oil
should lie between that of methadone and morphine but probably 
nearer to methadone. It should be less than lambda for fentanyl 
in octenol.
A value of 500 was chosen as a first approximation but given the 
variability in Table 13.1 this amounts to little more than a 
guess.
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Table 13.2: Solubility of Fentanyl, Methadone, and Morphine in 
Heptane, Octenol, and Olive Oil. After Davis [125].
OLIVE OIL 
morphine
0.05 e
HEPTANE
morphine
< 0.00004 b
OCTENOL
morphine
6.23 d 
6.6 c
OLIVE OIL 
fentanyl
HEPTANE
fentanyl
12 to 
227 a
OCTENOL
fentanyl
539 to 
11220 a
OLIVE OIL 
methadone
716 e
HEPTANE
methadone
3298 b
OCTENOL
methadone
8621 d
Values are true partitition coefficients of the unionised 
species (lambda) if necessary calculated from the measured 
apparent partition coefficient (lambdax ) using pKa values as in 
table 13.1 or as given by Kaufman and colleagues [133].
a see table 13.1
b [160] measured at room temperature pH 7.4.
c [153] measured at 37*C pH 7.4
d [133] measured at 37*C
e [183] lamdax measured at 37*C pH 7.55 to 7.58
Some of these data appear in more than one publication. Although 
the situation is not completely unambiguous, the values quoted 
by Davis [125] from Kutter and colleagues [184] and from 
Kosterlitz and colleagues [185] almost certainly derive from the 
experiments reported in [160] .
Table 13.2
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Distribution in Blood 
Three groups of investigators have examined the distribution of 
fentanyl between erythrocytes and plasma. All three determined 
very similar values for the ratio
(13.21)
total fentanyl concentration in red cells (mg ml”1)
eprat = -------------- ----------------- ---- —  -----------------
total fentanyl concentration in plasma (mg ml”1)
under normal physiological conditions:
Lehman and colleagues [157] 1.01
Meuldermans and colleagues [34] 0.92
Bower [158] 0.98
Mean 0.97
Bower [158] carried out the most detailed investigation. As 
might be expected eprat is independent of haematocrit and of
_ i
total blood fentanyl concentration up to at least 0.5 mg ml . 
Plasma dilution experiments confirm that the concentration of 
fentanyl in the red cells is a linear function of the unbound 
fentanyl concentration in plasma with epratfree = 5 . 0 2  
where
(13.22)
total fentanyl concentration in red cells (mg ml" ) 
epratfree - ~
unbound fentanyl concentration in plasma (mg ml )
Unexpectedly, eprat is also independent of plasma pH over at 
least the range 5.04 to 7.56 [157, 158] which implies that
epratfree is dependent on plasma (not red cell) pH in exactly 
the same manner as 1 - ]3, the ratio of free to total 
concentrations of drug in the plasma (see protein binding
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above). As most erythrocyte binding of fentanyl is accounted for 
by binding to haemoglobin a more detailed investigation of this 
problem would involve examining fentanyl binding to haemoglobin 
over a range of pH.
The simplest and most robust way of using this information in 
the present model is to incorporate eprat directly to relate the 
total plasma concentration of fentanyl to the total red cell 
concentration. This will be valid in the face of the plasma pH 
changes already possible with the present version and will 
remain valid should the model be extended to allow changes of
haematocrit. However it would not be valid should either the
plasma protein concentration or the red cell haemoglobin 
concentration be changed.
As concentrations in the model are expressed per unit mass 
rather than per unit volume eprat must be corrected for the
densities of blood and plasma:
(13.23) ePratmodel = eP rat x density of plasma
density of erythrocytes
= 0.908
Elimination
Davis models pethidine elimination by dividing it between 
hepatic metabolism and renal excretion. Hepatic clearance was 
calculated from
(13.24)
hepatic clearance = whole body clearance - renal clearance
Whole body clearance and renal clearance (or rather an 
expression which relates renal clearance to urine pH) were
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derived from published pharmacokinetic studies. For convenience 
of modelling the clearances are expressed as the respective 
extraction fractions where the extraction fraction is the 
fraction of drug in the incoming blood removed by the organ. 
Thus
(13.25) extraction fraction = clearance / perfusion
This also has the advantage of relating elimination to organ 
blood flow such that decreased blood flow results in decreased 
elimination and vice versa. As both fentanyl' and pethidine have 
relatively high extraction fractions and are likely to show 
perfusion-limited clearance [see 167] this should result in at 
least qualitatively correct effects should the model be 
extended to permit changes in the distribution of cardiac 
output.
Since fentanyl is mainly removed from the body by hepatic 
metabolism with a small amount excreted unchanged in the urine 
(chapter 1) broadly the same procedure may be applied here. 
However two potential inaccuracies must first be considered. The 
first source of potential error is the difference between blood 
and plasma clearance. Clearance is often given as plasma 
clearance:
(13.26) plasma clearance = rate of elimination
plasma concentration
where rate of elimination is the rate of elimination of drug 
from the system. The units are volume time"1 where volume can be 
conceptualised as the volume of plasma that would be required to 
contain the mass of drug being eliminated per unit time at the
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concentration concerned. Blood clearance is given by
(13.27) blood clearance = rate of elimination
blood concentration
Hence
(13.28)
blood clearance = plasma clearance x plasma concentration
blood concentration
_ i
Again the units are volume time A and the volume on this 
occasion is the volume of blood that contains the mass of drug 
being eliminated per unit time at the concentration concerned. 
Obviously the clearance required for equation 13.25 is blood 
clearance. Note also that plasma clearance and plasma perfusion 
cannot be substituted in equation 13.25 to give the observed 
hepatic plasma extraction fraction since this gives the plasma 
extraction fraction that would occur if all eliminated drug were 
to be accounted for from the plasma (rather than red cells and 
plasma) and may result in an extraction ratio > 1 .
For fentanyl since the plasma / blood concentration ratio is 
approximately unity blood clearance may in practice be used 
interchangeably with plasma clearance though a correction factor 
has been used below for the sake of logical rigour. Davis 
apparently made no distinction between blood and plasma 
clearance in his quantification of the pethidine model. Since 
the blood / plasma concentration ratio of pethidine has been 
estimated between 0.68 and 1.43 [125] this is a possible source 
of error.
The second source of potential error is that whole body
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clearance refers to clearance of arterial (or sometimes mixed 
venous) blood. Strictly speaking hepatic clearance for equation 
13.25 should be calculated from the drug concentration in liver 
afferent blood. If this differs from the drug concentration in 
arterial blood because of portal mixing, then the clearances of 
liver afferent blood and arterial blood will differ and an 
extraction fraction based on arterial blood clearance will be in 
error.
In practice the error will only be important in the distributive 
phase during the first few minutes after administration when the 
part played by elimination in determining drug concentration is 
small anyway. After the distributive phase there should be 
little concentration difference between arterial and liver 
afferent blood and the calculated extraction fraction should 
provide the required observed arterial blood clearance.
There are analogous problems in comparing pharmacokinetic 
parameters calculated from arterial and venous blood 
concentrations.
Table 13.3 shows values for fentanyl plasma clearance obtained 
from conventional pharmacokinetic studies in volunteers and 
patients undergoing non-cardiac surgery. There is considerable 
variation between studies. Reilly and colleagues [20] have 
examined the variability of fentanyl kinetics. Variation may be 
due to experimental error, to differences in methods of 
parameters calculation or to measurement of real differences 
in the subjects under study. It is likely that several different 
factors are involved and that they will not be clearly delimited 
without further careful experimental work.
Most investigators have fitted their data to two or three-
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chapter 13
compartmental models. Duthie and colleagues [10] and Singleton 
and colleagues [175] both use non-compartmental methods of 
calculation. Holley and Van Steenis [176] and Nimmo and Todd 
[1 1 ] calculate clearance from steady state infusion 
concentrations. Fung and Eisele [174] present their data 
processed in three different ways. There are considerable
_ i
differences: clearance was 440 ml min A calculated from a two- 
compartment model compared with 160 ml min"1 calculated from a 
three-compartment model which was a better fit to the combined 
group concentration curve but could not be fitted to the 
individual subject concentration curves.
Reilly and colleagues [20] point out that many existing studies 
are on small numbers of subjects and are of short duration 
compared with the elimination half life. Scott and Stanski [178] 
argue that short studies tend to overestimate clearance and 
underestimate terminal half life. However there is no obvious 
relationship between study length and clearance in these 
investigations (figure 13.7).
Assay inaccuracy is another possible contributing factor. In 
general insensitive assays produce uncertainty in estimates of 
kinetic parameters. However an assay that fails to discriminate 
between a drug and its metabolites or that over estimates drug 
concentration such that measured concentration is a constant 
multiple of the real concentration will underestimate clearance. 
Most studies have used radioimmunoassay to determine fentanyl 
concentrations in plasma. Schleimer and colleagues [179] and 
Fung and Eisele [174] both used the earliest available assay 
[181]. Their clearance values are by far the smallest published. 
Michiels and colleagues [180] developed a more sensitive assay
163
Figure 13.7
Relationship Between Study Length and Plasma Clearance 
Fentanyl for the Studies Listed in Table 13.3
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soon afterwards. This has become the commercially available 
standard and was used by all the other investigators who 
employed radioimmunoassay/ with the exception of Bower and Hull 
[161] who used their own assay to determine the largest 
published clearance. In 1984 Schuttler and White [112] pointed 
out that the assay procedure then recommended for the commercial 
version of Michiels and colleagues' assay was very susceptible 
to small variations in experimental technique and prone to 
overestimation of fentanyl concentration. A more robust 
procedure was introduced and was used by subsequent 
investigators.
No unequivocal associations have been discovered between the 
size of pharmacokinetic parameters and the characteristics of 
healthy subjects. Three groups of investigators report no 
correlation between fentanyl pharmacokinetic parameters and age 
or body weight [161, 176, 178]. Bentley and colleagues [169]
studied five obese and three non-obese patients and found no 
difference in volume of distribution, clearance or terminal half 
life. Singleton and colleagues [175] using non compartmental 
methods of calculation found a reduced volume of distribution in 
seven elderly (over 71 y) patients but no difference from 
younger controls in clearance or terminal half life. Bentley and 
colleagues [171] by contrast found a prolonged terminal half 
life, markedly reduced clearance and unchanged volumes of 
distribution in four elderly ( over 60 y) patients. Anaesthesia 
and surgery might be expected to change fentanyl 
pharmacokinetics, clearance, for instance, might be smaller on 
account of reduced liver perfusion. There is some indirect 
evidence for this [182] but with the exception of Bower and Hull
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[161] (seven subjects) pharmacokinetic parameters measured in 
unanaesthetised volunteers are not noticeably different from 
those measured in non-cardiac surgical patients.
The model requires a value for fentanyl clearance ideally 
derived from young fit adult male subjects. However the two 
studies that fit these requirements [2 1 / 161] are both on small 
numbers of patients and show different results: 1537 ml min"1
_ i
and 882 ml min A respectively. An average plasma clearance for 
patients and volunteers combined can be calculated from the 
investigations in table 13.3. The two lowest values may be 
excluded since it is highly likely they reflect inadequacies in 
fentanyl assay. It also seems reasonable to use only the control 
groups from studies into the effects of age, weight, disease, or 
cardiac by-pass. Otherwise all data are included. The result, 
879 ml min"1 (or 881 ml min"1 weighted for the square root of 
the number of subjects) is almost identical to that determined 
by McLean and Hug [21] in fit young male volunteers and I thus 
chose a plasma clearance of 880 ml min"1 as the basis for 
further calculations: 
from equation 13.28
blood clearance = plasma clearance x 1.01
= 889 ml min"1
but if 6% of the total elimination of fentanyl occurs through 
the kidney
renal blood clearance = 889 x 6/100
= 53 ml min"1
metabolic blood clearance = total clearance - renal clearance
= 836 ml min”1
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From equation 13.25 if liver perfusion = 1554 ml min" 1 [125] 
hepatic extraction fraction = 0.538
Renal elimination: Renal clearance could be expressed as a renal 
extraction fraction and inserted directly into the model. 
However renal elimination would then show no dependence on urine 
pH. This is unfortunate as by analogy with similar drugs it is 
highly likely that fentanyl excretion is dependent on urine pH. 
and urine pH is readily measurable. The original model mimics 
this aspect of pethidine excretion. As there is no experimental 
evidence with which to define an empirical relationship between 
fentanyl excretion and urine pH a theoretical model must be 
used.
Existing models have been reviewed by Davis [125] and are based 
on renal clearance or on adding drug to and subtracting drug 
from the glomerular filtrate. I have adopted an alternative 
approach which avoids the problems of modelling the complex 
sequential changes in the glomerular filtrate.
On the premise that distribution of fentanyl within the kidney 
occurs as a result of passive diffusion (i.e. that fentanyl is 
not actively secreted into the kidney tubules) the starting 
point is to assume that fentanyl equilibrates between perfusing 
renal blood, kidney tissue (cells and ecf) and the final urine 
volume. However this is an oversimplification since the kidney 
could be divided into a large number of functional compartments 
and concentrations will often not be at equilibrium. A higher 
concentration of fentanyl in the urine than would occur by 
simple equilibrium partition may occur as a result of the faster 
diffusion of water than fentanyl from the filtrate. The
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countercurrent mechanism in the renal medulla may possibly 
magnify such concentration differences [168]. To allow for this 
I have introduced a concentrating factor. This operates by 
temporarily decreasing the mass of the kidney and its perfusing 
fractional stroke volume after the total mass of drug in blood 
and kidney have been calculated thus avoiding any change in the 
total mass of drug in the body (see chapter 14).
To determine a suitable value the program was initially 
constructed with a concentrating factor (F) of 1 (i.e. simple
partitioning of drug between blood, tissue and urine). This was 
then adjusted until renal elimination accounted for 
approximately 6% of total elimination with a normal urine output 
which gave F = 17.
The finished program allows urine flow to be specified for each 
simulation.
In life, urine is formed from the perfusing renal plasma. 
Strictly speaking therefore, urine volume should be subtracted 
from the plasma volume. However the mass of urine is very small 
compared with the mass of plasma and may be treated as a 
separate extra compartment without noticeably affecting the 
calculation, which simplifies the model considerably.
This sub-model of urinary excretion is compatible with rather 
than derived from the meagre quantitative information available 
and is hence speculative. Its merits are discussed further in 
chapter 15.
Conclusions
The numerical information corresponding to that used by Davis to 
quantify the model for pethidine is not all available for 
fentanyl and where information exists there is often poor
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agreement between different investigators. However it has been 
possible to devise a fentanyl version of the model by estimating 
parameters for which there are no experimental values and by 
altering the method of calculating drug distribution within the 
blood and between blood and tissue to fit the available data. 
Evaluation of the model is discussed in chapter 15.
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CHAPTER 14
The Fentanyl Model
chapter 14
The following is a summary of the physiological model of 
fentanyl pharmacokinetics. It assumes the description of the 
original pethidine model in chapter 10. The complete fully 
commented text version of the computer program is given as 
appendix 1 and includes definitions of all variables used 
therein and their initial values.
Calculation of Blood-Tissue Distribution 
The total amount of fentanyl present in the blood and tissue of 
a tissue block and its (fractional) stroke volume (Aa^) is 
related to the aqueous concentration of unionised drug (Cs) by
( 1 4 . 1 )  A a b t  =
W t p . C s . ( ( 1 0 * p K a  ' p H p ) .ki + k s ) . g p p + f w p + 1 0 * p K a  ' p H p ^ . f w p )
+
W t r . e p r a t .  Cs . ( ( 1 0 ^ p K a  ' p H p ^ . k i  + k s ) . g p p + f w p + 1 0 ^ p K a  ' p H p ^ . f w p )
+
W t c . C s . ( ( 1 0 ^ p K a  " p H c ).ki + ks ) .g p c + 1 a m d  a . f 1 c + f w c + 1 0 ^ p K a  ' p H c ^ . f w c )
+
W t e . C s . ( ( 1 0 ^ p K a  ' p H e * .ki + k s ) . g p e + f w g + 1 0 * p K a  " p H e ^ . f w e )
where
eprat = erythrocyte : plasma concentration ratio 
ki = protein binding constant ionised species 
ks = protein binding constant unionised species 
and other variables are as in chapter 10 
Equation 14.1 is derived in the same way as equation 10.13 
except that Cp is given by equation 13.14 rather than equation 
1 0 .11,. there is no term for plasma lipid or ecf lipid (i.e. Clp 
= Cle = 0) and the -total red cell concentration of fentanyl is 
calculated from the total plasma concentration using eprat (see
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equation 13.21).
As in the original model A a ^  is known from the amount of drug 
in the incoming blood fraction and the amount of drug left in 
the tissue at the end of the previous cycle. In all the tissue 
blocks except the nasal and kidney blocks 14.1 is solved to 
give the equilibrium Cs (note equation 14.1 is linear and can 
be solved directly whereas equation 10.13 is cubic and requires 
an iterative method) . Cs is then used to calculate the 
equilibrium total drug concentrations and amounts in the 
individual compartments.
Nose: In the nasal block there is an extra compartment, the
nasal mucous, to be included in the calculation. The total 
amount of drug in the nasal block tissue, fractional stroke 
volume and mucus is given by:
(14.2) Aabtm = Aabt + Aam
where Aam the total amount of drug in the mucous is given by
(14.3) Aam = Wtpj. (Cpm .gpm + Cs.fwm + Cim .fwm )
Substitution for Cpm from equation 13.14 and for Cim from 
equation 10.9 gives an expression in terms of Cs:
( 1 4 . 4 )
A 3 = W t m . ( C s . ( 1 0 ( p K a  ' p H m ) . k i  + k s ) . g p _  + C s . f w _ . ( 1  + 1 0 ^ p K a  " P H m )))m m ' v 7 m m ' 77
where pHm = pH mucus
Equations 14.4 and 14.1 are combined in equation 14.2 to 
calculate Cs and thence the total equilibrium concentrations and 
amounts in each compartment including the mucus.
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Kidnev; In the kidney block there is also an extra compartment, 
the urine. In addition the concentrating factor F operates to 
increase the effective equilibrium concentration governing 
partition of drug into the urine. The total amount of drug in 
blood, kidney tissue and urine (Aa^^) is given by:
(14.5) Aabtu = Aabt + Aau
where Aau , the total amount of drug in the urine is given by
(14.6) Aau = Wtu .( Cs + Ciu )
where = mass of water in the urine produced
during calculation cycle (kg)
Wtu approximates to the urine flow (Urine is made up of water 
and solutes. In practice the quantitative distinction between 
urine water and urine is relatively unimportant but is made here 
for completeness).
Substitution for Ciu from the Henderson Hasselbach equation 
(11.9) gives an expression in terms of Cs.
(14.7) Aau = W t^.Cs .(1 + 10<PKa " PHu)) 
where pHu = urine pH
A a ^  is calculated as for other tissue blocks. Aau before 
equilibration = 0. Equations 14.1 and 14.7 are combined in
equation 14.5 . However further substitutions of Wtp/F for Wtp/ 
Wtr/F for Wtr , Wte/F for Wte and Wtc/F for Wtc are made before 
the equation is used to calculate the apparent aqueous unionised 
drug concentration (Csconc) for this weighted equilibrium. The 
total amounts of drug (Aax) in each individual compartment at 
equilibrium are then calculated from Csconc still using the
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terras Wtx/F. Finally the equilibrium concentrations in all the 
compartments apart from the urine are calculated from the 
amounts Aax and the actual compartment masses Wtx . The true 
aqueous unionised concentration (Cs) for all the compartments 
except the urine is calculated from:
(14.8) Cs = Csconc / F
5
Calculation Sequence
1) The amounts of drug in the (fractional) stroke volumes 
leaving each pool and the amount of drug left behind in 
each pool are calculated from the drug concentrations in 
the pools (see chapter 10).
2) The fractional stroke volumes for the liver from the 
arterial and portal pools are added together.
3) The amount of drug metabolised is removed from the combined 
liver fractional stroke volume according to the extraction 
fraction.
4) Drug is equilibrated between the blood fractions and the
destination tissue blocks: The new amounts and
concentrations of blood in the tissue blocks, the blood 
fractions leaving for the downstream pools, the nasal mucus 
and the urine are calculated (see above) . All drug in the 
urine is excreted.
5) The equilibrated (fractional) stroke volumes are added to
the downstream pools and the new amounts and concentrations
of drug in the pools are calculated (see chapter 10).
6 ) If appropriate, increments of new drug are added to the
injection pool, the intramuscular injection site , the lung 
or the nasal mucosa. Each increment is the amount of each
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prescribed dose that would be administered during the 
current calculation cycle given the total duration of
administration.
Program Input
The remarks in this and the following section, program output, 
apply both to the fentanyl program and to the new version
of the pethidine program.
Input is from a standard keyboard. The program can be easily 
operated by anyone minimally familiar with computers. Particular 
attention was paid to preventing the accidental and unnoticed 
entry of erroneous information. The input routine contains 
simple error traps and there are opportunities to examine and 
correct all important entries. All simulation conditions must be 
specified in advance at the start of the simulation.
Simulation duration: Any simulation duration may be specified.
Drug administration: Drug may be administered intravenously,
intramuscularly, intranasally or into the lung. Any number of 
doses may be given in any combination. For each dose the total
amount of drug and the simulation time at which administration
is to commence are required. For all apart from the 
intramuscular doses the duration over which the drug is 
administered must also be given. Bolus doses are thus allocated 
a short duration. Constant infusions are modelled by giving the 
total dose over a long administration period. Variable infusions 
must be modelled by making each change of infusion rate the 
start of a new dose.
U r i n e *  m h o  nr-ino n H  a n H  f h o  lirino -Flow r-a-Ho m a v  "ho o n o n i  -F-i o H  f o rW - ~ _  ---------— ---------—  ---------- W W    J  ~  ~  —   ------- --- —  —
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any time during the simulation. Default values are 6.2 and 
100 g h "1
Cardiac output: The cardiac output may be specified for any time 
in the simulation. The default value is 6.^8 1 min”*.
Plasma p H: The plasma pH may be specified for any time in the 
simulation. The default value is 7.40.
Calculation time: The elapsed simulation time represented by one 
calculation cycle may be varied up to about 6 seconds at which 
point, with the default cardiac output, the circulating stroke 
volumes start to become larger than the pools. There is a 
checking routine in the program which notifies the user and 
automatically reduces the calculation time if this occurs. This 
is necessary because cardiac output can be varied independently 
but is also a useful safeguard in case the model should be 
extended in future to allow changes of blood distribution.
A large calculation time means that a simulation of given 
duration is completed more quickly. A small calculation time is 
necessary to follow the initial distribution changes with high 
temporal resolution. The size of the calculation cycle time also 
directly affects the distribution of drug in the body during the 
first seconds after drug administration (see chapter 15) . 
Different calculation cycle times may be specified for any time 
in the simulation.
Program Output
The program has optional outputs to screen, data file and 
printer.
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to six body regions to a suitable visual display unit as the 
simulation progresses. Both time and drug concentration are 
plotted on a logarithmic scale to show the differences between 
concentrations in the first few minutes after drug 
administration. The following concentrations are available: 
peripheral arterial plasma (peripheral shunt compartment), 
central venous plasma (central venous pool), fat tissue, lean 
tissue, lung tissue and brain tissue.
Printer: Details of variable changes and administered doses are 
optionally printed as the simulation progresses. (This facility 
was provided as there is no indication of these events on the 
screen display).
Data file: The program outputs its main results to a data file 
whose name must be specified at the beginning of each 
simulation. The following results are given:
Total amounts of drug administered, in blood, in tissues, 
excreted, and metabolised.
Amount and concentration of drug in each tissue block. 
Aqueous unionised concentration in each tissue block.
Tissue / arterial blood and tissue / arterial plasma 
concentration ratios for all the tissue blocks. 
Concentration in blood and plasma and unionised aqueous 
concentration in all the blood pools, peripheral shunt and 
notional peripheral venous blood (as above).
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The results are available according to one of two sampling 
schemes:
standard scheme
frequent scheme
time from dose 
or variable change
0 to 1 hour
1 hour onwards
0 to 2 min
2 rain to 20 min 
20 min to 1 hour
1 hour to 6 hours 
6 hours onwards
results
1 min 
5 min
every 5 min 
every 30 min
every few seconds 
every 30 seconds 
every 2 min 
every 10 min 
every 30 min
The frequent scheme is useful for following detailed changes 
immediately after drug administration or variable changes but 
generates a large amount of data. All the results are calculated 
at the end of a cycle (ie after equilibration of drug between 
tissue and blood and addition of equilibrated (fractional) 
stroke volumes to pools) with the exception of the 
tissue / arterial blood and plasma concentration ratios where 
peripheral shunt concentration is used as arterial concentration 
and tissue concentrations are those at the start of the cycle 
before equilibration.
The following information is also given at the end of each 
simulation:
Times of concentration maxima for tissue blocks 1 to 9.
The tissue / blood and tissue / plasma concentration 
ratios for each tissue block at diffusion equilibrium.
The erythrocyte / plasma and blood / plasma concentration 
ratios.
An indication of the cumulative calculational rounding
error which also serves as a check on the calculation
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integrity: amount of drug remaining in body + amount of
drug eliminated - amount of drug administered.
All details of drug doses and variable changes are notified to 
the results file.
In addition the program will optionally list to a separate file 
the basic data used to quantify the model.
Note on the pethidine model: In the fentanyl model the
tissue / blood and blood / plasma equilibrium concentration 
ratios are fixed (unlike the tissue / arterial blood
concentration ratios). In the pethidine model these ratios may
change with total drug concentration and in Davis's original 
program [125] these ratios were calculated for the results file 
every 100 cycles. However Davis found that for concentrations 
produced by clinically realistic doses of pethidine the changes 
were negligible. The new pethidine program thus uses the same 
results scheme as the fentanyl program and calculates the 
equilibrium and erythrocyte / plasma ratios only once from the 
concentrations at the end of the last cycle of the program.
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Evaluation and Discussion
chapter 15
The assessment and validation of models is a major topic in 
systems science. An excellent account is given by Leaning [130]. 
A formal validation of the model according to a scheme such as 
that proposed by Leaning has not been possible in the time 
available for this project. However I have made some attempt 
below not only to assess the overall performance of the model in 
terms of the likelihood of the computed plasma concentrations 
but also to examine the component parts with the aim of 
identifying areas where further development would be both 
practical and profitable.
Drug Concentrations in Plasma; Simulation of Existing Studies 
Figures 15.1 to 15.3 show simulations of three studies from
table 13.13 which examine fentanyl kinetics in young healthy 
volunteers (comparison is not made with the fourth volunteer 
study as Fung and Eisele [174] used an early and possibly 
inaccurate radioimmunoassay). Michiels and colleagues [180] gave 
an intravenous bolus of 200 pg each to six volunteers of 
unspecified weight and sex. Bower and Hull [161] gave 170 pg 
each as a short (2.5 min.) infusion to five males (weight range 
65.1 to 83.8 kg) and two females (weights 54.9 and 61.2 kg).
Both sets of investigators measured fentanyl concentrations in 
peripheral venous blood. Mclean and Hug [21] gave 6.4 pg kg "1 to 
five male volunteers the arterial plasma concentrations from
four of whom (weight range 65.0 to 84.5 kg) are presented. The 
weight of the model man is 70 kg in all simulations. (The
present model has the correct proportion of fat tissue for a 
non-obese 70 kg man. Adjusting the model weight without 
adjusting the relative proportion of different body tissues will 
not necessarily result in a closer fit to experimental subjects
181
Figure 15.1
E
c 10^A
C
O
0»
c
z'o
*—
<ce
i—
z
UJCJzou
<
</>
<
Q.
hours
® experimental data 
• simulated, data
Adapted from Michiels and colleagues [/go]. Experimental points 
are logarithmic mean values from peripheral venous plasma 
(definition of error bars not given in original) . See text for 
details.
Figure 15.2
co
a 0o
oo
b)o
i ime
+ simulated data
Adapted from Bower apd Hull [161]. Lines are the log- 
concentration (ng m l ' 1)-time (h) data given by the two 
compartment model fitted to the experimental data of each 
subject by Bower and Hull. See text for further details.
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since no relationship has been determined between fentanyl 
kinetic variables or plasma concentrations and subject weight). 
After the first 30 minutes simulated concentrations are higher 
than the experimental concentrations reported by Bower and Hull. 
The model gives a better fit to the data of the other two 
groups, simulated concentrations being mostly slightly lower 
than experimental in both cases.
In order to make a simultaneous study of fentanyl 
pharmacodynamics and pharmacokinetics Scott and colleagues [31] 
administered a 5 minute intravenous infusion of fentanyl to 12 
unpremedicated healthy male patients before anaesthesia. This 
study is useful because the investigators present a detailed 
plot of plasma concentrations during and for 30 minutes after 
the infusion i.e. at the time when the concentration profile is 
determined by drug distribution. Unfortunately it is not clear 
whether the plot represents the results from a representative 
subject or the whole group combined. There is no indication of 
scatter. The weight of subjects in the study ranged from 73 to 
104 kg (weight of model subject 70 kg). A simulation of this 
study is shown in figure 15.4. It clearly approximates the 
experimental results moderately well both qualitatively and 
after the end of the infusion, quantitatively. During and 
immediately after the infusion both the initial rise in 
concentration and the terminal fall appear too steep and the 
peak concentration too great but this conclusion remains 
tentative without a knowledge of the experimental inter-subject 
variation. Figure 15.5 shows the same simulation repeated but in 
this case the model has been altered to increase partitioning 
into lung tissue by increasing the mass of the lung sevenfold
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150 pg min'1 for five minutes. Timing from start of Infusion. 
See text for further details.
Figure 15.5
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leaving other variables, including the absolute lung perfusion, 
unchanged. (This is simply a quick and easy method of altering 
the overall equilibrium partition coefficient of a tissue block 
to assess the consequent effect. Within the present model 
framework any permanent alteration of distribution coefficients 
would have to be expressed in terms of drug distribution to lung 
water, fat and protein). The peak concentration during infusion 
is now a much better fit and the decline at the end of infusion 
less steep.
Figures 15.6 and 15.7 show results from two studies of prolonged 
intravenous infusions of fentanyl with the corresponding 
simulations. Both groups of investigators studied the kinetics 
in surgical patients of constant rate intravenous fentanyl 
infusions started before anaesthesia and continued for 24 hours. 
Duthie and colleagues [10] measured fentanyl concentrations in 
the peripheral venous plasma of a number of patients grouped 
according to the type of surgery. There were no significant 
differences in concentrations between the groups and figure 15.6 
shows results from 10 orthopaedic patients of weight 69 (s.d.
12) kg and unspecified sex. Holley and Van Steenis [176] 
measured fentanyl concentration in the arterial plasma of 
patients undergoing various surgical procedures grouped 
according to infusion regimen, The results from two groups (10 
men weight 76 (s.d. 7) kg and 9 men weight 77 (s.d. 5) kg) are 
shown in figure 15.7. The plasma fentanyl concentrations 
reported by both groups agree reasonably well with each other 
and with the simulation.
Figure 15.8 shows a simulation of the inhaled nebulised fentanyl
study reported in r>art 1 of this thesis fsee fioures 6.1 to 6.4w     ~    - —  *   » * - -   ~  ’ - - -
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for the experimental results). The simulation was set up 
assuming 12% of the fentanyl delivered from the nebuliser would 
be deposited in the patients' lungs and that a further 8% would 
be deposited nasally. (This is a fairly crude simplification as 
a variety of respiratory patterns including both nose and mouth 
breathing were seen). Again no attempt was made to adjust the 
model weight to that of the experimental subjects three of whom 
were female. As with the simulation of Scott and colleagues' 
work [31] there is a suggestion (even more tentative this time 
given the uncertainties) that the initial^concentrations during 
nebulisation may be too high.
Note on peripheral venous concentrations: Peripheral venous drug 
concentration is modelled, after Davis [125] by calculating the 
concentration in an equal mix of blood from the lean pool, fat 
pool and peripheral shunt. However this device is arbitrary and 
unvalidated in that the likely proportions for the mix are 
actually unknown and are likely to vary from person to person, 
with site of venous access and with circumstances. Whereas the 
concentration difference between arterial and central venous 
blood becomes negligible a few minutes after simulated drug 
administration (figure 15.9) the concentration difference 
between arterial and the notional peripheral venous blood 
persists since it reflects closely the slower uptake and release 
of drug in the lean and fat compartments (This pattern has also 
been described experimentally in sheep using thiopentone [131]). 
The inclusion of a greater proportion of lean at the expense of 
fat tissue blood (which might be appropriate in modelling 
forearm venous blood from a non-obese male) would lessen the 
difference slightly between arterial and peripheral venous
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blood. With the exception of the inhaled fentanyl study, changes 
in the modelling of venous plasma would not have an important 
effect on the fit of the above simulations to the experimental 
data. Blood concentrations during the first few minutes of the 
inhalation study however are governed mainly by the effects of 
drug distribution, simulated arterial concentrations are up to 
three times higher than simulated peripheral venous 
concentrations and changes in the modelling of mixed venous 
blood might well affect the apparent fit of the model.
Tissue Distribution 
Only 7.4% of the administered dose remains in the blood 2 
minutes after simulated intravenous injection (100 pg over 1 s) 
which agrees approximately with experimental findings in man of 
5% 2 min after an intravenous bolus [180] and 6% (i.e. 3% in
plasma) 2 min after the end of a 2 min infusion [3 9 ].
Studies of the tissue distribution of fentanyl in rat [33] and 
rabbit [23] are described briefly in chapter one. Data from 
these studies are presented for comparison with the model output 
in figures 15.10 to 15.13. There are differences between the 
species.
The equilibrium tissue / plasma concentration ratios for the 
fentanyl model are fairly similar for all the tissue blocks with 
the exception of fat tissue (table 15.1). (The equilibrium 
tissue / plasma concentration ratios for the pethidine model are 
less uniform). For the fentanyl model differences between the 
tissues in tissue / arterial plasma concentration ratios are 
thus mainly determined by differences in tissue perfusion.
After a single intravenous bolus (see figure 15.11), for all 
tissues apart from lung, fat, liver and kidney the
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Table 15.1: tissue / plasma concentration ratios at distribution 
equilibrium for fentanyl and pethidine models
TISSUE RATIO
FENTANYL PETHIDINE
Lung 3.24 5.62
Kidney 3.88 4.30
Gut and Spleen 4.26 6.77
Liver 4.37 4.54
Other Viscera 4.65 4.72
Lean Tissue 4.37 64.98
Fat tissue 20.28 1.30
Brain 4.03 2.15
Intramuscular injection site 3.45 57.65
Nasal mucosa 3.60 3.40
Ratios for the pethidine model were calculated 30 min 
after simulating intravenous administration of 100 mg 
pethidine over 1 s
Table 15.1
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tissue / arterial plasma concentration ratio is at first lower 
than the equilibrium ratio, becomes equal to the equilibrium 
ratio at the time of maximum tissue concentration, overshoots as 
tissue concentration initially declines more slowly than plasma 
concentration, then approaches the equilibrium concentration 
once more as tissue concentration declines faster than and 
finally in parallel with plasma concentration. The time course 
of these changes is very different in different tissues.
Liver and kidney follow roughly the same pattern but post 
equilibrium tissue concentrations and hence tissue / arterial 
plasma ratios are lowered as a result of removal of drug for 
elimination. The tissue / arterial plasma concentration ratio 
for fat tissue is still increasing 24 hours after drug 
administration as tissue concentration continues to decline more 
slowly than plasma concentration.
The tissue / arterial plasma ratio in lung reflects the dilution 
of pulmonary venous blood in the arterial pool. In this last 
case the marked changes of the first two minutes or so are very 
influenced by changes in calculation cycle time and must be 
regarded as artifactual since the circulatory model was not 
designed to reflect detailed flow patterns in the heart and 
large vessels (Mapleson's model M [127] simulates longitudinal 
mixing of blood along stylised vessels and in this respect an 
elaboration of model M might be more suitable than the adopted 
model P ) .
Times of maximum tissue concentrations after a simulated single 
intravenous injection are shown in table 15.2. The absolute 
times differ from those found in the animal studies (see chapter 
1) but the pattern is similar with maximum concentration in fat
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Table 15.2: Times of concentration maxiraima after a simulated 
single intravenous bolus of fentanyl (500 }ig given over 5 s)
TISSUE TIME
Lung 11 s
Kidney 47 s
Brain 1 min 35 s
Gut and Spleen 1 min 51 s
Other Viscera 2 min 15 s
Liver 6 min 39 s
Lean Tissue 35 min 8 s
Fat tissue 294 min 6 s
Table 15.2
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occurring many times later than in other tissues, maximum 
concentration in lean tissue also delayed but to a much lesser 
extent than in fat tissue, and early maximum concentrations in a 
group of tissues including lung, brain and kidney.
It is noticeable that tissue / plasma concentration ratios in 
the lung are high compared to other tissues in both rat and
rabbit but this is not mirrored in the model simulation.
Distribution to lung; Taeger and colleagues [24] examined the 
uptake into the lungs of a bolus of fentanyl administered 
simultaneously from a central venous catheter with a dye which 
would not diffuse out of the circulation. They found uptake to 
range from 55 to 85% in five patients over the first pass of the 
fentanyl bolus through the lung. Apparently, most of this 
fentanyl was released from the lung over the next 14 minutes 
(figure 15.14). Roerig and colleagues [25] also examined first 
pass uptake, but not subsequent washout, using a similar
experimental arrangement. They found a mean of 75% (range 63 to 
87%) of the fentanyl dose was absorbed by the lung in eight
subjects. The model is based on the assumption that distribution
of fentanyl between blood and tissue occurs according to a 
diffusion equilibrium. The data of Roerig and colleagues [25] is 
consistent with this proposition. They calculated the extraction 
ratio (proportion of fentanyl content removed from the blood) at 
each moment of the arterial first pass concentration-time curve. 
(They call this the "instantaneous extraction ratio" although 
for each volume element of blood it represents the cumulative 
extraction ratio for its passage through the entire lung). At 
the beginning of the first pass (i.e. for the first portion of 
the blood in which the bolus was distributed) it was greater
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than 90%. During the remainder of the first pass it decreased 
rapidly but was still positive at the end. Peak arterial 
fentanyl concentration also occurred later than that of the 
simultaneously injected dye. Together these facts suggest a 
flux of fentanyl was occurring in both directions (into and out 
of the lung). If fentanyl was binding to sites in the lung from 
which it had a long dissociation time constant or the 
diffusional process was so far from equilibrium that flux out of 
the lungs was negligible compared to flux into the lungs then 
the extraction ratio would remain constant and there would be no 
delay of the fentanyl peak.
Figure 15.15 shows a plot of the amount of drug in lung tissue 
as a percentage of a simulated rapid (1 s) intravenous dose for 
the first minute after administration. The proportion of the 
simulated dose partitioning into the lung in the first few 
seconds after administration is slightly too low and the 
washout is far too rapid. Figure 15.16 shows the simulation of 
figure 15.15 repeated with the model altered by increasing the 
mass of the lung tissue block 5, 10, and 15 fold leaving all
other variables including absolute lung perfusion unchanged 
(note the change in timescale). An increase in lung "binding" of 
10 or 15 times provides a reasonable approximation to the 
experimental washout data. A note of caution: Taeger and
colleagues [24] present their data in an abstract. Fentanyl 
washout was calculated "from the arterial- mixed venous (a-v) 
concentration difference" using the initially measured cardiac 
output. No other details are given. Clearly the pulmonary 
release of fentanyl cannot be calculated from the instantaneous 
a-v difference since this will also depend on the flux of
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fentanyl between blood and other body tissues, in theory it 
should be possible to estimate systemic and pulmonary fluxes 
separately by taking into.account the respective transit times, 
but the likely accuracy of this method (if this indeed was the 
method used) cannot be judged without a more detailed 
presentation.
In all three simulations of figure 15.16 simulated maximum lung 
content of fentanyl is at or just above the upper end of the 
range for lung content at the end of first pass in the 
experimental subjects. (The experimental fentanyl lung content 
is calculated as total dose minus amount in first pass blood. 
This is not strictly accurate as by the time the last first pass 
blood leaves the lungs further exchange has already taken place 
with the capillary blood immediately upstream). Unfortunately 
the simulated data not directly comparable to the
experimental as the model does not allow the first passage of a
bolus of drug to be simulated realistically. This would require 
capillary volume to be taken into account together with a more 
realistic representation of blood flow and longitudinal mixing. 
In the present case the maximum lung content is influenced by 
the calculation cycle time. For instance in the case of the
middle simulation of figure 15.16 (lung binding x 10) when the
cycle time is set to 1 s as shown, maximum lung content is 87%
5
of the dose at 20 s whereas with a cycle time of 6 s maximum 
lung content is 92% at 6 s. Setting a small calculation cycle 
time gives, as in life, a rising then falling concentration in 
the peripheral arterial blood with the peak concentration
occurring slightly earlier than life at around 16 s. However the 
concentration of blood entering the lung during this time is
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steadily decreasing as a result of venous blood entering and 
diluting the injection pool. In life the concentration in the 
pulmonary artery blood as the drug bolus passes through is
increasing then decreasing. When the cycle time is set to six
/
seconds virtually the whole of the drug bolus is in the blood 
which equilibrates with the lungs at the first calculation cycle 
after injection. The largest fentanyl concentration in arterial 
blood is the first calculated concentration and thereafter 
arterial concentration steadily decreases. There will be similar 
artefacts in the modelling of initial drug concentrations in 
other tissues, which may be of importance if these transient 
initial changes have any relevance for drug effect.
Note on calculation cvcle time: The effect of calculation cycle 
time on the uptake of drug into the lung and on lung 
tissue arterial plasma concentration ratios has already been 
discussed. Figure 15.17 shows the effect on arterial plasma and 
brain tissue concentrations of simulating a brief (6 s) 
intravenous injection with cycle times of 6, 1, and 0.1 seconds. 
The influence of cycle time on the simulation is negligible at 
cycle times of less than one second and after the first few 
seconds of simulation. Where the effect of cycle time is 
noticeable it is not clear whether it is more realistic to set 
it large or a small. A cycle time of 1 s has been adopted as 
standard and was used for all simulations unless specified 
otherwise.
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Pharmacokinetic Constants 
The volume of distribution at steady (Vss) state may be 
calculated directly from the total mass of plasma, red cells and 
tissue blocks and the respective equilibrium distribution 
ratios. This gives
V ss = 468 kg = 454 1 plasma
which comparison with table 13.3 shows to be larger than all but 
one of the experimental values. Of this 454 1 270 1 is accounted 
for by the fat-tissue block and 156 1 by the lean..
Plasma clearance was explicitly set when the model was 
constructed (chapter 13).
Plasma Clearance = 880 ml min-1
Plasma clearance will vary slightly depending on urine flow and 
pH.
The terminal half life may be calculated after fitting an 
exponential function to the simulated concentration time curve 
after intravenous administration, which also provides an 
opportunity to examine the model output in terms of a 
conventional compartmental pharmacokinetic model. (This is done 
to provide evidence of the realism or otherwise of the simulated 
results. Experimental arterial concentration profiles treated in 
this way yield certain values for the standard pharmacokinetic 
constants. Do the simulation results yield similar values? The 
results must be interpreted with caution. The concentrations in 
the physiological model are determined by a relatively small 
number of approximately exponential processes and there are 
bound to be systematic errors in fitting simulated concentration
;
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time curves to bi or tri exponential functions. To assess the 
respective merits of the physiological and conventional models 
it would be necessary to compare the output of each separately 
against sets of actual measured concentration-time data). 
Arterial plasma concentration-time data for the 24 hours 
following a single simulated bolus intravenous injection was 
fitted to bi and tri exponential functions of the form
(15.1) C = P.e"nt + A.e"at +'B.e"Pt
where C is concentration, t is time P, A and B are the zero time 
intercepts and a, {3 and n the rate constants for the exponential 
terms.
Fitting was carried out using a computer curve-fitting program 
based on the Levenberg-Marquardt routine [166]. To prevent the 
fitted values declining to zero after the first few hours it was 
necessary to exclude data from the first few minutes of the 
simulation. The bi-exponential curve is fitted to data from 6 
minutes onwards and the triexponential curve to data from 2
minutes onwards. Figures 15.18 and 15.19 show the simulated and
fitted curves. Intercompartmental rate constants for a standard 
two compartment and mamillary three compartment models and the 
corresponding pharmacokinetic variables were calculated from P, 
A # B, a, ]3, and n according to standard formulae [132, 134].
They are shown in table 15.3. Experimental values for comparison
are found in table 13.3.
The terminal half lives are within the range of experimentally 
determined values. The actual model clearance is overestimated 
and the actual model V ss underestimated by this technique but
clearance and V ss as calculated by this method are within the
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Figure 15.18
Simulated Concentrations of Fentanyl in Arterial Plasma and 
Fitted Bi-exponential Curve
6 
5 
4 
3 
2 
1 
0
i
plasma concentration (ng /  ml)
1.0 
0.8 
0.6 
0.4 
0.2
0.0
0 500 1000 1500
time (min)
simulated + compartmental model
2-com partm ent model 
+ first 60 min not shown
v ■
'++^ + ;
+ +
plasma concentration (ng /  ml)
+ 2 -com partm ent model
\ first 60 min
+
4-
-f
-  - .. + + +
3 20 40 60 80
time (min)
simulated + compartmental model
500 pg intravenously over 5 s
Figure 15.19
Simulated Concentrations of Fentanyl in Arterial Plasma and 
Fitted Tri-exponential Curve
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Table 15.3: Pharmacokinetic Constants Calculated from Simulated 
Data According to Two and Three Compartment Models
two compartment three compartment
n half life 0.7 min
a half life 10.4 min 10.8 min
{3 half life 303 min 311 min
Clearance 1248 ml IT1 1099 ml h"1
v ss 410 1 326 1
v p
546 1 493 1
See text for details.
V ss volume of distribution at a steady state
Vp volume of distribution during elimination
Table 15.3
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upper end of the experimental range. Vp is greater than any of 
the experimental values.
Nasal Compartment 
Figure 15.20 shows a plot of the percentage of the administered 
dose remaining in the nasal mucosa for the first 20 minutes 
after the simulation of a bolus administration to the nose. Less 
than five percent of the administered dose remains in the nasal 
mucous at the end of the first calculation cycle reflecting its 
small mass compared to the mass of the nasal mucosa. The effect 
of mucus clearance will thus be negligible. Peak arterial plasma 
concentration occurred at 2 min 27 s.
Intrapulmonarv Administration 
Figure 15.21 shows the arterial plasma and brain concentrations 
during the first minute after the administration of 100 pg of 
fentanyl over 1 s either into the lung or intravenously. The 
calculation cycle time is one second. Brain concentration is 
greater over the first 40 s or so after pulmonary than after 
intravenous administration. The pulmonary administration can be 
considered a "best case" in which drug is delivered uniformly 
throughout the lungs and thence diffuses freely into the 
circulation. Unfortunately, as discussed in relation to first 
pass lung uptake, the model does not have the resolution to 
simulate the transient local concentration changes consequent on 
a bolus of drug mixing with the blood, and equilibrating 
realistically across a capillary bed. The quantification of the 
difference between the two modes of administration must 
therefore be regarded as artifactual. As might be expected, when 
the calculation time is set to 6 s and the volume of the
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Figure 15.20
Fentanyl Content of Nasal Mucosa Following Simulated Nasal 
Administration of 100 pg over 1 s
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Figure 15.21
Concentrations of Fentanyl in Brain and Arterial Plasma 
Following Simulated Intravenous and Intrapulmonary 
Administration (100 pg over 1 s)
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circulating blood approximates the volume of the injection pool, 
the difference between the routes is virtually eliminated.
Tissue and Plasma Binding 
The characterisation of all tissue binding in terms of a 
distribution between water, protein and fat is conceptually 
elegant. However one cannot help but have reservations as to the 
practicality of fully quantifying such a scheme given the 
heterogeneity of body proteins (and to a lesser extent fats), 
and the difficulties with such a circumscribed and accessible 
system as binding to plasma proteins.
It may be that the present scheme could be simplified and that 
information on whole cell binding would be easier to collect 
experimentally. For fentanyl, and probably other potent lipid 
soluble drugs, protein binding of unionised drug at 
pharmacological concentrations can apparently be approximately 
characterised by a simple partition coefficient (see chapter 
13) . Since most of the protein-bound and all the lipid- 
dissolved drug is in the unionised form it should be possible to 
characterise distribution of unionised drug between cell and 
extra cellular fluid (ecf) in terms of a single combined 
partition coefficient. Ionised drug would be distributed between 
cell water and ecf water according to the respective pH.
The question of how to proceed is essentially empirical since it 
depends on how detailed a characterisation is necessary before 
the model begins to fulfil its functions satisfactorily. If the 
model is to be quantitatively useful one measure of this must be 
its ability to outperform the predictive ability of conventional 
compartmental models.
In the short term a measure of the solubility of pethidine and
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fentanyl in human or animal lipids is clearly needed. 
Experiments would involve measuring aqueous / lipid partition 
coefficients over a range of pH for standard industrial solvents 
and extracted subcutaneous and intra-abdominal fat, ideally 
using tritiated drug. Since this would allow a series of 
estimates of the effective pKa (see chapter 13) the opportunity 
could also be taken to estimate pKa directly by electrometric 
titration [133] using exactly the same pH-measuring system. The 
results should either convincingly resolve the uncertainty in 
the present published data or else delineate real discrepancies 
for future investigation.
Elimination
Metabolism: In life, clearance will vary with factors such as 
liver blood flow, perhaps drug concentration and probably plasma 
pH through its effects on drug dissociation and tissue 
distribution. The overall model is specifically constructed to 
simulate the effect of these influences on drug distribution. By 
contrast the simulation of metabolism in both fentanyl and 
pethidine models is based on values of total body clearance 
derived from conventional group pharmacokinetic analysis. This 
seems a relative weakness in terms of the model1s adaptability 
to individual physiological conditions.
As the hepatic extraction ratio in the models is fixed 
metabolism will in fact increase with increased hepatic blood 
flow. However this relationship is unlikely to be quantitatively 
correct. In life, for a first order elimination process, as 
hepatic blood flow increases, clearance would be expected to 
increase towards intrinsic clearance but the extraction ratio to 
decrease [167].
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An experimentally validated sub model of metabolism based on 
hepatocyte drug concentration would be ideal but certainly for 
fentanyl there is no data at present with which to build one.
It would be possible however to incorporate existing clearance 
data into the model in a slightly more elaborate way than at 
present by relating it to intrinsic clearance and thence 
calculating an internally consistent relationship between rate 
of metabolism and hepatic drug concentration.
Thus for instance:
(Eq 15.2) C l e a r a n c e ( b l o o d ) = Clearance(blood) / (1 - ER)
where Clearance(blood)ini- is intrinsic hepatic clearance 
expressed in terms of concentration in blood, Clearance(blood) 
is the measured blood clearance and ER is the extraction ratio 
[167] .
But, by definition
(Eq 15.3) Clearance(blood)int = V /
where V is the rate of elimination and Cbi00(ji is the 
concentration of drug in blood.
combining equations 15.2 and 15.3 and rearranging
(Eq 15.4) V = Clearance (blood) x
(1 - ER)
For a first order process at relatively low substrate 
concentration [134]
(Eq 15.5) V
chep
vvmax
Km
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where Chep is the concentration of drug in the hepatocyte, Vmax 
is the maximum attainable reaction velocity and Km is the 
Michaelis constant.
Thus substituting for V in equation 15.5 from equation 15.4
(Eq 15.6) Vmax Clearance(blood) x Cblood
Km (1 - ER) x Chep
Vmax / Km raaY ke calculated using the steady state 
tissue / arterial blood ratio generated by the model for 
cblood / chep* steady state value is meant the value to
which this ratio tends once the distribution phase is over: see
tissue distribution above). Finally equation 15.5 could be
inserted into the model to calculate metabolism in the place of 
the present extraction ratio.
Essentially the process is that of calculating (by using the 
model to compute a numerical solution) the ratio V / C^ep 
associated with the measured experimental clearance given the 
prevalent model conditions and assumptions. The advantage is 
that in the case of deviations from these conditions (changes in 
liver blood flow or tissue / arterial concentration ratios) 
metabolism will now behave according to a theoretically correct 
model. It may be argued that the procedure is too contrived yet 
conversion of the experimentally measured metabolic clearance to 
an extraction ratio is similarly contrived in that liver 
perfusion was not measured at the time of the experiments but 
the model value assumed.
Excretion A theoretical as opposed to an empirical submodel was 
adopted for fentanyl urinary excretion from necessity and it
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remains speculative and untested. It has the merits however of 
varying urinary excretion with urine flow , urine pH , kidney 
blood flow and plasma fentanyl concentration in a manner that by 
analogy with urea [168] is qualitatively plausible. For instance 
increased urine flow will be associated with increased fentanyl 
excretion but decreased urinary fentanyl concentration. 
Excretion will increase with higher plasma fentanyl 
concentration or higher renal blood flow.
With the exception of renal blood flow the physiological 
variables used in the sub-model are relatively easily measurable 
and experimental assessment should thus be possible. One 
difficulty is the concentrating factor which I introduced as a 
constant but might be expected to vary with renal blood flow or 
glomerular filtration rate. Experiments to study fentanyl renal 
excretion would be justified by the present almost complete lack 
of data.
Summary
The model fulfils admirably its qualitative function of 
providing a disciplined framework for considering drug 
disposition. By this I mean not only that it illustrates how 
basic principles lead to results that may not be immediately 
intuitively obvious, as for instance in the detailed time course 
of tissue / arterial plasma ratios under different conditions, 
but also that the natural examination of the model's limits and 
assumptions promotes a closer scrutiny of physical mechanisms. 
The overall performance of the fentanyl model in simulating 
plasma concentrations to match published studies appears at this 
brief initial assessment to be quite reasonable. However ideally 
further development would be undertaken before prospective
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evaluation is performed. In particular a better estimate should 
be made of solubility in body lipids in view of the large part 
this plays in drug distribution. The present total volume of 
distribution is probably slightly too large.
There is also evidence that the affinity of the lung for 
fentanyl is too low at present. Certainly, on account of its 
massive perfusion, distribution to lung plays a 
disproportionately large part in determining plasma 
concentrations in the first few minutes after intravenous and 
intrapulmonary administration. In addition the lung and its 
circulation are routinely and uniquely accessible in vivo 
allowing a direct assessment of predictions made from laboratory 
data. Proper determination of binding to lung tissue should 
probably therefore have a high priority.
The model was less useful for detailed realistic simulation of 
the very transient concentration changes that occur immediately 
after drug administration. (The study of inhaled fentanyl and 
its associated theoretical background reported in part one had 
created the suggestion that the pattern of these transient 
changes might have a bearing on drug effect) . It would be 
straightforward to build a more detailed circulatory model, 
perhaps using Mapleson's model M as a starting point, but to 
model the transient changes accurately it would also be 
necessary to design a more sophisticated model of blood / tissue 
exchange incorporating a representation of capillary volume and 
probably, concentration gradients within the tissues. It would 
thus involve a considerable increase in computational 
complexity.
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Summary and Conclusions
chapter 16
1. An existing physiological model of intravenously and 
intramuscularly administered pethidine has been extended to 
allow intranasal and intrapulmonary administration and 
adapted to describe fentanyl.
2. The original model exists as a computer program in several 
different versions. During the present modifications, with 
help from the original author, several errors were 
identified in these programs. Some of these are present in 
published versions. Simulation results which had been used 
for initial evaluation of the model are affected.
3. A preliminary evaluation of the fentanyl model against 
published data suggests that simulated arterial and venous 
plasma concentrations are similar to those obtained 
experimentally.
4. Elements of the model have been examined individually and 
its future development discussed.
5. The model proved only of limited use for simulating the 
transient concentration changes which occur in the few 
seconds following drug administration, the examination of 
which was suggested by work reported in part 1 of this 
thesis. Despite this the model is a useful conceptual tool 
in the examination of questions arising from the 
development of new routes of drug delivery.
5. A lack of agreement between published studies of aspects of
fentanyl pharmacology has been noted. This was particularly 
surprising for the physiochemical variables lipid 
solubility and pKa.
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APPENDIX 1
Program Listing
T h i s  is a w o r d - p r o c e s s e d  v e r s i o n  of the l is t i n g  u se d f o r  the e n c l o s e d  c o m p i l e d  
p r o g r a m .  S o m e  long p r o g r a m  l ine s have been b r o k e n  up u s i n g  the  T u r b o  B a s i c  
line c o n t i n u a t i o n  s ign  and c o m m e n t s  hav e bee n u n d e r l i n e d .
D E F D B L  A-Z ' d e f a u l t  v a r i a b l e  type d o u b l e  p r e c i s i o n  f l o a t i n g  p o i n t
' D e f i n e  b a s i c  data.
nc = 11 
t o t w  = 70. 00 1
q do t  = 6 .4 8 
b den  = 1.0 6 
p den  = 1.03 
r den = 1.10
f wt b = 0 . 0 7 8 5 7  
fr = 0 . 4 5 0 0  
f p p k g  = 0 . 0 6 8 0  
fwp = 0 . 9 1 5 5  
D I M  f w t # ( 1 : n c )
'The model  man: v a l ue s  D a v i s  87 w i t h  
' a d d i t i o n s  H i g g i n s  90 
nc$ = "no. of c o m p a r t m e n t s  " 
t o t w $  = " bo dy  m as s  Kg " 
q d o t $  = " c a r d i a c  o u t p u t  1 / m i n  ( d e f a u l t )  
b d e n $  = " d e n s i t y  of b l o o d  Kg/1 "
p d e n $  = " d e n s i t y  of p l a s m a  Kg/1 "
r d e n $  = " d e n s i t y  of e r y t h r o c y t e s  Kg/1 "
f w t b $  = "Kg b lo od / Kg b o d y  m a s s  "
fr$ = "Kg e r y t h r o c y t e  /Kg b l o o d  " 
fpp$ = "Kg p r o t e i n  / Kg p l a s m a  " 
fwp $ = "Kg w a t e r  /Kg p l a s m a  " 
fwt $ = "Kg t i s su e  / Kg t ot al m a s s "
R E S T O R E  n u m e r i c a l d a t a  
FOR x = 1 TO nc 
REA D f w t # ( x )
N E X T  x
n ume ri  cal data:
D AT A  0 . 0 0 6 6 2 8 , 0 . 0 0 0 0 0 , 0 . 0 0 4 0 5  7 , 0 . 0 1 9 8 7 0 0 , 0 . 0 2 4 5  9 
D AT A  0.02 6 8 6 , 0 . 5 2 4 4 6 , 0 . 1 9 5 5 7 , 0 . 0 0 0 1 0 , 0 . 0 0 0 1 4 , 0 . 0 0 0 1 1 8 6  
DI M  f c # ( 1 : n c )  : fc$ = "Kg cells / Kg t i s s u e "
FOR x = 1 TO nc 
REA D fc# (x )
N EX T  x
D ATA  0 . 8 0 0 0 , 0 . 0 0 0 0 , 0 . 8 0 0 0 , 0 . 8 0 0 0 , 0 . 8 0 0 0  
D ATA  0 . 8 0 0 0 , 0 . 8 0 0 0 , 0 . 9 2  5 0 , 0 . 7  0 0 0 , 0 . 8 0 0 0 , 0 . 8 0 0 0  
DI M  f l # ( l : n c )  : f1$ = "Kg lipid / Kg t i s s u e "
FOR x = 1 TO nc 
R EAD  f l # ( x )
N E X T  x
D AT A  0 . 0 1 2 0 , 0 . 0 0 0 0 , 0 . 0 5  2 0 , 0 . 0 5 7  0 , 0 . 0 6 7 0  
D A T A  0 . 1 0 5 0 , 0 . 0 4 5 0 , 0 . 8 0 0 0 , 0 . 1 1 0 0 , 0 . 0 2 0 0 , 0 . 0 6 1 7  
D IM  f p # ( 1 : n c )  : f p $ = "Kg p ro t e i n  / Kg t i s s u e "
FOR x = 1 TO nc 
R EAD  fp# (x )
N E X T  x
D AT A  0 . 1 8 0 0 , 0 . 0 0 0 0 , 0 . 1 7  0 0 , 0 . 1 4 1 0 , 0 . 1 8 0 0  
D AT A  0 . 0 9 7  0 , 0 . 1 9 1 0 , 0 . 0 4 9 0 , 0 . 0 8 0 0 , 0 . 1 7 0 0 , 0 . 1 3 3 3  
D IM  f w # ( 1 : n c )  : fw$ = "Kg w a t e r  / Kg t i s s u e "
FOR x = 1 TO nc 
R EAD f w # ( x )
N E X T  x
D AT A  0.7 5 0 0 , 0 . 0 0 0 0 , 0 . 7 7  0 0 , 0 . 7 8 4 0 , 0 . 7 2  00 
D AT A  0.77 4 0 , 0 . 7  47 0 , 0 . 1 4 9 0 , 0 . 7  9 0 0 , 0 . 7 9 0 0 , 0 . 7  917 
D IM  f p e k g # ( 1 : n c )  : f pe $ = " Kg p r o t e i n  / Kg ECF "
FOR x = 1 TO nc 
R EA D f p e k g # (x )
N E X T  x
D AT A  0 . 0 3 5 0 , 0 . 0 3 5 0 , 0 . 0 3 5 0 , 0 . 0 3 5 0 , 0 . 0 3 5 0
D AT A  0 .03  5 0 , 0 . 0 3 5  0 , 0 . 0 3  5 0 , 0 . 0 1 0 0 , 0 . 0 3  5 0 , 0 . 0 3 5 0
D IM  f w e # ( 1 : n c )  : fwe $ = "Kg w a t e r  / Kg ECF"
FOR x = 1 TO nc
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R EA D  f w e # ( x )
N E X T  x
D A T A  0 . 9 6 5 0 , 0 . 9 6 5 0 , 0 . 9 6 5 0 , 0 . 9 6 5 0 , 0 . 9 6 5 0
D AT A  0 . 9 6 5 0 , 0 . 9 6 5  0 , 0 . 9 6 5 0 , 0 . 9 9 0 0 , 0 . 9 6 5 0 , 0 . 9 6 5 0
fra = 0 . 1 3 0 0  : fra $
frf = 0 . 1 0 1 0  : f r f $
fri = 0 .1 3  00 : fri$
frl = 0 . 3 3 8 0  : frl$
frp = 0 . 1 7 1 0  : frp$
frv = 0 . 1 3 0 0  : frv$
D I M  f # ( 1 : n c )  : f$ =
FOR x = 1 TO nc 
R EA D  f # ( x )
N E X T  x
D AT A  1 . 0 0 0 0 0 , 0 . 1 5 1 0 0 , 0 . 1 8 8 0 0 , 0 . 1 7 1 0 0 , 0 . 0 6 9 0 0
D A T A  0 . 1 9 1 0 0 , 0 . 1 7  6 9 0 , 0 . 0 5 3 0 0 , 0 . 0 0 1 0 5 , 0 . 0 0 0 0 3 , 0 . 0 0 0 6 4 0
' c o r r e c t i o n  f a c t o r  to m a k e  
1v o l u m e s  = 1.0"
/ 1 . 0 0 1 6 2
= " f r a c t i o n  of b l o o d  v o l u m e  a r t e r i a l  pool "
= " f r a c t i o n  of b l o o d  v o l u m e  fat  pool "
= " f r a c t i o n  of b l o o d  v o l u m e  i n j e c t i o n  pool "
= " f r a c t i o n  of b l o o d  v o l u m e  lean pool "
= " f r a c t i o n  of b l o o d  v o l u m e  p ort al  pool "
= " f r a c t i o n  of b lo o d  v o l u m e  m i x e d  v e n o u s  pool " 
" f r a c t i o n  of total c a r d i a c  o u t p u t "  'to t i s s u e  block'
sum f r a c t i o n a l  s t r o k e
s e a l e f a c t o r  = 1 
FOR x = 2 TO nc
f #( x) = f #( x) * s c a l e f a c t o r
N E X T  x
m wp  = 9 1 0 0 0 m wp $
m w e  = 9 1 0 0 0 m we $
m w e  = 9 1 0 0 0 m wc $
php = 7 . 4 0 0 0 php$
D I M  a p h # ( 1 : nc) aph$
FOR x = 1 TO 11
R EA D a p h # ( x )
N E X T  x
' c o r r e c t e d  f r a c t i o n s "
'mean m o l a r  m a s s  p l a s m a  p r o t e i n s  "
'mean m o l a r  m as s  ECF p r o t e i n s  "
'mean m o l a r  m as s  of t i s s u e  cell p r o t e i n s "
'pH p l a s m a  ( d e f a u l t )  "
'o ff se ts  i n t r a c e l l u l a r  pH e q u a t i o n "  't i s s u e s
D A T A  - 0 . 4 0 , 0 . 0 0 , - 0 . 3 0 , - 0 . 6 0 , - 0 . 3 0  
D A T A  - 0 . 6 0 , - 0 . 4 6 , - 0 . 2 0 , - 0 . 3 0 , - 0 . 4 6 , - 0 . 3 0
-0 . 80  
6.2 
= 1 0 0 . 0  
= 17.0 
= 4.0 /
= 6.77 
94
bph = 
phu  = 
u r o u t  
f c o n c  
w t m u c  
p r o t m u c  
f w m  = 0 
m w t m u c  = 9 1 0 0 0  
p h m  = 6.0  
dt = 1.0
10000  
/ 1000
bph $ = " s l o p e  i n t r a c e l l u l a r  pH e q u a t i o n  "
phu $ = " u r i n e  pH ( d e f a u l t )  "
u r o u t $  = " u r i n e  w a t e r  o u t p u t  g / h ( d e f a u l t )
f c o n c $  = " u r in e  c o n c e n t r a t i n g  f a c t o r  "
w t m u c $  = "Kg m u c o u s  in nasal a b s o r b t i o n  s it e
p r o t m u c $  = "Kg p r o t e i n  / Kg m u c o u s  "
fwm$ = "Kg w a t e r  / Kg m u c o u s  "
m w t m u c $  = "av mol w t  m u c o u s  p r o t e i n s  "
phm$ = "pH nasal s e c r e t i o n s  "
dt$ = " c y c l e  t ime  s e c o n d s  ( d e f a u l t ) "
'drug v a r i a b l e s :
m e t f $  = " m e t a b o l i c  e x t r a c t i o n  f r a c t i o n  "
l a m lw $  = " l i p i d / w a t e r  p a r t i t i o n  c o e f f i c i e n t  f o r  f e n t a n y l
pka $ = "pKa f e n t a n y l  "
a c i d $  = " a c i d - b a s e  d rug  I n d i c a t o r  "
d fa c$  = " do se  c o n v e r s i o n  f a c t o r  ug f e n t a n y l  b a s e  to umol
m e t f  = 0.5 5 
l a m l w  = 5 0 0 . 0  
pka  = 7.8 5 
a c i d  = 1
d f a c  = 1.0 / 3 3 6 . 6 0  
e p r a t  = 0 . 9 0 8
e p r a t $  = "umol d rug  p e r  Kg e r y t h r o c y t e  / umol dru g pe r  Kg p l a s m a  "
: nki $ = " p r o t e i n  b i n d i n g  c o n s t a n t  i o n i s d  f o r m  "
: nks $ = " p r o t e i n  b i n d i n g  c o n s t a n t  u n i o n i s e d  f o r m
nki = 0 . 0 0 1 2 4 6  
nks  = 0 . 0 1 9 1 2 1
D I M  f w c # ( 1 :nc) 
D I M  f p c # ( 1 : n c )  
D I M  f 1 c # ( 1 : n c ) 
D I M  w f # ( 1 : nc) 
D I M  w t # ( 1 :n c ) 
D I M  p h c # ( 1 : n c )
' D i m e n s i o n  a r r ay s  for  i n t e r m e d i a t e  v a l u e s
'Kg w a t e r  / Kg t i s s u e  c e l l s
'umol or Kg p r o t e i n  / Kg t i s s u e  c el ls
'Kg l ip id / Kg t i s s u e  c e l l s
'mass s t r o k e  vol f r a c t i o n s  Kg
'mass t i s s u e  b l o ck s  Kg
'pH ti s su e cel 1 s
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D I M  x # ( 1 : n c )
D I M  b # ( 1 :nc)
D I M  e# ( 1 : n c )
D I M  c # ( 1 : n c )
D I M  c s o l d # ( l :n c ) 
D I M  c s # ( 1 : nc)
D I M  a f # ( 1 : nc)
D I M  a a b # ( 1 : n c )
D I M  a a t o l d # ( 1 :nc) 
D I M  a a t # ( 1 :nc)
D I M  a a b t # ( 1 :nc)
' c o n v e n i e n c e  v a r i a b l e s  see sub p h c a l c
'umol u n i o n i s e d  dru g / Kg w a t e r  b e f o r e  e q u i l i b r a t i o n
1 umol drug i n b l o o d e n t e r i n g  t i s s u e  b l o c k s
' umo 1 druq i n b l o o d f r a c t i o n  a f t e r  e o u l 1 1 b r a t l o n
' umo 1 druq i n t i s s u e bl o c k  b e f or e  e c u i 1 i br at 1 on
' umo 1 druq i n ti ssu e bl o c k  a f t e r  e q u i l i b r a t i o n
' umo 1 drug i n bl ood and t i s su e  a f t e r  e o u i 1 i b r a t i o n
FOR 1 
IF NOT
' c a l c u l a t e  s om e  i n t e r m e d i a t e  v a r i a b l e s  for use in f i r s t  or 
' s u b s e q u e n t  s i m u l a t i o n s  
= 1 TO nc
fwc#(i) 
fpc# (i)
= 2 T H E N  
= (fw #( 1 )
= (fP #(i )
= (fl #(1 )
(f w e # ( i ) * 
( f p e k g # ( 1 ) 
(fie * (1f 1 c #  ( 1 )
END IF 
N E X T  i
fpp = (fp pk g  / mwp) * E X P 1 0 ( 9 . 0 )  
fp m  = ( p r o t m u c  / m w t m u c )  * E X P 1 0 ( 9 . 0 )
D I M  f p e # ( 1 : nc)
FOR  i = 1 TO nc
f p e # ( i )  = ( f p e k g # ( i )  / mwe) * E X P 1 0 ( 9 . 0 )  
f p c # ( i )  = ( f p c# ( i)  / mwe) * E X P 1 0 ( 9 . 0 )
'Kg w a t e r  / Kg t i s s u e  c e l l s  
(1 - f c # ( 1 ) ) ) )  / f c # ( i )
'Kg p r o t e i n  / Kg t i s s u e  c e l l s  
* (1 - f c # ( 1 ) ) ) )  / f c f ( 1)
'Kg lipid / Kg t i s s u e  c e l l s  
f c f ( i ) ) ) )  / fcf(i)
N E X T  i
w p a  = t ot w  * fwt b * fra
w p v  = t o t w  * fwtb * f rv
wpi = t o t w  * fwt b * f r i
w p p  = t ot w  * fwt b * f rp
w p f  = t o t w  * fwt b * frf
wpl = t o t w  * fwtb * frl
FOR i = 1 TO nc
w t # ( i )  = t o t w  * f w t # ( 1 )
N E X T  i
a g a i n  = 0
begi ni n g :
S C R E E N  0
CLS
n u 1 $ = INK EY $
e$ =
IF a g a i n  = 1 T H E N
' umo 1 p r o t e i n  / Ka m u c u s
' umol p r o t e i n  / Ka ECF
' umo 1 p r o t e i n  Kq t i s s u e cel 1
'mass a rt er i al  pool Ka
'mass m i x e d  v e n o u s  pool Kq
'mass i n j e c t i o n  pool Ka
' m ass portal pool Kq
'mass fat pool Ka
' m as s lean pool Ka
'mass t i s s u e  b l o c k s  Ka
' i n d i c a t e s  f i r s t  s i m u l a t i o n  
' p r o g r a m  r e s t a r t s  h ere  for  s e c o n d  and 
' s u b s e q u e n t  s i m u l a t i o n s
DO U N T I L  U C A S E $ ( e $ )  = "Y" OR U C A S E $ ( e $ )  = ”N 
L O C A T E  2,1
P R I N T  " A n o t h e r  s i m u l a t i o n  Y or N?' 
e$ = I NKE Y$
LOO P
IF U C A S E $ ( e $ )  
q d o t  = 6.4 8 
p hp  = 7 .40  
ph u  = 6.2 
dt = 1.0
N" T H E N  G OT O f i n i s h
'input r o u t i n e  to c o n t i n u e  r e r u n
're set s v a r i a b l e  d e f a u l t  v a l u e s  
'for r e p ea t  s i m u l a t i o n
u r o u t  
END  IF
1 0 0 . 0
apa 
ap v
' i n i t i a l i s e s  or r e s e t s  some i n t e r m e d i a t e  v a r i a b l e s  
'umol drug ar t er i al  pool
'umol drug m i x e d  v e n ou s  pool
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ap 1 = 0 
ap 1 = 0 
a pf = 0 
app = 0 
aa m  = 0 
a a b t m  = 0 
FOR i = 1 TO nc 
a a t # ( i ) = 0 
a a t o 1d # ( i ) = 0 
a a b # (i ) = 0 
a a b t # ( i ) = 0 
c s # ( i ) = 0 
c s o l d # (1) = 0 
N E X T  i 
cs a = 0 
c sc v = 0 
c sp v  = 0 
csi = 0 
csp = 0 
cs 1 = 0 
cs f = 0 
css = 0 
b ab a  = 0 
b a b c v  = 0 
b a b p v  = 0 
babi = 0 
b abp = 0 
babl = 0 
b ab f  = 0 
b ab s = 0 
b ap a  = 0 
b a p c v  = 0 
b a p p v  = 0 
b a p i = 0 
b ap p = 0 
bapl = 0 
b ap f  = 0 
b aps  - 0 
t o t a l a m t e x c  = 0 
t o t a l a m t m e t  = 0 
t t i m e  = 0 
r t i m e  = 0 
p t i m e  = 0 
d s t o t  = 0 
v d l e f t  = 0 
l d l e f t  = 0 
n d l e f t  = 0 
v d u r n  = 0 
l dur n = 0 
n d u r n  = 0 
v d i n c  = 0 
1 d i n c = 0 
n d i n c = 0 
i v d o s e  = 0 
i m d o s e  = 0 
n o s d o s e  = 0 
l u n g d o s e  = 0 
i v n u m  = 0 
i m n u m  = 0 
n o s n u m  = 0 
l u n g n u m  = 0
' umo 1 druq lean pool
' umo 1 druq fat pool
' umo 1 druq portal pool
' umo 1 druq nasal m u c u s
'umol dru g nasal b l o o d . t i s s u e  and m u c o u s  
'umol drug in tis su e  b l o c k
'umol drug in blood  f r a c t i o n
'urn! dru g in blood  and t i s s u e  c o m b i n e d
'umol u n i o n i s e d  druq / Kq w a t e r
' u n i o n i s e d druq umol / 1 w a t e r a r t e r i a l  pool
' u n i o n i s e d druq umol / 1 w a t e r c en tr a l  v e n o u s  pool
' u n i o n i s e d druq umol / 1 w a t e r p e r i p h e r a l  v e n o u s  b l o o d
' u n i o n i s e d druq umol / 1 w a t e r i n i e c t i o n  pool
'uni on i  sed druq umol / 1 w a t e r porta l pool
'uni on i sed druq umol / 1 w a t e r lean pool
'uni on i sed druq umol / 1 w a t e r fat pool
' u n i o n i s e d druq umol / 1 w a t e r s h u n t  b lo od
' umo 1 druq / 1 a rt er ia l pool b l o o d
' umo 1 druq / 1 centr al  v e n o u s  b l o o d
' umo 1 druq / 1 p e r i p h e r a l  v e n o u s  b lo od
' umo 1 druq / 1 i n i e c t i o n  pool b l o o d
' umo  1 druq / 1 portal pool b l o o d
' umo 1 druq / 1 lean pool b l o o d
' umo 1 druq / 1 fat pool b l o o d
' umo 1 druq / 1 s hu nt b l o o d
' umo 1 druq / 1 a rt er ia l pool p l a s m a
' umo 1 druq / 1 cen tra l v e n o u s  p l a s m a
' umo 1 druq / 1 p e r i p h e r a l  v e n o u s  p l a s m a
' umol druq / 1 i n i e c t i o n  pool p l a s m a
' umol druq / 1 portal pool p l a s m a
' umo 1 druq / 1 lean pool p l a s m a
' umo 1 druq / 1 fat pool p l a s m a
' umo 1 druq / 1 s hu nt p l a s m a
c u m u l a t i v e  umol drug e x c r e t e d
c u m u l a t i v e  umol druq m e t a b o l i s e d  
s i m u l a t i o n  l eng th  s e c o n d s  
e l a p s e d  time s ec on d s
e l a p s e d  tim e since  d os e or p a r a m e t e r  c h a n g e  s e c o n d s  
umol druq a d m i n i s t e r e d  
u n a d m i n i s t e r e d  p o r t i o n  of iv d os e  umol 
u n a d m i n i s t e r e d  p o r t i o n  of i n t r a p u l m o n a r y  d os e  umol
u n a d m i n i s t e r e d  p o r t i o n  of i n t r n a s a l  d os e  umol
' d u r a t i o n of a d m i n i s t r a t i o n  of 1v dose
'd u r a t i o n of a d m i n i s t r a t i o n  of p u l m o n a r y  dos e
'd u r a t i o n of a d m i n i s t r a t i o n  of nasal d ose
' c u r r e n t iv dos e i n c r e m e n t  umol
1 c u r r e n t i n t r a p u l m o n a r y  d os e  i n c r e m e n t  umol
'c u r r e n t i n t ra n as a l  d ose  i n c r e m e n t  umol
'c u r r e n t iv dos e umol
'c u r r e n t im dos e umol
'c u r r e n t i nt ra n as a l  d ose  umol
'c u r r e n t i n t r a p u l m o n a r y  d o s e  umol
n u m b e r  of iv doses
n u m b e r  of im doses
n u m b e r  of i nt ran asa l d o s e s
n u m b e r  of i n t r a p u l m o n a r y  d o s e s
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u n u m  = 0 ' n u m b e r of u ri ne  pHs if d e f a u l t  c h a n g e d
p n u m  = 0 ' n u m b e r of p l a s m a  ohs if d e f a u l t  c h a n g e d
q n u m  = 0 ' n u m b e r of c a r d i a c  o u t p u t s  if d e f a u l t  c h a n c e d
t n u m  = 0 ' n u m b e r of c vc le  t i m e s  if d e f a u l t  c h a n c e d
u r o u t n u m  = 0 ' n u m b e r of u r i n e  o u t p u t s  1f d e f a u l t  c h a n c e d
m a x n u m = 0 ' n u m b e r of p o s s i b l e  c o n c e n t r a t i o n  m a x i m u m s  + 1
r c o u n t  = 0 
i m c o u n t  = 0 
I v c o u n t  = 0 
n o s c o u n t  = 0 
l u n g c o u n t  = 0 
u c o u n t  = 0 
p c o u n t  = 0 
q c o u n t  = 0 
t c o u n t  = 0 
u r o u t c o u n t  = 0
gra ph l  
g r a p h 2  
g r a p h 3  
g r a p h 4  
g r a p h s  
g r a p h 6  
p a p e r  = 0 
d i s k 1 = 0 
d i s k 2  = 0 
l e g ! e a n  = 0 
l e g f a t  = 0 
l eg cv  = 0 
legp = 0
l e g b r a i n  = I 
l e g a r t  = 0
x1 %  = 
x2 %  = 
x3 %  = 
x 4 %  = 
x5 %  = 
x6 %  =
yi % = 
y 2 %  = 
y 3 %  = 
y 4 %  = 
y 5 %  = 
y 6 %  =
P% = I
CLS
P R I N T
P R I N T
P R I N T
P R I N T
P R I N T
P R I N T
P R I N T
P R I N T
P R I N T
P R I N T
P R I N T
P R I N T
' i n i t i a l i s e s  or r e s e t s  som e i n d i c a t o r s  and c o u n t e r s  
' c o u n t e r  for r e s u 1t s (a a t # M )) p r i n t i n g  
' p o s i t i o n  i n d i c a t o r  fo r  p e n d i n g  i m d os e  a r r a y
' p o s i t i o n  i n d i c a t o r  f o r  p e n d i n g  i v d os e  a r r a y
' p o s i t i o n  i n d i c a t o r  f o r  p e n d i n g  nasal dos e a r r a y
' p o s i t i o n  i n d i c a t o r  fo r  p e n d i n g  p u l m o n a r y  d ose  a r r a y
' p o s i t i o n  i n d i c a t o r  f o r  p e n d i n g  u r i n e  ph a r r a y
' p o s i t i o n  i n d i c a t o r  f o r  p e n d i n g  p l a s m a  ph a r r a y
' p o s i t i o n  i n d i c a t o r  fo r  p e n d i n g  c a r d i a c  o u t p u t  a r r a y
' p o s i t i o n  i n d i c a t o r  fo r  p e n d i n g  c y c l e  tim e a r r a y
' p o s i t i o n  i n d i c a t o r  f o r  p e n d i n g  u r i n e  o u t p u t  a r r a y
' i n d i c a t o r s  for  r e s u l t s  g r a p h  d i s p l a y  s e l e c t i o n
' i n d i c a t o r  for  p r i n t e r  d i s p l a y  s e l e c t i o n  
' i n d i c a t o r s  for r e s u l t s  f il e  s e l e c t i o n
' i n d i c a t o r s  s ho w  w h e t h e r  r e s u l t s  g r a p h  lab el s  in p l a c e
x c o o r d i n a t e s  for r e s u l t s  g r a p h  label s
‘y c o o r d i n a t e s  for r e s u l t s  g r a p h  l abe ls
' i n d i c a t o r  for  use in sub d s e n t r v
' P r i n t s  initial i n s t r u c t i o n s  on s c r e e n  and o r g a n i s e s  
' m e t h o d s  of p r o g r a m  o u t p u t
F E N T A N Y L  P H A R M A C O K I N E T I C  S I M U L A T I O N "
' S i m u l a t i o n  O u t p u t :  T h e  p r o g r a m  will p r e s e n t  r e s u l t s  g r a p h i c a l l y "  
to th e  s c r e e n  a n d / o r  e n t e r  d e t a i l e d  i n f o r m a t i o n  in a r e s u l t s  file"
’F i l e : "
'The p r o g r a m  c a l c u l a t e s ,  at int er v al s ,  d ru g c o n c e n t r a t i o n  in e ac h  t i s s u e "  
'bl ock  and the dru g c o n c e n t r a t i o n s  in b l o o d  and p l a s m a  at v a r i o u s  l oc a t i o n s '  
'in th e  c i r c u l a t i o n .  T i m e s  of c o n c e n t r a t i o n  m a x i m a  and b l o o d / t i s s u e "  
' c o n c e n t r a t i o n  r a t i o s  are also giv en"
P R I N T  ""
P R I N T  " Tw o s a m p l i n g  s c h e m e s  are  a v a i l a b l e  a s t a n d a r d  s c h e m e  and a m o r e "
P R I N T  " f r e q u e n t  s ch em e .  T h e  f r e q u e n t  s c h em e  al l ow s  c o n c e n t r a t i o n  c h a n g e s "  
P R I N T  " c o n s e q u e n t  on d ru g d i s t r i b u t i o n  to be f o l l o w e d  v e r y  c l o s e l y  but"
P R I N T  " g e n e r a t e s  a l ar ge a m o u n t  of data"
L O C A T E  2 4 , 4 5
P R I N T  " P r e s s  any key to c o n t i n u e . . . " ;
W H I L E  NOT I N S T A T :W EN D
n u 1 $ = INK EY S
CLS
P R I N T  " Sc r e e n :  Th e  p r o g r a m  will p l o t  drug c o n c e n t r a t i o n s  to an a p p r o p r i a t e "  
P R I N T  " m o n i t o r  s c r e e n  as the s i m u l a t i o n  p r o g r e s s e s . "
P R I N T  ""
P R I N T  " P r i n t e r :  If y o u  h av e  a p r i n t e r  the p r o g r a m  will p r i n t  d e t a i l s  of d ru g"  
P R I N T  "do ses , and v a r i a b l e  c h a n g e s  d u r in g  the s i m u l a t i o n . "
P R I N T  ""
P R I N T  ""
P R I N T  "A s t a r  * at the b o t t o m  left of the s cr ee n "
P R I N T  " i n d i c a t e s  the s i m u l a t i o n  is c o m p l e t e "
P R I N T  ""
P R I N T  ""
P R I N T  "At the end of the s i m u l a t i o n  p re ss any key to r e t u r n  to the p r o g r a m . "  
P R I N T  " ”
P R I N T  "";
L O C A T E  2 4, 4 5
P R I N T  " P r e s s  a ny  key to c o n t i n u e . . . " ;
W H I L E  NOT I N S T A T :W EN D 
nu 1 $ = INK EY S  
e $ = ""
CLS
DO U N T I L  U C A S E S ( e S )  = "Y" OR U C A S E S ( e S )  = "N"
L O C A T E  2,1
P R I N T  "Do y o u  hav e a p r i n t e r ? "
P R I N T  " P r e s s  Y or N"; 
e$ = I N K EY S  
LOOP
IF U C A S E S ( e S )  = "N" T H E N  p a p e r  = 0 ' in st r u c t s  the p r o g r a m
IF U C A S E S ( e S )  = "Y" T HE N  ' wh e t h e r  p r i n t e r  in use or no t
p a p e r  = 1  
L O C A T E  5,1
P R I N T  "DO NOT  F O R G E T  TO S W I T C H  T H E  P R I N T E R  ON"
L O C A T E  2 4 , 4 5
P R I N T  " p r e s s  an y  key to c o n t i n u e . . . "
W H I L E  NO T  I N S T A T :W END  
END IF
nu 1S = IN K EY S 
e$ = ""
CLS
DO U N T I L  U C A S E S ( e S )  = "Y" OR U C A S E S ( e S )  = "N"
L O C A T E  1,1
P R I N T  "Do y o u  w a n t  r e s u l t s  s t o r e d  on disk d u r i n g  the s i m u l a t i o n ? "
P R I N T  " P r e s s  Y or N"; 
eS = I N K EY S  
LOOP
IF U C A S E $ ( e $ )  = "N" T HE N
d i s k 1 = 0 ' i n s t r u c t s  p r o g r a m  r e s u l t s  o u t p u t
d i s k 2 = 0 'to d a t a f i l e  not r e q u i r e d
L O C A T E  2 4 , 6 0  
P R I N T  " p l e a s e  w a i t . . . . " ;
ELSE
n u 1S = I N K EY S
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e$ = ""
DO U N T I L  U C A S E $ ( e $ )  = "S" 
L O C A T E  5,1
OR U C A S E $ ( e $ )  = "F
P R I N T  " 
P R I N T  " 
P R I N T  ""
t ime  f ro m  dose 
or v a r i a b l e  c h a n g e
r e s u 1ts
P R I N T  " S T A N D A R D  s c h e m e : 0 to 1 h ou r 1 m 1 n "
5 mi n" 
e v e r y  5 min " 
e v e r y  30 mi n
P R I N T  " 
P R I N T  " 
P R I N T  " 
P R I N T  ""
1 h o u r  o n w a r d s
P R I N T  " F R E Q U E N T  s c h e m e :  
P R I N T  "
0 to 2 min e v e r y  f ew  s e c o n d s  
e v e r y  30 s" 
e v e r y  2 m in"  
e v e r y  10 m in "  
e v e r y  30 m in " ;
P R I N T  " 
P R I N T  " 
P R I N T  "
2 mi n  to 20 min 
20 m in  to 1 h our
1 h o u r  to 6 h ou rs  
6 h o u r s  o n w a r d s
L O C A T E  21,1
P R I N T  "NB Th e  f r e q u e n t  s c h e m e  g e n e r a t e s  a l ar ge a m o u n t  of d ata ";
L O C A T E  24,1
P R I N T  " P r es s  S f o r  the  S t a n d a r d  s c h e m e  or F for the  F r e q u e n t  s c h e m e " ;  
e$ = INK EY$
LOOP
IF U C A S E $ ( e $ )  = "S" T H E N  di s k 1 = 1
IF U C A S E $ ( e $ )  = "F" T H E N  d i s k 1 = 2
e $ = ""
DO U N T I L  U C A S E $ ( e $ )  = "Y"
CLS
L O C A T E  2,1
P R I N T  " G i v e  the full n am e  of a f il e to s t o r e  the  m a i n  r e s u l t s . "
P R I N T  "Us e the s t a n d a r d  f o r m a t  d r i v e :\ d i r e c t o r y \ f i 1e n a m e .f i 1e t y p e "  
P R I N T  "to s p e c i f y  the d riv e,  s u b d i r e c t o r i e (s ) ( o p t i o n a l )  and"
P R I N T  " f i l e n a m e  e x t e n s i o n  ( o p t i o n a l ) "
P R I N T  ""
P R I N T  "e.g. b : \ d i r 1 \ r e s u 1 t s . d a t "
P R I N T  " a : r e s u 1 t s "
P R I N T  ""
INPUT, f i 1e 1 $
P R I N T  ""; 
n u 1 $ = INK EY$  
e$ = "" 
d i s k 2 = 0 
DO
L O C A T E  12,1
P R I N T  "If yo u  w i s h  the p r o g r a m  will a ls o  list to a s e p a r a t e  f i l e "  
P R I N T  "the b a s i c  d at a  on w h i c h  the m od el  is b a s e d . "
P R I N T  ""
P R I N T  "Do yo u  w a n t  t his  Y or N?"; 
e$ = I NKE Y$
LOOP U N T I L  U C A S E $ ( e $ )  = "Y" OR U C A S E $ ( e $ )  = "N"
IF U C A S E $ (e $ ) = "Y" T H E N  
d i s k 2 = 1 
nu 1 $ = I NKE Y$  
e$ = ""
L O C A T E  17,1
P R I N T  " G i v e  the full n a m e  of a file to s t o r e  the dat a. "
P R I N T  "Us e the s t a n d a r d  f o r m a t  d r i v e :\ d i r e c t o r y \ f i 1e n a m e .f i 1e t y p e " 
P R I N T  ""
INPUT, f i 1e 2$
END IF
n u 1 $ = I NKE Y$
e$
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DO U N T I L  U C A S E $ ( e $ )  = "Y" OR U C A S E S ( e S )  
L O C A T E  22,1
P R I N T  " H a p p y  w i t h  f i l e n a m e ( s )  Y or N?" 
e$ = INK EY $
L OOP
L OOP
L O C A T E  2 4 , 6 0
P R I N T  " p l e a s e  w a i t . . . . " ;
O P E N  fi 
P R I N T  § 
P R I N T  I 
P R I N T  # 
P R I N T  i
P R I N T  §
P R I N T  § 
P R I N T  # 
C L O S E  # 
END  IF
e 1 $ FOR O U T P U T  AS #1 
F E N T A N Y L  S I M U L A T I O N
' en te r s  ke y  in m a i n  r e s u l t s  file
RESULTS'
abr evi  at i ons  :"
ca c e n t r a l  a r t er i al  (pool) pa
cv c e n t r a l  v e n o u s  pool lean
p e r i p h e r a l  a r t e r i a l  ( s h u n t ) "  
lean pool"
P R I N T #1 , " p o r  p o r ta l  pool pv p e r i p h e r a l  v e n o u s
P R I N T #1 , "f at  fat p o o l m  inj i n j e c t i o n  pool"
P R I N T #1 , " ti ssue 1 : lungs"
P R I N T #1 . " t i s s u e 2 : p e r i p h e r a l  s h u n t  (no t i s s u e ) "
P R I N T #1 . " t i s s u e 3 : k i d n e y s "
P R I N T #1 . " t i s s u e 4 : p ort al  bed (gut and s p l e e n ) "
P R I N T #1 , " ti ssue 5 : liver"
P R I N T #1 . " t i s s u e 6 : o t h e r  v is c e r a "
P R I N T #1 . " t i s s u e 7 : m u s c l e "
P R I N T #1 . " t i s s u e 8 : fat"
P R I N T #1 . " t i s s u e 9 : s a m p l e  b rai n"
P R I N T #1 . " t i s s u e 10 : i .m. in j ec t  ion si te"
P R I N T #1 . " t i s s u e 11 : nasal a b s o r b t i o n  s it e"
P R I N T #1 . " u n i o n i s e d aq - a q u e o u s  c o n c e n t r a t i o n  u n i o n i s e d  dru g ug /
ti s :a rte ri  al b l o o d  -" 
ug d r u g / K g  a r t e r i a l  b lo od ug d r u g / K g  t i s s u e  b e f o r e  e q u i l i b r a t i o n "
' en te r s  v a l u e s  and  d e f i n i t i o n s  of b a s i c  d at a  
'used by by p r o g r a m  in p r o g r a m  d ata  fil e
IF di s k 2 = 1 T HE N
O P E N  fil e2$ FOR O U T P U T  AS #1
P R I N T #1 . " F E N T A N Y L  P H A R M A C O K I N E T I C  SIM
P R I N T #1 t
P R I N T #1 , " Basi c dat a :"
P R I N T #1 i
P R I N T #1 ,” ti ssu e 1: 1ungs"
P R I N T #1 , " ti ssu e 2: p e r i p h e r a l  s h u n t
P R I N T #1 . " t i s s u e 3: ki d ney s"
P R I N T #1 . " t i s s u e 4: p ortal  bed (gut a
P R I N T #1 , " ti ssu e 5: liver"
P R I N T #1 , " ti ssu e 6: o t h e r  v i s c e r a "
P R I N T #1 , " ti s sue 7: m u s c l e "
P R I N T #1 . " t i s s u e 8: fat"
P R I N T #1 , " ti ssu e 9: s a m p l e  bra in"
P R I N T #1 , " ti ssu e 10: i.m. i n j e c t i o n  si
P R I N T #1 . " t i s s u e 11 : nasal a b s o r b t i o n
P R I N T #1 i
P R I N T #1 , U S I N G "&# # " ; n c $; n c
P R I N T #1 , U S I N G " & # # # . # # # # " ; t o t w $ ; t o t w
P R I N T #1 , U S I N G "&## . # # " ; q d o t $ ;q dot
P R I N T #1 , U S I N G "&#. # # " ; b d e n $ ; b d e n
P R I N T #1 , U S I N G "&#. # # " ; p d e n $ ; pden
P R I N T #1 , U S I N G "&#. # # " ; r d e n $ ; r d e n
P R I N T #1 , U S I N G " & . # # # # " ; f w t b $ ;fwt b
P R I N T #1 , U S I N G f r $ ;f r
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P R I N T  #1. U S I N G  " & . # # # " ; f p p $ ;f pp kg  
P R I N T  #1, U S I N G  " & . # # # # " ; f w p $ ;fwp 
P R I N T  #1, U S I N G  " t i s s u e  & " ; f w t $
FOR 1 = 1 TO nc
P R I N T  # 1 , U S I N G  " ## # . # # # # # # " ; i ;fw t# (1 )
N E X T  i
P R I N T  # 1 . U S I N G  " t i s s u e  & " ; f c $
FOR i = 1 TO nc
P R I N T  # 1 . U S I N G  " ## # .# # # " ;  i ; f c #( i )
N E X T  i
P R I N T  #1, U S I N G  " t i s s u e  & " ; f l $
FOR i = 1 TO nc
P R I N T  # 1 , U S I N G  " ## # . # # # ” ; i ;f 1 # ( i )
N E X T  i
P R I N T  #1, U S I N G  " t i s s u e  & " ; fp $
FOR i = 1 TO nc
P R I N T  # 1 , U S I N G  " ## # . # # # " ; i ; f p # ( i )
N E X T  i
P R I N T  #1, U S I N G  " t i s s u e  V ; f w $
FOR i = 1 TO nc
P R I N T  # 1 , U S I N G  " ## # . # # # " ; i ;f w # ( i )
N E X T  i
P R I N T  #1, U S I N G  " t i s s u e  & " ; f p e $
FOR 1 = 1 TO nc
P R I N T  #1, U S I N G  " ## # . # # # " ; i ;f p e k g # ( i )
N E X T  i
P R I N T  #1, U SI NG  " t i s s u e  & " ; f w e $
FOR i = 1 TO nc
P R I N T #1, U S I N G  " ##
N E X T  1
P R I N T #1 , U SI NG "&# ###" f r a $ ; f r a
P R I N T #1 , U SI NG "&# ###" f r f $ ; frf
P R I N T #1 , U SI NG "&# ###" f ri $; f r i
P R I N T #1 , U SI NG "&# ###" f r 1 $; f r 1
P R I N T #1 , U S I N G "&# ###" f r p $ ; f r p
P R I N T #1 , U S I N G "&# ###" f r v $ ; f r v
P R I N T #1 ,U SI NG t i s s u e &"; f $
FOR  i = 1 TO nc
P R I N T  # 1 , U S I N G  " ## # . # # # # # " ; i ;f # ( i )
N E X T  i
P R I N T  #1, U S I N G  " & # # # # # " ; m w p $ ; m w p  
P R I N T  #1, U S I N G  " & # # # # # " ; m w e $ ; m w e  
P R I N T  #1, U S I N G  " & # # # # # " ; m w c $ ; m w c  
P R I N T  #1, U S I N G  ” & # . # # # " ; p h p $ ; ph p  
P R I N T  # 1 , U S I N G  " t i s s u e  & " ; a p h $
FOR  i = 1 TO nc
P R I N T  #1 . USI NG 1
e
N E X T  i
P R I N T #1 . U SI NG " & - # . ! # " ; b p h $ ; b p h
P R I N T #1 , U S I N G " & # . # # # ” ; p h u $ ; p h u
P R I N T #1, U S I N G " & # # # " ; u r o u t $ ; u r o u t
P R I N T #1 , U SI NG " & # # # " ; f c o n c $ ; f c o n c
P R I N T #1, U SI NG " & # . # # # # # " ; w t m u c $ ; w t m u c
P R I N T #1, U SI NG ” & # . # # # # # " ; p r o t m u c $ ; p r o t m u c
P R I N T #1 , U SI NG " & # . # # " ; f w m $ ; f w m
P R I N T #1. U S I N G " & # # # # # " ; m w t m u c $ ; m w t m u c
P R I N T #1 , U SI NG " & # . # # " ; p h m $ ;phm
P R I N T #1 . U SI NG " & # # " ; dt $ ;d t
P R I N T #1. U S I N G " & # . # # # " ; m e t f $ ; m e t f
P R I N T #1, U SI NG "& # ## " ;1  a m i w $ ; 1 a mi w
P R I N T #1 , U SI NG " & # . # # # " ; p k a $ ; p k a
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P R I N T  #1, U S I N G  " & # " ; a c 1 d $ ; aci d 
P R I N T  #1, U S I N G  " & # . # # # # # # " ; nk i$; nki  
P R I N T  #1. U S I N G  " & # . # # # # # # " ; n k s $ ; n k s  
P R I N T  #1, U S I N G  " & # . # # # " ; e p r a t $ ; e p r a t  
P R I N T  #1, U S I N G  " & # . # # # # # " ; d f a c $ ; d f a c  
C L O S E  #1 
END IF
' Pr int s h e a d i n g  if p r i n t e r  in use 
IF p a p e r  = 1 T H E N
L P R I N T  " F E N T A N Y L  P H A R M A C O K I N E T I C  S I M U L A T I O N "
L P R I N T  ""
END IF
'e n tr y  r o u t i n e s  fo r  r u n t i m e  data:
' s i m u l a t i o n  d u r a t i o n
CLS
DO U N T I L  t t i m e  > 0 
L O C A T E  1,1
I N P U T  " G i v e  the total s i m u l a t i o n  time in m i n u t e s  " . t t i m e  
IF NO T  t t i m e  > 0 T HE N  
L O C A T E  1,1
I N P U T  " p l e a s e  r e - e n t e r  s i m u l a t i o n  time ( m i n u t e s )  " . t t i m e
END IF 
LOOP
t t i m e  = t t i m e  * 60 ' s i m u l a t i o n  t im e  s e c o n d s
KEY 1, "1" 'la bels f u n c t i o n  keys f o r  i n p u t
KEY 2, "2" 'and c l e a r s  k e y b o a r d  b u f f e r
KEY  3, "3"
KEY  4, "4"
n u 1 $ = IN KEY S
e$ = ""
'drug dos e d e t a i l s
CLS
W H I L E  -1 
L O C A T E  4,1
P R I N T  " You  m a y  g i v e  as m a n y  i n t r a v e n o u s  doses, i n t r a m u s c u l a r  d o s e s , "  
P R I N T  " i n t r a n a s a l  doses, or i n t r a p u l m o n a r y  d o s e s  as y o u  w ish , in a n y  " 
P R I N T  " c o m b i n a t i o n : "
P R I N T  ""
P R I N T  ""
P R I N T  "F1 i n t r a v e n o u s "
IF i v n u m  > 0 T H E N  'pr int s * s ig n  on s c r e e n  d i s p l a y
L O C A T E  9 , 2 4  'next to c h o s e n  d o s e  r o u t e s
P R I N T  "*"
END IF
P R I N T  "F2 i n t r a m u s c u l a r "
IF i m n u m  > 0 T HE N 
L O C A T E  10, 24 
P R I N T  ”*"
END IF
P R I N T  " F3 i n t r a n a s a l "
IF n o s n u m  > 0 T HE N 
L O C A T E  1 1 , 2 4  
P R I N T  
END IF
P R I N T  "F4 i n t r a p u l m o n a r y "
IF l u n g n u m  > 0 T HE N 
L O C A T E  1 2 , 2 4  
P R I N T  "*"
END IF 
P R I N T  ""
P R I N T  ""
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P R I N T  " P r e s s  the c o r r e s p o n d i n g  f u n c t i o n  b u t t o n  to e n t e r  dos e d e t a i l s  for" 
P R I N T  " a n y  rou te"
P R I N T  ""
P R I N T  "NB You  m a y  c ome  b ac k  to this s c r e e n  as o f t e n  as yo u  wis h."
P R I N T  "If y ou  hav e a l r e a d y  e n t e r e d  d os es by a p a r t i c u l a r  r ou te  "
P R I N T  " r e t y p i n g  the a p p r o p r i a t e  f u n c t i o n  key  will e r a s e  them"
P R I N T  ""
P R I N T  " W h e n  all d os e s  are  e n t e r e d  press R E T U R N  to c o n t i n u e  the p r o g r a m "  
e$ = I N K E Y S
' dos e d e t a i l s  are s t o r e d  in t e m p o r a r y  a r r a y s  as t he y  are e nt ere d.
'two t e m p o r a r y  a r r a y s  are used, a c u m m u l a t e d  d os e  d e t a i l s  are c o p i e d  
' fr o m  on e  to the o t h e r  b e f o r e  each a d d i t i o n a l  d os e  is e nt er ed , the 
' r e c i p i e n t  a r r a y  h a v i n g  b e i n g  era se d  and r e d i m e n s i o n e d  large  e n o u g h  to 
' al so a c c o m o d a t e  d e t a i l s  of the new d ose  to be e n t e r e d .  W he n all 
' do se s  h ave  been e n t e r e d  fo r  g ive n r o u t e  d e t a i l s  are t r a n s f e r e d  
'to a s e p a r a t e  a r r a y  f or  use l at er  in the  p r o g r a m  
S E L E C T  C ASE  e$
C AS E "2"
CLS
P R I N T  " You  m a y  e n t e r  as m a n y  im doses as y o u  w an t.  D o s e s  m us t  be e n t e r e d  in 
P R I N T  " o r d e r  f ro m the  s t a r t  of the s i m u l a t i o n "
C A L L  s c r ( " i m " )  'sets dose e n t r y  d i s p l a y  up on s c r ee n  and
'i n i t i a l i s e s  d os e  t i m e s  and d u r a t i o n s
IF i m n u m  > 0 T HE N  E R A S E  p i m d o s e #
i m c o u n t  = 0 
W H I L E  -1
i m c o u n t  = i m c o u n t  + 1
IF i m c o u n t  > 1 T H E N  E R A S E  p i m d o s e l #
D I M  p i m d o s e l # ( 1 : i m c o u n t , 1:3)
' er a s e s  an y  p r e v i u o s  a r r a y  
' b e f o r e  e n t e r i n g  loop 
' i n i t i a l i s e s  d os e c o u n t e r
' i n c r e m e n t s  d os e c o u n t e r  
' er a s e s  p r e v i o u s  temp, a r r a y  1 
' d i m e n s i o n s  new temp, a r r a y  1
' d i m e n s i o n s  tem p a r r a y  2 if f i r s t  pass t h r o u g h  loop 
IF i m c o u n t  = 1 T H E N  D I M  p i m d o s e 2 # ( 1 : i m c o u n t ,1:3)
' e n tr y  r o u t i n e  for  d ose  d e t a i l s  
C A L L  d s e n t r y ( 1 , m d u r n , i m c o u n t , " i m " , p i m d o s e 1 # ( ) , p i m d o s e 2 # ( ) )
IF p% > 0 T HE N  E X I T  LOO P ' i n d i c a t e s  all im d os es  e n t e r e d
i m c o u n t  = i m c o u n t  + 1 ' i n c r e m e n t s  d ose  c o u n t e r
E R A S E  p i m d o s e 2 #  ' e r a s e s  p r e v i o u s  temp, a r r a y  2
D I M  p i m d o s e 2 # ( 1 : i m c o u n t , 1 :3) ' d i m e n s i o n s  ne w  temp, a r r a y  2
' e n t r y  r o u t i n e  fo r  dos e d e t a i l s  
C A L L  d s e n t r y ( 2 , m d u r n , i m c o u n t , " i m " , p i m d o s e 2 # ( ) , p i m d o s e 1 # ( ) )
IF pX > 0 T HE N  E X I T  LOOP ' i n d i c a t e s  all im d os es  e n t e r e d
W EN D
i m n u m  = i m c o u n t  - 1 'total n u m b e r  of d os es
i m c o u n t  = 1 're sets dose c o u n t e r  as p o s i t i o n  i n d i c a t o r
IF i m n u m  > 0 T HEN
D I M  p i m d o s e # ( l :i m n u m , 1 :3)
FOR xX = 1 TO i m n u m  
S E L E C T  CASE pX 
C AS E  1
p i m d o s e # (x % , 1) = p i m d o s e 2 # ( x X , 1) 
p i m d o s e # ( x % , 2) = p i m d o s e 2 # ( x X , 2)
C AS E  2
p i m d o s e # ( x % , 1) = p i m d o s e l # ( x X , 1) 
p i m d o s e # ( x X , 2) = p i m d o s e l # ( x X , 2)
END S E L E C T  
N E X T  xX 
END  IF
E R A S E  p i m d o s e l #
E R A S E  p i m d o s e 2 #
CLS
' e n t e r s  d os e  d e t a i l s  
1 i nto a r r a y  for  use 
'i n p r o g r a m
' e r a s e s  t e m p o r a r y  a r r a y s
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C A S E  "4"
CLS 
P R I N T  
P R I N T  
P R I N T  
P R I N T  
P R I N T  
P R I N T  
P R I N T  
P R I N T  
P R I N T  
C AL L s c r ( " i p " )
IF l u n g n u m  > 0
'The p u l m o n a r y  d os e  is the dose of drug d e p o s i t e d  in the" 
'terminal a i r w a y s .  Th e  P r o g r a m  does not model  the p r o c e s s e s "  
'which d e t e r m i n e  the p r o p o r t i o n  of a g i v e n  d i s p e n s e d  dose" 
' re ac h in g  t hi s r e g io n "
You m a y  e n t e r  as m a n y  d o s e s  as y ou  w an t. D o s e s  m u s t  be e n t e r e d  in 
o r d e r  f r o m  the s t a r t  of the s i m u l a t i o n . "
I n t r a p u l m o n a r y  d os es  m u s t  not o v e r l a p  each o t h e r ”
'sets d os e  e n t r y  d i s p l a y  up on s c r e e n  and 
' i n i t i a l i s e s  dose t ime s and d u r a t i o n s  
T H E N  E R A S E  p l u n g d o s e #  'er ase s any  p r e v i o u s  a r r a y
' be for e e n t e r i n g  loop
l u n g c o u n t  = 0 
W H I L E  -1
l u n g c o u n t  = l u n g c o u n t  + 1
' i n i t i a l i s e s  dose c o u n t e r
' i n c r e m e n t s  d os e c o u n t e r
IF l u n g c o u n t  > 1 T HEN  E R A S E  p l u n g d o s e l #  ' er as e s  p r e v i o u s
't e m p o r a r y  a r r a y  1 
D I M  pi u n g do s el  #( 1:1 u n g c o u n t ,  1:3) ' d i m e n s i o n s  new temp, a r r a y  1
' d i m e n s i o n s  temp a r r a y  2 if f i r s t  pass t h r o u g h  loo p 
IF l u n g c o u n t  = 1 T HE N  DIM  p i u n g d o s e 2 # ( 1 : 1 u n g c o u n t , 1:3)
' entry  r o u t i n e  for dos e d e t a i l s  
C A L L  d s e n t r y ( 1 , l d u r n , 1u n g c o u n t ,  " i p " , p l u n g d o s e 1 # ( ) , p l u n g d o s e 2 # ( ) )
IF p% > 0 T H E N  E X I T  LOOP 
l u n g c o u n t  = l u n g c o u n t  + 1 
E R A S E  p l u n g d o s e 2 #
D I M  p 1u n g d o s e 2 # ( 1 : 1 u n g c o u n t , 1:3)
'i n di c a t e s  all ip d ose s e n t e r e d  
' i n c r e m e n t s  dos e c o u n t e r  
'er ase s p r e v i o u s  temp a r r a y  2 
' d i m e n s i o n s  new  temp a r r a y  2 
'en try r o u t i n e  for  dose d e t a i l s  
C A L L  d s e n t r y ( 2 , l d u r n , l u n g c o u n t , " i p " , p l u n g d o s e 2 # ( ) , p 1 u n g d o s e 1 # ( ) )
IF p% > 0 T HE N  E XI T  LOOP ' in d i c a t e s  all ip d os es  e n t e r e d
W END
l u n g n u m  = l u n g c o u n t  - 1 'total n u m b e r  of d os es
1-ungcount = 1 ' re s e t s  d os e c o u n t e r  as p o s i t i o n  i n d i c a t o r
IF l u n g n u m  > 0 T HE N
D I M  p 1u n g d o s e # ( 1 : 1 u n g n u m , 1:3)
F OR x% = 1 TO l u n g n u m
S E L E C T  CASE p%
C AS E  1
p 1u n g d o s e # (x % , 1) 
p i u n g d o s e # (x % , 2) 
p i u n g d o s e # ( x % , 3) 
C ASE  2
p l u n g d o s e # ( x % , 1) 
p i u n g d o s e # ( x % , 2) 
p i u n g d o s e # ( x % , 3) 
END S E L E C T  
N E X T  x%
END  IF
E R A S E  p l u n g d o s e l #
E R A S E  p l u n g d o s e 2 #
CLS
p i u n g d o s e 2 # ( x % , 1) 
p i u n g d o s e 2 # ( x % , 2) 
p i u n g d o s e 2 # (x % , 3)
p i u n g d o s e l # ( x % , 1) 
p i u n g d o s e l # ( x % , 2) 
p i u n g d o s e l # ( x % , 3)
'en te r s  d os e d e t a i l s  
'into a r r a y  for use  
'in p r o g r a m
'er as e s  t e m p o r a r y  a r r a y s
C A S E  "3"
K EY  O F F  
CLS
P R I N T  " The  p r o g r a m  a s s u m e s  tha t nasal d os es  are d i s p e n s e d  as a dry a e r o s o l  
P R I N T  "of f e n ta n yl  c i t r a t e  or are d i s s o l v e d  in a small v o l u m e  of s o l u t i o n "  
P R I N T  "an d are d i s p e r s e d  w i d e l y  o v e r  the nasal m u c o s a "
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P R I N T
P R I N T
P R I N T
P R I N T
P R I N T
'You m a y  e n t e r  as m a n y  d o s e s  as y o u  want. D os es m u s t  be e n t e r e d  
'order f r o m  the s t a r t  of the s i m u l a t i o n "
’I n t r a n a s a l  d os es  m u s t  no t  o v e r l a p  each o the r"
1 n
C AL L  s c r ( " i n " ) 'sets  d ose  e n t r y  d i s p l a y  u p  on s c r e e n  and 
' i n i t i a l i s e s  dos e t im es and d u r a t i o n s
IF n o s n u m  > 0 T H E N  E R A S E  p n o s d o s e #
n o s c o u n t  = 0 
W H I L E  -1
n o s c o u n t  = n o s c o u n t  + 1
IF n o s c o u n t  > 1 T H E N  E R A S E  p n o s d o s e l #
D I M  p n o s d o s e l # ( 1 : n o s c o u n t , 1:3)
'er ase s any p r e v i o u s  a r r a y  
'be for e e n t e r i n g  loop 
' i n i t i a l i s e s  d ose  c o u n t e r
' i n c r e m e n t s  d ose  c o u n t e r  
'er ase s p r e v i o u s  t emp  a r r a y  1 
' d i m e n s i o n s  new  t em p  a r r a y  1
' d i m e n s i o n s  t e m p a r a y  2 if f i r s t  pas s t h r o u g h  loop 
IF n o s c o u n t  = 1 T H E N  D I M  p n o s d o s e 2 # (1 : n o s c o u n t , 1:3)
' e n t r y  r o u t i n e  for dose d e t a i l s  
C AL L  d s e n t r y ( l , n d u r n , n o s c o u n t , " i n " , p n o s d o s e l # ( ) , p n o s d o s e 2 # ( ) )
IF p% > 0 T H E N  E X I T  LOOP ' i n d i c a t e s  all in d os e s  e n t e r e d
n o s c o u n t  = n o s c o u n t  + 1 ' i n c r e m e n t s  dos e c o u n t e r
E R A S E  p n o s d o s e 2 #  'er ase s p r e v i o u s  t emp  a r r a y  2
DIM  p n o s d o s e 2 # ( 1 : n o s c o u n t , 1:3) ' d i m e n s i o n s  new  t em p  a r r a y  2
' e n t r y  r o u t i n e  for  dos e d e t a i l s  
C AL L d s e n t r y ( 2 , n d u r n , n o s c o u n t , ” i n " , p n o s d o s e 2 # ( ) , p n o s d o s e l #())
IF p% > 0 T H E N  E X I T  LOOP ' i n d i c a t e s  all in d o s e s  e n t e r e d
WEN D
n o s n u m  = n o s c o u n t  - 1 'total n u m b e r  of d o s e s
n o s c o u n t  = 1 ' r e s e t s  d ose  c o u n t e r  as p o s i t i o n  i n d i c a t o r
IF n o s n u m  > 0 T H E N
DIM p n o s d o s e # ( 1 : n o s n u m , 1:3)
FOR x% = 1 TO n o s n u m  
S E L E C T  CASE p%
C ASE  1
p n o s d o s e # ( x % , 1) 
p n o s d o s e # ( x % , 2) 
p n o s d o s e # ( x % , 3)
C ASE  2
p n o s d o s e # ( x % , 1) 
p n o s d o s e # ( x % , 2) 
p n o s d o s e # ( x % , 3)
END S E L E C T  
N E X T  x%
END IF
E R A S E  p n o s d o s e l #
E R A S E  p n o s d o s e 2 #
CLS
p n o s d o s e 2 # (x % , 1) 
p n o s d o s e 2 # (x%, 2) 
p n o s d o s e 2 # ( x % , 3)
p n o s d o s e l # ( x % , 1) 
p n o s d o s e l # ( x % , 2) 
p n o s d o s e l # ( x % , 3)
'ente rs  dos e d e t a i l s  
' into a r r a y  for use 
' in p r o g r a m
'er as e s  t e m p o r a r y  a r r a y s
C AS E  "1"
KEY OFF 
CLS
P R I N T  "You m a y  e n t e r  as m a n y  i n t r a v e n o u s  d o s e s  as yo u  w an t.  "
P R I N T  " D o s e s  m u s t  be e n t e r e d  in o r d e r  f r o m  the s ta r t  of the  s i m u l a t i o n "  
P R I N T  " I n t r a v e n o u s  d o s e s  m u s t  not  o v e r l a p  e ac h  oth er"
C A L L  s c r ( " i v " )  'sets d os e  e n t r y  d i s p l a y  u p  on s c r e e n  and
' i n i t i a l i s e s  d os e  t im es  and d u r a t i o n s  
IF i v n u m  > 0 T H E N  E R A S E  p i v d o s e #  ' er as e s  any p r e v i o u s  a r r a y
' b e f o r e  e n t e r i n g  loop 
i v c o u n t  = 0 ' i n i t i a l i s e s  d ose  c o u n t e r
W H I L E  -1
i v c o u n t  = i v c o u n t  + 1 ' i n c r e m e n t s  dose c o u n t e r
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IF I v c o u n t  > 1 T H E N  E R A S E  p i v d o s e l #  ' e r a s e s  p r e v i o u s  tem p a r r a y  1 
D I M  p i v d o s e l # ( 1 : i v c o u n t , 1 :3) ' d i m e n s i o n s  ne w  tem p a r r a y  1
' d i m e n s i o n s  temo a r r a y  2 if f i r s t  p as s t h r o u g h  loop 
IF i v c o u n t  = 1 T H E N  D I M  p i v d o s e 2 # ( 1 : i v c o u n t ,1:3)
'en tr y  r o u t i n e  f or  dos e d e t a i l s  
C A L L  d s e n t r y ( 1 , v d u r n , i v c o u n t , " i v " , p i v d o s e 1 # ( ) , p i v d o s e 2 # ( ) )
IF pX > 0 T H E N  E X I T  LOO P ' i n d i c a t e s  all iv d os es  e n t e r e d
i v c o u n t  = i v c o u n t  + 1 ' i n c r e m e n t s  d os e c o u n t e r
E R A S E  p i v d o s e 2 #  ' er a s e s  p r e v i o u s  temp a r r a y  2
D I M  p i v d o s e 2 # ( 1 : i v c o u n t , 1:3) ' d i m e n s i o n s  ne w  t e m p o r a r y  a r r a y  2
'e n tr y  r o u t i n e  fo r  d ose  d e t a i l s  
C A L L  d s e n t r y ( 2 , v d u r n , i v c o u n t , " i v " , p i v d o s e 2 # ( ) , p i v d o s e 1 # ( ) )
IF pX > 0 T H E N  E X I T  LOO P ' i n d i c a t e s  all iv d os es  e n t e r e d
W EN D
i v n u m  = i v c o u n t  - 1 'total n u m b e r  of d os es
i v c o u n t  = 1 ' re set s dose c o u n t e r  as p o s i t i o n  i n d i c a t o r
IF i v n u m  > 0 T HE N
D I M  p i v d o s e # ( 1 : i v n u m , 1:3)
FOR  xX = 1 TO i v n u m  
S E L E C T  C AS E pX 
C A S E  1
pi v d o s e # (x X , 1) 
p i v d o s e # (xX, 2) 
p i v d o s e # (x X , 3)
C AS E  2
p i v d o s e # (xX, 1) 
p i v d o s e # (x X , 2) 
pi v d o s e # (x X , 3)
END S E L E C T  
N E X T  xX 
END IF
E R A S E  p i v d o s e l #
E R A S E  p i v d o s e 2 #
CLS
pi v d o s e 2 # (xX, 1) 
pi v d o s e 2 # ( x X , 2) 
p i v d o s e 2 # ( x X , 3 )
pi v d o s e l # ( x X , 1) 
pi v d o s e l # ( x X , 2) 
p i v d o s e 1 # ( x X , 3 )
' e n t e r s  d os e d e t a i l s  into 
' a r r a y  f or  use  in 
'p r o g r a m
'e r a s e s  t e m p o r a r y  a r r a y s
C AS E C H R $ (13)
IF i m n u m  > 0 OR i v n u m  > 0 OR l u n g n u m >  0 OR n o s n u m >  0 T H E N  
E X I T  L OO P 
E LSE  
CLS
L O C A T E  22,1
P R I N T  "NO D O S E S  H AV E  BEEN E N T E R E D  YET";
P R I N T  " E N T E R  D O S E ( S )  TO C O N T I N U E  P R O G R A M " ;
P R I N T  ""
E X I T  S E L E C T  
END IF 
CAS E E LS E  
E X I T  S E L E C T  
END S E L E C T  
W EN D
' a l l o w s  c e r t a i n  b a s i c  v a r i a b l e s  to be c h a n g e d  at r un t i m e ;
'phu. php. odot. dt. u r o u t
' d e t a i l s  a r e  s t o r e d  in t e m p o r a r y  a r r a y s  as t h e y  are e n t e r e d .
'two t e m p o r a r y  a r r a y s  are  used, a c u m m u l a t e d  d e t a i l s  are c o p i e d  
' fr om  o n e  to the  o t h e r  b e f o r e  eac h a d d i t i o n a l  c h a n g e  is e n t e r e d .  the 
' r e c i p i e n t  a r r a y  h a v i n g  b e i n g  e r a s e d  and r e d i m e n s i o n e d  l a r g e  e n o u g h  to 
' al so a c c o m o d a t e  d e t a i l s  of the new  c h a n g e  to be e n t e r e d ,  w h e n  all 
' c h a n g e s  h a v e  b ee n  e n t e r e d  for g i v e n  v a r i a b l e  d e t a i l s  are t r a n s f e r e d  
'to a s e p a r a t e  a r r a y  fo r  use l at er  in the p r o g r a m  
W H I L E  -1
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KE Y  1, "W"
KEY 2, "U"
KEY 3, "P" ' D e fi n es  f u n c t i o n  keys and c l e a r s
KEY 4, "Q" ' k e y b o a r d  b u f f e r
KEY  5, "T"
n u 1 $ = I N K E Y S
e$ = ""
CLS
P R I N T  " You  m a y  c h a n g e  the f o l l o w i n g  v a r i a b l e s . "
P R I N T  " Th e c u r r e n t  v a l ue s  are as s ho wn : "
L O C A T E  4,1
IF u r o u t n u m  > 0 T HE N
P R I N T  "* F1 U r i n e  w a t e r  o u t p u t  ( a p p r o x i m a t e s  to u r i n e  v o l u m e ) :  AS E N T E R E D  *" 
E LSE
P R I N T  US I NG _
" F 1 U r i n e  w a t e r  o u t p u t  ( a p p r o x i m a t e s  to u r i n e  v o l u m e )  = ### # ml / h o u r " ; u r o u t  
END IF
IF u n u m  > 0 T HE N
P R I N T  "* F2 U r i n e  pH: AS E N T E R E D  *"
E LSE
P R I N T  U S I N G  "F2 U r i n e  pH = # . # " ; p h u  
END IF
IF p n u m  > 0 T H E N  ' s c re e n  d i s p l a y
P R I N T  "* F3 P l a s m a  pH: AS E N T E R E D  *"
ELSE
P R I N T  U S I N G  "F3 P l a s m a  pH = # . # # # # " ; p h p  
END IF
IF q n u m  > 0 T HEN
P R I N T  "* F4 C a r d i a c  o ut pu t :  AS E N T E R E D  *"
ELSE
P R I N T  U S I N G  "F4 C a r d i a c  o u t p u t  = #.## 1 / m i n " ; q d o t  
END IF
IF t n u m  > 0 T HE N
P R I N T  "* F5 C y c l e  time: AS E N T E R E D  *"
ELS E
P R I N T  U S I N G  "F5 C a l c u l a t i o n  c yc le  t im e  = ## s " ; d t  
END IF 
L O C A T E  11,1
P R I N T  " P r e s s  the c o r r e s p o n d i n g  f u n c t i o n  key to e n t e r  d e t a i l s  of the"
P R I N T  " v a r i a b l e  y o u  w a n t  to cha ng e "
L O C A T E  15,1
P R I N T  "NB You  m a y  c om e back to this s c r e e n  as o f t e n  as y o u  w i s h . "
P R I N T  "If y o u  h ave  a l r e a d y  m a d e  c h a n g e s  to a p a r t i c u l a r  v a r i a b l e ,  r e t y p i n g "
P R I N T  " the  a p p r o p r i a t e  f u n c t i o n  key will e r a s e  t h e m  and  r e s t o r e  the d e f a u l t "  
L O C A T E  19,1
P R I N T  " P r e s s  R E T U R N  w he n  yo u  have f i n i s h e d  e n t e r i n g  c h a n g e s "
P R I N T  "an d are r e a d y  to go w it h  the p r o g r a m  "
W H I L E  N O T  I N S T A T :W E N D  
e$ = I N K E Y S  
S E L E C T  C AS E e$
C AS E  "U"
C A L L  v s c r ( " u r i n e  p H " ,p h u)
IF u n u m  > 0 T H E N  E R A S E  p ph u#
u c o u n t  = 1 
W H I L E  -1
u c o u n t  = u c o u n t  + 1 
IF u c o u n t  > 2 T H E N  E R A S E  p p h ul #
D I M  p p h u l # ( 1 : u c o u n t , 1:2)
' d i m e n s i o n s  temp a r r a y  2 if f i r s t  p ass  t h r o u g h  loop
'sets e n t r y  d i s p l a y  up on s c r e e n  and 
' i n i t i a l i s e s  v a r i a b l e  c h a n g e  t i m e s  
' er ase s an y  p r e v i o u s  a r r a y  b e f o r e  
' e n t e r i n g  loop
' i n i t i a l i s e s  v a r i a b l e  c h a n g e  c o u n t e r
' i n c r e m e n t s  c o u n t e r
' er a s e s  t e m p o r a r y  a r r a y  1 
' d i m e n s i o n s  t emp  a r r a y  1
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IF u c o u n t  = 2 T HE N  OI M  p p h u 2 # ( 1 : u c o u n t , 1:2)
1v a r i a b l e - c h a n a e  e n t r y  r o u t i n e
C AL L  v a r e n t r y ( 1 , u c o u n t , " u r i n e  pH' 
IF p% = 1 T HE N  E XI T  LOOP 
u c o u n t  = u c o u n t  + 1 
E R A S E  p p h u 2 #
DIM  p p h u 2 # ( 1 : u c o u n t , 1:2)
, " H , p h u , p p h u 1 # ( ) , pp hu 2 #()) 
' I n d i c a t e s  all phu c h a n g e s  e n t e r e d  
' i n c r e m e n t s  c o u n t e r  
'er ase s temp a r r a y  2 
' d i m e n s i o n s  t emp  a r r a y  2
' v a r i a b i e - c h a n g e  e n t r y  r o u t i n e
C A L L  v a r e n t r y ( 2 , u c o u n t , " u r i n e  pH' 
IF p% = 2 T HE N  E XI T  LOOP 
WE ND
u n u m  = u c o u n t  -1 
u c o u n t  = 1 
IF u n u m  > 0 T HE N
D IM  p p h u # ( 1 : u n u m , 1:2)
FOR x% = 1 TO u nu m  
S E L E C T  CASE p%
C AS E 1
p p h u # ( x % , 1) 
p p h u # ( x % , 2)
CAS E 2
p p h u # (x % , 1) 
p p h u # ( x % , 2)
END S E L E C T  
N E X T  x%
END IF
E R A S E  p p h u 2 #
E R A S E  p p h u l #
C AS E "P"
C AL L v s c r ( " p l a s m a  p H " , p h p )
IF p n u m  > 0 T HE N  E R A S E  p p h p #
, ,  p h u , p p h u 2 # ( ) , p p h u l #())
' i n d i c a t e s  all phu c h a n g e s  e n t e r e d
'total n u m b e r  of c h a n g e s
're set s c o u n t e r  as p o s i t i o n  i n d i c a t o r
p p h u 2 # ( x % , 1) 
p p h u 2 # ( x % , 2)
p p h u 1 # ( x % , 1) 
p p h u l # ( x % , 2)
'en te r s  d e t a i l s  into 
'ar ra y  f or  use  in 
'p r o g r a m
p c o u n t  = 1 
W H I L E  -1
p c o u n t  = p c o u n t
'er ase s t e m p o r a r y  a r r a y s
'sets e n t r y  d i s p l a y  up on s c r e e n  and 
' i n i t i a l i s e s  v a r i a b l e  c h a n g e  t i m e s  
'er ase s any  p r e v i o u s  a r r a y  b e f o r e  
' e n t e r i n g  loop
' i n i t i a l i s e s  v a r i a b l e  c h a n g e  c o u n t e r
+ 1
IF p c o u n t  > 2 T H E N  E R A S E  p p h p 1# 
D IM  p p h p l # ( 1 : p c o u n t , 1:2)
' i n c r e m e n t s  c o u n t e r
'er as e s  t e m p o r a r y  a r r a y  1 
' d i m e n s i o n s  t e m p  a r r a y  1 
' d i m e n s i o n s  t emp  a r r a y  2 if f i r s t  p as s  t h r o u g h  loop 
IF p c o u n t  = 2 T H E N  D I M  p p h p 2 # ( 1 : p c o u n t , 1:2)
' v a r i a b i e - c h a n g e  e n t r y  r o u t i n e  
C AL L  v a r e n t r y ( 1, p c o un t ,  " p 1a s m a  p H p h p , pphpl # ( ) , p p h p 2 # ())
' i n d i c a t e s  all php  c h a n g e s  e n t e r e d  
' i n c r e m e n t s  c o u n t e r  
'er ases temp a r r a y  2 
' d i m e n s i o n s  t em p  a r r a y  2
IF p% = 1 T H E N  E X I T  LOOP 
p c o u n t  = p c o u n t  + 1 
E R A S E  p p h p 2 #
D I M  p p h p 2 # ( 1 : p c o u n t , 1:2)
' v a r i a b i e - c h a n g e  e n t r y  r o u t i n e  
C A L L  v a r e n t r y ( 2 , p c o u n t , " p l a s m a  p H " , " " , p h p ,p p h p 2 # ( ) , p p h p 1#())
IF pX = 2 T HE N  E XIT  LOOP 
W END
p n u m  = p c o u n t  -1 
p c o u n t  = 1 
IF p n u m  > 0 T HEN
DIM  p p h p # ( 1 : p n u m , 1 :2)
FOR x% = 1 TO p nu m 
S E L E C T  CAS E pX 
CA SE  1
p p h p # ( x % , 1) = p p h p 2 # (x % , 1) 
p p h p # ( x % , 2) = p p h p 2 # (x % , 2) 
CA SE  2
p p h p # (x % , 1) = p p h p 1 # ( x % , 1)
' i n d i c a t e s  all php c h a n g e s  e n t e r e d
'total n u m b e r  of c h a n g e s
're sets c o u n t e r  as p o s i t i o n  i n d i c a t o r
'en ter s d e t a i l s  into 
'arra y f or  use  in 
'p r o g r a m
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p p h p # ( x X , 2) = p p h p 1 # ( x X , 2)
END S E L E C T  
N E X T  xX 
END IF
E R A S E  p p h p 2 #  'erases t e m p o r a r y  a r r ay s
E R A S E  p p h p l #
CAS E "W"
C AL L v s c r ( " u r i n e  w a t e r  o u t p u t " ,urout) 
IF u r o u t n u m  > 0 T H E N  E R A S E  p ur o u t #
1
's e t s  e n t r y  d i s p l a y  u p  on s c r e e n  an d 
' i n i t i a l i s e s  v a r i a b l e  c h a n g e  t i m e s  
' e r a s e s  a n y  p r e v i o u s  a r r a y  b e f o r e  
' e n t e r i n g  loop
' i n i t i a l i s e s  v a r i a b l e  c h a n g e  c o u n t e ru r o u t c o u n t  =
W H I L E  -1
u r o u t c o u n t  = u r o u t c o u n t  + 1 
IF u r o u t c o u n t  > 2 T H E N  E RA S E  p ur o u t l #
D I M  p u r o u t l # ( 1 : u r o u t c o u n t , 1:2)
' d i m e n s i o n s  temp a rr ay  2 if f i r s t  pas s t h r o u g h  loop 
IF u r o u t c o u n t  = 2 T H E N  DI M  p u r o u t 2 # ( 1 : u r o u t c o u n t ,  1 :2)
' i n c r e m e n t s  c o u n t e r
' era s e s  t e m p o r a r y  a r r a y  1 
' d i m e n s i o n s  tem o a r r a y  1
' v a r i a b i e - c h a n g e  e n t r y  r o u t i n e  
C AL L  v a r e n t r y ( 1 , u r o u t c o u n t , " u r i n e  w a t e r  o u t p u t " , _
" ML PER H O U R " ,u r o u t , p u r o u t l # ( ) , p u r o u t 2 # ( ))
IF pX = 1 T H E N  E X I T  LOO P ' i n d i c a t e s  all u r o u t  c h a n g e s  e n t e r e d
u r o u t c o u n t  = u r o u t c o u n t  + 1 ' i n c r e m e n t s  c o u n t e r
E R A S E  p u r o u t 2 #  'er as e s  temp a r r a y  2
D I M  p u r o u t 2 # ( 1 : u r o u t c o u n t , 1:2) ' d i m e n s i o n s  temp a r r a y  2
' v a r i a b i e - c h a n g e  e n t r y  r o u t i n e  
C AL L v a r e n t r y ( 2 , u r o u t c o u n t , " u r i n e  w a t e r  o u t p u t " , _
" ML PER H O U R " , u r o u t , p u r o u t 2 # ( ) , p u r o u t l # ( ))
IF pX = 2 T H E N  E X I T  LOOP 
W EN D
u r o u t n u m  = u r o u t c o u n t  -1 
u r o u t c o u n t  = 1 
IF u r o u t n u m  > 0 T H E N
D I M  p u r o u t # ( 1 : u r o u t n u m , 1:2) 
FOR  xX = 1 TO u r o u t n u m  
S E L E C T  CAS E pX 
CAS E 1 
p u r o u t # ( x X , 1) 
p u r o u t # (x X , 2)
CAS E 2 
p u r o u t # ( x X , 1) 
p u r o u t # (x X , 2)
END S E L E C T  
N E X T  xX 
END IF
E R A S E  p u r o u t 2 #
E R A S E  p u r o u t l #
' i n d i c a t e s  all u r o u t  c h a n g e s  e n t e r e d
'total n u m b e r  of c h a n g e s
're se t s  c o u n t e r  as p o s i t i o n  i n d i c a t o r
p u r o u t 2 # (x X , 1) 
p u r o u t 2 # ( x X , 2)
p u r o u t l # ( xX, 1) 
p u r o u t 1 # ( x X , 2)
' ent e r s  d e t a i l s  int o 
' ar ra y  for use in 
'p r o g r a m
' er ase s t e m p o r a r y  a r r a y s
C ASE  "T"
C AL L v s c r ( " c y c l e  t i m e " , d t )
IF t n u m  > 0 T H E N  E R A S E  pdt #
t c o u n t  = 1 
W H I L E  -1
t c o u n t  = t c o u n t  + 1
IF t c o u n t  > 2 T H E N  E R A S E  p d t 1#
D I M  p d t l # ( 1 : t c o u n t , 1 :2)
'sets e n t r y  d i s p l a y  up on s c r e e n  and 
' i n i t i a l i s e s  v a r i a b l e  c h a n g e  t i m e s  
'er ases any  p r e v i o u s  a r r a y s  b e f o r e  
' e n t e r i n g  loop
' i n i t i a l i s e s  v a r i a b l e  c h a n g e  c o u n t e r
' i n c r e m e n t s  c o u n t e r
' er as e s  t e m p o r a r y  a r r a y  1 
' d i m e n s i o n s  tem p a r r a y  1
d i m e n s i o n s  temp a rr ay  2 if f i r s t  p ass  t h r o u g h  loop
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IF t c o u n t 2 T H E N  D IM  pdt 2#( 1 
' v a r i a b i e - c h a n g e
:t c o u n t ,1:2) 
e n t r y  r o u t i n e
C A L L  v a r e n t r y ( 1 , t c o u n t , " c y c l e  
IF p% = 1 T HE N  E XI T  LOOP 
t c o u n t  = t c o u n t  + 1 
E R A S E  p d t 2 #
DI M  p d 1 2 # ( 1 i t c o u n t , 1:2)
1vari a b l e - c h a n g e
t ime  S E C O N D S " ,d t , p d t l # ( ) , p d t 2 # ( )) 
' i n d i c a t e s  all dt c h a n g e s  e n t e r e d  
' i n c r e m e n t s  c o u n t e r  
' e r a s e s  temp a r r a y  2 
' d i m e n s i o n s  temp a r r a y  2 
e n t r y  r o u t i n e
C A L L  v a r e n t r y ( 2 , t c o u n t , " c y c l e  
IF pH = 2 T H E N  E XI T  LOOP 
W END
t nu m  = t c o u n t  -1 
t c o u n t  = 1 
IF t n u m  > 0 T HE N
D I M  p d t # ( 1 : t n u m ,1:2)
t i m e " , " S E C O N D S " , d t , p d t 2 # ( ),p d t 1#()) 
' i n d i c a t e s  all dt c h a n g e s  e n t e r e d
'total n u m b e r  of c h a n g e s
' re s e t s  c o u n t e r  as p o s i t i o n  i n d i c a t o r
FOR xX = 1 TO tnu m
S E L E C T  CASE p% 
CAS E 1
p d t # (x % , 1) = 
p d t # (x % , 2) = 
C AS E 2
pd t # (x X , 1) = 
p d t # ( x X , 2) = 
END S E L E C T  
N E X T  xX 
END IF 
E R A S E  p d t 2 #
E R A S E  p d t l #
p d t 2 # ( x X , 1) 
p d t 2 # ( x X , 2)
p d t l # ( x X , 1) 
p d t l # ( x X , 2)
'en te r s  d e t a i l s  into 
' a r ra y  for use in 
'p r o g r a m
' e r a s e s  t e m p o r a r y  a r r a y s
C AS E "Q"
C ALL  v s c r ( " c a r d i a c  o u t p u t " ,q d o t )
IF q n u m  > 0 T HE N  E R A S E  pq d ot #
q c o u n t  = 1 
W H I L E  -1
q c o u n t  = q c o u n t  + 1
IF q c o u n t  > 2 T H E N  E RA SE  p q d o t l #
D I M  p q d o t l # ( 1 : q c o u n t ,1:2)
'sets e n t r y  d i s p l a y  up on s c r e e n  and 
' i n i t i a l i s e s  v a r i a b l e  c h a n g e  t i m e s  ■ 
' e r a s e s  any  p r e v i o u s  a r r ay s  b e f o r e  
' e n t e r i n g  loop
' i n i t i a l i s e s  v a r i a b l e  c h a n g e  c o u n t e r  
' i n c r e m e n t s  c o u n t e r
' er as e s  t e m p o r a r y  a r r a y  1 
' d i m e n s i o n s  temp a r r a y  1 
' d i m e n s i o n s  temp a r r a y  2 if f i r s t  pass t h r o u g h  loop 
IF q c o u n t  = 2 T H E N  DI M  p q d o t 2 # ( 1 : q c o u n t ,1:2)
' v a r i a b i e - c h a n g e  e n t r y  r o u t i n e  
C A L L  v a r e n t r y { 1 , q c o u n t , " c a r d i a c  o u t p u t " , "  L I T RE S  PER M I N U T E " , q d o t ,p q d o t 1#(), p q d o t 2 #  ( 
IF pX = 1 T H E N  E XI T  LOOP ' i n d i c a t e s  all qdo t c h a n g e s  e n t e r e d
q c o u n t  = q c o u n t  + 1 ' i n c r e m e n t s  c o u n t e r
E R A S E  p q d o t 2 #  ' e r a s e s  tem p a r r a y  2
D I M  p q d o t 2 # ( 1 : q c o u n t , 1 :2) ' d i m e n s i o n s  tem p a r r a y  2
' v a r i a b i e - c h a n g e  e n t r y  r o u t i n e  
C AL L  v a r e n t r y ( 2 , q c o u n t , " c a r d i a c  o u t p u t " , "  L I T RE S  PER M I N U T E " , q d o t , p q d o t 2 # (), p q d o t !  # (
IF pX = 2 T H E N  E X I T  LOOP 
WE ND
q n u m  = q c o u n t  -1 
q c o u n t  = 1 
IF q n u m  > 0 T HE N
D IM  p q d o t # ( 1 : q n u m , 1:2)
FOR xX = 1 TO q nu m  
S E L E C T  CASE pX 
C AS E  1
p q d o t # ( x X , 1 )  = p q d o t 2 # ( x X , 1) 
p q d o t # ( x X , 2 )  = p q d o t 2 # ( x X , 2)
' i n d i c a t e s  all gdo t c h a n g e s  e n t e r e d
'total n u m b e r  of c h a n g e s
' re s e t s  c o u n t e r  as p o s i t i o n  i n d i c a t o r
' e n t e r s  d e t a i l s  into 
' a r r a y  for use in 
'p r o g r a m
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C A S E  2
p q d o t # (x % , 1) = p q d o t l # ( x X , 1 ) 
p q d o t # ( x % , 2 )  = p q d o t 1 # ( x X ,2)
E ND  S E L E C T  
N E X T  xX 
END IF
E R A S E  p q d o t 2 #  ' er as e s  t e m p o r a r y  a r r a y s
E R A S E  p q d o t l #
C AS E  C H R $ (13)
IF u c o u n t  = 1 OR t c o u n t  = 1 OR q c o u n t  = 1 OR p c o u n t  = 1 OR u r o u t c o u n t  = 1 T H E N  
E X I T  LOOP 
EL SE
L O C A T E  23,1
P R I N T  "NO C H A N G E S  MADE YET";
e$ = ""
n u 1 $ = INK EY $
DO U N T I L  U C A S E $ (e $) = "Y" OR U C A S E $ ( e $ )  = "N"
L O C A T E  24,1
P R I N T  "Do y o u  w a n t  to m a k e  c h a n g e s  Y or N?"; 
e$ = INK EY S  
LOOP
S E L E C T  CASE U C A S E $ (e $ )
C ASE  "N"
E X I T  LOOP 
C AS E  "Y"
E X I T  S E L E C T  
END S E L E C T  
END IF 
CAS E ELS E 
E X I T  S E L E C T  
END S E L E C T  
W E N D
D I M  r e s u 1 t s # ( 1 : 5 0 , 1 : 7 7 )  ' a r r a y  to s to re  m ai n  r e s u l t s
' n u m b e r  of p o s s i b l e  c o n c e n t r a t i o n  m a x i m a  + 1 
m a x n u m  = i m n u m  + i v n u m  + n o s n u m  + l u n g n u m  + p nu m  + 1 
D I M  t i s s u e m a x ( 1 : 9 , 1 : m a x n u m )
D I M  t m a x X ( 1 :9)
D I M  m a x c o u n t X ( 1:9)
C A L L  g r a p h s c a l e  'sets up s c r e e n  d i s p l a y  for  p l o t i n q  r e s u l t s
' c a l c u l a t e s  d e p e n d a n t  v a r i a b l e s  f r o m  b a s i c  
IF p n u m  = 0 T H E N  C A L L  p h c a l c  ' v a r i a b l e s  w h e r e  d e f a u l t  v a l u e s  still a p p l y
IF q n u m  = 0 AND t n u m  = 0 AND w o n u m  = 0 T H E N  CAL L q d t c a l c
'main  c a l c u l a t i o n  c yc le
WHILE, r t i m e  < ( t t im e  + dt)
' w h i l s t  u n e x e c u t e d  c h a n g e s  r e m a i n  in a r r a y s  
' ca ll s  pen d to c he ck  w h e t h e r  c h a n g e  of v a r i a b l e  
' v a l u e  due, m a k e  a p p r o p r i a t e  c h a n g e s  and 
' r e c a l c u l a t e  d e p e n d a n t  v a r i a b l e s  if a p p r o p r i a t e  
IF u c o u n t  < ( un um  + 1) AND u n u m  > 0 T H E N _
C A L L  p e n d (p p h u # ( ) , p h u ,u c o u n t , " u r i n e  p H" , " " )
IF p c o u n t  < ( p n u m  + 1) AND p n u m  > 0 T H E N _
C A L L  p e n d ( p p h p # ( ) , p h p ,p c o u n t , " p 1a s m a  p H" , " " )
IF q c o u n t  < ( q n u m  + 1) AND q n u m  > 0 T H E N _
C A L L  p e n d ( p q d o t # ( ) , q d o t , q c o u n t , " c a r d i a c  o u t p u t " , " !  /s")
IF t c o u n t  < ( tn um  + 1) AND t n u m  > 0 T H E N _
C A L L  p e n d ( p d t # ( ) , d t , t c o u n t , " c y c l e  t i m e " , " s " )
IF u r o u t c o u n t  < ( u r o u t n u m  + 1) AND  u r o u t n u m  > 0 T H E N _
C A L L  p e n d (p u r o u t # ( ) , u r o u t ,u r o u t c o u n t , " u r i n e  w a t e r  o u t p u t " , " m l / h o u r " )
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IF r t i m e  = 0 T H E N  
IF p a p e r  = 1 T H E N
L P R I N T  " i n it i al  c o n d i t i o n s : "  
L P R I N T  ""
L P R I N T  U S I N G  
L P R I N T  U S I N G  
L P R I N T  U S I N G  
L P R I N T  U S I N G  
L P R I N T  U S I N G  
L P R I N T  U S I N G  
L P R I N T  ""
END IF
'initial c o n d i t i o n s  to p r i n t e r
C a r d i a c  o u t p u t  = # # . # # 1 / m i n " ; q d o t  
U r i n e  pH = # . # # # # # " ; phu
U r i n e  w a t e r  o u t p u t  #### ml / h o u r " ; u r o u t  
P l a s m a  pH = # . # # # # # " ; p h p  
C y c l e  t im e  = # ## .# s ";dt
S i m u l a t i o n  d u r a t i o n  = # # # # # # . #  m i n " ; t t i m e  / 60
d i s k 1 > 0 T HE N
O P E N  f i 1 el $ FOR
P R I N T #1 ,n "
P R I N T #1 -, " i n i t :
P R I N T #1 , U S I N G
P R I N T #1 -, U S I N G
P R I N T #1,, U S I N G
P R I N T #1 , U S I N G
P R I N T #1 , U S I N G
P R I N T #1 , U S I N G
C L O S E #1
'initial c o n d i t i o n s  to r e s u l t s  file
'Ca rdi ac o u t p u t  = ##.## l / m i n " ; q d o t
'Urine pH = # . # # # # # " ; p h u
'Urine w a t e r  o u t p u t  # f f # ml / h o u r " ; u r o u t
'Pl asma pH = # . # # # # # " ; p h p
'Cycle t im e = ### .# #  s "; dt
' S i m u l a t i o n  d u r a t i o n  = # # # # # # . #  m i n " ;t t i m e / 6 0
END IF 
END IF
' cal ls  d o s p e n d  to c h e c k  c u r r e n t  dru q d ose  s t a tu s  
' w h i l s t  u n a d m i n i s t e r e d  d os e s  r e m a i n  in a r r a y s  
IF i v c o u n t  < ( i v n u m  + 1) AND i v n u m  > 0 T H E N _
C AL L  d o s p e n d ( v d u r n , i v d o s e , " i n t r a v e n o u s l y " , v d l e f t , i v c o u n t , p i v d o s e # ( ) )
IF i m c o u n t  < ( i m nu m  + 1) AND  i m n u m  > 0 T H E N _
C AL L  d o s p e n d ( m d u r n , i m d o s e , " i n t r a m u s c u l a r l y " , m d l e f t , i m c o u n t , p i m d o s e # ( ) )
IF n o s c o u n t  < ( n o s n u m  + 1) AND n o s n u m  > 0 T H E N _
C ALL  d o s p e n d ( n d u r n , n o s d o s e , " i n t r a n a s a l 1 y " , n d l e f t , n o s c o u n t , p n o s d o s e # ( ) )
IF l u n g c o u n t  < ( l u n g n u m  + 1) AND l u n g n u m  > 0 T H E N _
C AL L  d o s p e n d ( l d u r n , l u n g d o s e , " i n t r a p u l  m o n a r i l y " , l d l e f t , l u n g c o u n t , p l u n g d o s e # ( ) )
' c a l c u l a t e s  iv.ip and in d os e  i n c r e m e n t s  
T H E N  C AL L  d o s e (v d 1 e f t , i v d o s e ,v d u r n , v d i n c )
T HE N  C AL L  d o s e ( 1 d 1 e f t , 1 u n g d o s e , 1 d u r n , 1 d i n c )
T HE N  C AL L  d o s e (n d 1 e f t ,n o s d o s e , n d u r n , n d i n c )
'main c a l c u l a t i o n  
' o u t p u t  r o u ti n es  
'i n c r e m e n t s  times
IF v d l e f t  >
IF l d l e f t  >
IF n d l e f t  >
CA LL  m o d e l  
C AL L  r e s u l t s  
p t i m e  = p t i m e  + dt
r t i m e  = r t i m e  + dt
i m d o s e  = 0 
n d i n c = 0
1 d i n c = 0
v d i n c = 0
WEN D
L O C A T E  25,1 
n u 1 $ = I N K E Y S  
P R I N T
W H I L E  N O T  I N S T A T : W E N D  
a g a i n  = 1 
E R A S E  r e s u l t s #
E R A S E  t i s s u e m a x #
E R A S E  t m a x %
ER A S E  m a x c o u n t X
IF i v n u m  > 0 T H E N  E R A S E  p i v d o s e #
IF i m n u m  > 0 T H E N  E R A S E  p i m d o s e #
IF n o s n u m  > 0 T HE N  E R A S E  p n o s d o s e #
IF l u n g n u m  > 0 T HE N  E R A S E  p l u n g d o s e #
' re s e t s  im dose fo r  n ex t  c y c l e  
' re se t s  dose i n c r e m e n t s  fo r  n e x t  c y c l e
' c l ea r  k e y b o a r d  b u f f e r  
'wait  for  k e y s t r o k e
' i n d i c a t e s  f ir st  s i m u l a t i o n  c o m p l e t e  
'er as e  r es u i t s  and maxi m u m  c o n c e n t r a t i o n  
' i n d i c a t o r  arr ay s  f ro m  c o m p l e t e d  s i m u l t i o n
'er ase an y  a r r a y s  c o n t a i n i n g  druq 
'doses and v a r i a b l e  c h a n g e s  
'from  c o m p l e t e d  s i m u l a t i o n
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IF t n u m  > 0 T H E N  E R A S E  p dt #
IF q nu m  > 0 T H E N  E R A S E  p q d o t #
IF u nu m  > 0 T H E N  E R A S E  p p h u #
IF p nu m  > 0 T H E N  E R A S E  p p h p #
IF u r o u t n u m  > 0 T H E N  E R A S E  p u r o u t #
G O T O  b e g l n l n g  ' r e st a rt  p r o g r a m  f r o m  label b e o i n i n a
finish:
END
$ I N C L U D E  " f s u b s l . b a s "  ' c o m p i l i n g  i n s t r u c t i o n
' S u b r o u t i n e s :  f ile  f s u b s l . b a s
SUB  model
'main c a l c u l a t i o n  c yc le  
S H A R E D  a f # ( ) fa p i , a p v , a p a , a p f , a p p , a p l , w p f , w p l , w p a , w p v , w p i , w p p , s v w  
S H A R E D  w f # ( ) , w t # ( ) 1 c s # ( ) , c s o l d # ( ) , a a t # ( ) , a a t o l d # ( ) , a a b # ( ) fa a b t # ( ) , n c , e p r a t  
S H A R E D  1 a m i w , a c i d , f r , f c # ( ) , n k s , n k i , d s t o t , m e t f , t o t a l  a m t e x c , t o t a l a m t m e t  
S H A R E D  f w p , f w c # ( ) , f w e # ( ) , f 1 c # ( ) , f p c # ( ) , f p e # ( ) , f p p , x e , x p , x # ( ) , x m , w u , p k a , p h u  
S H A R E D  a a b t m , w t m u c , f w m , f p m , a a m , n d i n c , i m d o s e f l d i n c , v d i n c , f c o n c , b # ( ) , c # ( ) , e # ( )  
S H A R E D  m, u
L O C A L  a f h , a f 5 o l d , a f l ,a f f , a f v , a f p , p , q , r , s , t , a m t e x c , a m t m e t , i
' a m ou n ts  of d ru g  in b loo d f r a c t i o n s  l e a v i n g  u p s t r e a m  pool 
a f #(1) = ap i * sv w  / wp i
a f #(2) = apa * w f # ( 2 )  / wp a
a f# (3 )  = apa * w f # ( 3 )  / w p a
a f# (4 )  = apa * w f # ( 4 )  / wp a
afh = apa * w f #{5) / w p a  ' fr ac t i o n  l e a v i n g  art  pool fo r  l i v e r
a f# (6 )  = apa * w f # ( 6 )  / wp a
a f# (7 )  = apa * w f # ( 7 )  / w p a
a f# (8 )  = apa * w f #(8) / w p a
a f# (9 )  = apa * w f # ( 9 )  / w p a
a f # ( 1 0 )  = apa * w f # ( 1 0 )  / wp a
a f # ( 1 1 )  = apa  * w f # (1 1)  / w p a
afp = app * w f # {4 )  / w p p  ' f r a c t i o n  l e a v i n g  por ta l  pool f or  l i v e r
afl = apl * w f #{7) / wpl
aff = apf * w f #(8) / w p f
afv = apv * svw  / wpv
' am ou n ts  of d ru g  left b e h in d  in p o o l s  
apa  = apa - <a f #(2) + a f # ( 3 )  + a f #(4) + afh + a f #(6) + a f #(7) + a f # ( 8 ) _
+ a f #(9) + a f #(10) + af # (11 ))  
apv = apv - afv
api = api - a f #(1)
apl = apl - afl
apf  = apf  - aff
app = app - afp
a f 5 o l d  = afh + afp 
wf #(5) = w f #(5) + w f #(4) 
a m t m e t  = m e t f  * a f 5 o l d  
a f # (5 )  = a f 5 o l d  - a m t m e t  
FOR 1 = 1 to nc 
c s o l d # ( i )  = cs #(1) 
a a t o l d # ( i ) = a a t # ( i )
N E X T  i
'adds a m o u n t s  in h e p a t i c  and  p o r ta l  f r a c t i o n s  
'add h e p a t i c  and  por ta l  b l o o d  
' c a l c u l a t e s  a m o u n t  m e t a b o l i s e d  
' su bt r a c t s  f r o m  b l o o d  e n t e r i n g  l i v e r
're cords  cs and  aa t  b e f o r e  e q u i l i b r a t i o n  
'for r e s u l t s  c a l c u l a t i o n s
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' t i s s u e  e q u i l i b r a t i o n  
FOR  i = 1 TO nc 
S E L E C T  CASE 1 
C ASE  1,4 TO 10
a a b t # ( i )  = a f ( i ) + a at # ( i )  'total a m o u n t  of d rug  in b lo od  and t i s s u e  
c s # ( i ) = a a b t # ( i ) / ( w f # ( i ) * b # (1 ) + w t # ( 1 ) * ( c # (1 ) + e # (1)))
' a m o u n t  in b l o o d  at c o n c e n t r a t i o n  e q u i l i b r i u m  
a a b # ( i ) = c s # (1 )  * w f # ( i )* b # ( i )
‘a m o u n t  in t i s s u e  at c o n c e n t r a t i o n  e q u i l i b r i u m  
a a t # ( i ) = cs # ( i ) * w t # ( i ) * ( c # ( i ) + e # (1))
CAS E 2
a a b # ( i ) = a f # ( i )  ' p e r i p h e r a l  s h u n t
a a t # ( i ) = 0
a a b t # ( 1 )  = a f #(1)
c s ( i ) = a f # ( i ) / (w f # ( 1 ) * b # (i ))
C AS E 11
a a b t m  = a f#( i)  + a a t # ( i ) + aam
c s( i) = a a b t m  / (w f # ( i )* b # (i ) + w t # ( i ) * ( c # ( i ) + e # ( i )) + m)
a a b # ( i )  = c s # ( i ) * w f # (i )  * b#(i)  'nasal a b s o r b t i o n  c o m p a r t m e n t
a a t # ( i )  = c s # (i )  * w t # (i )  * (e#(i) + c # ( i ))
aa m  = c s # ( i ) * m
a a b t # ( i )  = a a b # ( i ) + a at #( i )
C ASE  3
a a b t # ( i )  = a f # ( i ) + a at #( i )
b #(1 ) = b # ( i ) / f c o n c  : c#(1) = c # ( i ) / f c o n c  : e #( i) = e # ( i ) / f c o n c
c s(i ) = a a b t # ( i )  / ( w f # { i ) * b # ( i #) + w t # ( i ) * ( c # (i ) + e # ( i )) + u)
a a b # ( i ) = cs # ( i ) * w f # ( i ) * b # ( i )
a a t # ( i ) = c s # ( i ) * w t # ( i ) * ( c # ( i ) + e # ( i) >
a m t e x c  = cs # (i )  * u 'renal c o m p a r t m e n t
c s # ( i ) = c s # ( i ) / f c o n e
b# (i)  = b#(i) * f c o n c  : c#(i) = c#(i)  * f c o n c  : e #( 1) = e#(i) * f c o n c  
END S E L E C T  
N E X T  i
w f # ( 5 )  = w f # (5 )  - w f # ( 4 )  ' r e se t  m a s s  h e p a t i c  f r a c t i o n  fo r  n e x t  c y c l e
' a m o u n t s  of druq in d o w n s t r e a m  p o o l s  a f t e r  a d m i x t u r e
api = api + afv
apv = apv  + a a b # ( 2 )  + a ab # ( 3 )  + a a b #(5) + a a b # ( 6 )  + a a b # ( 9 ) _
+ a a b # ( 1 0 )  + a a b # ( 1 1 )  + afl + aff
apa = apa  + a a b # (1 )
apl = apl + a a b #( 7 )
apf  = apf  + a a b # (8)
app = app + a a b #(4)
' c a l c u l a t e  c u m u l a t i v e  a m o u n t  e x c r e t e d  m e t a b o l i s e d  and r e m a i n i n g  in b ody : 
t o t a l a m t e x c  = t o t a l a m t e x c  + a m t e x c  
t o t a l a m t m e t  = t o t a l a m t m e t  + a m t m e t  
d s t o t  = d s t o t  + I d i n c  + v d i n c  + i m d o s e  + n d i n c  
apl = api + v d i n c  'add iv d ose
a a t # ( 1 0 )  = a a t # ( 1 0 )  + i m d os e  'add im d ose
a a t # ( 1 )  = a a t #(1) + I d i n c  'add i n t r a p u l m o n a r y  d o s e
a a m  = aa m  + n d i n c  'add i n t r a n a s a l  dose
END SUB
S U B  p h e a l e
' c a l c u l a t e s  v a r i a b l e s  d e p e n d a n t  on p l a s m a  or m u c u s  pH 
S H A R E D  p h e , p h p , p h c # ( ) , p h m , a p h # ( ) , b p h , x p , x e , x # ( ) , x m , a c i d , p k a , n c , b # ( ) , c # ( ) , e # ( )  
S H A R E D  e p r a t , f r , f p p , n k s , n k 1 , f w p , f c # ( ) , f 1 c # ( ) , l a m l w , f p c # ( ) , f w c # ( )
S H A R E D  f p e # ( ) , f w e # ( ) , w t m u c , f w m , f p m , m  
L O C A L  i
p he = php 'pH of ecf
FOR i = 1 TO nc
262
p h e # (1) = phe + a p h # ( i ) + bph * (phe - 7.4) 'pH of t i s s u e  cells
N E X T  1
xp = E X P 1 0 ( a c i d  * (pka - php)) ' c o n v e n i a n c e  v a r i a b l e s
xe = E X P 1 0 ( a c i  d * (pka - phe)) 'for t i s s u e  d i s t r i b u t i o n
xm = E X P 1 0 ( a c i d  * (pka - phm)) 'c a l c u l a t 1 o n
m = w t m u c  * (fwm * (1 + xm) + fpm * (nks + xm * n k 1))
FOR i = 1 TO nc
x # ( i ) = E X P 1 0 ( a c i d  * (pka - p h c ( i ) ) )
b#(i)  = ( e p ra t  * fr + 1 - fr) * (fpp * (nks + nki * xp) + fwp * (1 + xp))
c#(i) = f c#( i)  * (flc# (i)  * l a m l w  + f p c #( i )  * (nks + nki * x # ( 1 ) ) _
+ f w c # ( i ) * ( x # ( 1) + 1))
e # ( i ) = (1 - f c # ( i )) * (fpe# (i)  * (nks + nki * xe) + f we # ( 1 )  * (1 + xe)) 
N E X T  1 
END SUB
SU B  q d t c a l c
' c a l c u l a t e s  u r i n e  w a t e r  o u t p u t  Kq / c yc le
' c a l c u l a t e s  ( f r a c t i o n a l )  s t r o k e  v o l u m e f s l  and c h e c k s  t he m  a g a i n s t  
'pool s i z e s  m a k i n g  a d j u s t m e n t  if n e c e s s a r y  
S H A R E D  w q d o t <q d o t , b d e n , s v w , f # ( ) , w p a , w p i , w p l , w p f , w p p Iw p v , d t , w f # ( ) , n c  
S H A R E D  w u ,u r o u t ,p a p e r , d i s k i ,f i 1 e l $ , r ti me  
S T A T I C  d t c h a n g e %
L OC A L  test. i
wu = (dt * u rou t)  / ( 10 0 0 . 0  * 6 0. 0  * 60.0) 'u r in e  w a t e r  o u t p u t  Kq / c y c l e  
w q d o t  = (qdot  * bden) / 60. 0 ' c a r d i a c  o u t p u t  Kq / s
sv w  = w q d o t  * dt 'mass of s t r o k e  v o l u m e  Kq
FOR i = 1 TO nc
w f # ( 1 )  = svw  * f#(i) 'mass of f r a c t i o n a l  s t r o k e  v o l u m e s  Ka
N E X T  i
IF w p a  > wpi T H E N  ' s m a l l e s t  pool c h o s e n  f ro m  the m a i n  p o o l s
t es t  = wpi 
E LSE
t es t  = wpa  
END IF
IF w pv  < t est  T H E N  tes t = wpv
'if any  pool s m a l l e r  tha n r e l e v a n t  ( f r a c t i o n a l !  s t r o k e  v o l u m e  
'then d e c r e a s e  c y c l e  tim e 
IF sv w  > t es t OR w f # (4 )  > wpp  OR w f # ( 7 )  > wpi OR w f # ( 8 )  > w p f  T HEN  
dt = dt - 1.0
d t c h a n g e X  = 1 ' i n d i c a t o r  tha t dt has bee n c h a n g e d
C AL L  q d t c a l c  'recall sub to c a l c u l a t e  s t r o k e  v o l u m e s
END IF 'and r e c h e c k  a g a i n s t  pool v o l u m e s
IF d t c h a n g e %  = 1 T H E N  'until s a t i s f a c t o r y
IF p a p e r  = 1 T HE N
L P R I N T  "" ' n o t i f i e s  p r i n t e r
L P R I N T  U S I N G  " ti me  # # # # . #  min: s t r o k e  v o l u m e  s ize  e r r o r r t i m e / 6 0  
L P R I N T  U S I N G  " C y cl e  time a u t o m a t i c a l y  r e s e t  to # # . # #  s " ; d t  
END IF
IF diski  > 0 T HE N  ' n o t i f i e s  r e s u l t s  f ile
O P E N  f i 1e 1 $ FOR A P P E N D  AS #1 
P R I N T  #1, ""
P R I N T  #1, U S I N G  " ti me # # # # . #  min: s t r o k e  v o l u m e  s iz e e r r o r : " ; r t i m e / 6 0  
P R I N T  #1, U S I N G  " C y cl e  tim e a u t o m a t i c a l y  r e s e t  to # # . # #  s "; dt  
C L O S E  #1 
END IF
d t c h a n g e X  = 0 ' res et  i n d i c a t o r
END IF
C A L L  u c a l c  ' c a l c u l a t e s  wu d e p e n d a n t  v a r i a b l e
END  SUB
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SUB u c a l c
■ c a l c u l a t e s  u r i n e  pH d e p e n d a n t  c o n v e n i a n c e  v a r i a b l e  for t i s s u e  
■ d i s t r i b u t i o n  c a l c u l a t i o n  
S H A R E D  u , w u , a c i d , p k a , p h u  
u = wu * (1 + E X P 1 0 ( a c i d  * (pka - phu)))
END SUB
SUB b 1 c o n e (c s ,a b ,w b , b a b , b a p )
■sub c a l c u l a t e s  total dru g c o n c e n t r a t i o n s  in b l o o d  p l a s m a  and 
■ e r y t h r o c y t e s  (umol /1  or n mo l / m l l  and a q u e o u s  c o n c e n t r a t i o n  
■of u n i o n i s e d  d rug  ( u m o l / K g  w ate r)  from the total m a s s  of drug 
■and b l o o d  p r e s e n t  
S H A R E D  e p r a t , f r , f w p , f p p , n k s , n k i , x p , b d e n , p d e n  
bab = ab / wb ‘total con e in b loo d umol / Kg
■ aq u e o u s  cone u n i o n i s e d  dru q umol / Kq w a t e r
cs = bab / ( ( e p r a t  * fr + 1 - fr) * (fpp * (nks + nki * xp) + fwp * (1 + x p) ))
b a p = b a b / ( e p r a t * f r + 1 - f r )  
bab = bab * b de n ‘umo l/l  ( nm ol/ ml)  b l o o d
bap = bap * pde n ’umo l/ l  (nm ol/ ml)  p l a s m a
END SUB
$ I N C L U D E  " f s u b s 2 . b a s "  ' c o m p i l i n n q  i n s t r u c t i o n
■file  f 2 s u b s . b a s
SUB r e s u l t s
■sub c a l c u l a t e s  and o r g a n i s e s  r es ul t s  
S H A R E D  r t i m e , p t i m e , t t i m e , n c , d f a c , d t , e p r a t , f r , b d e n , r d e n , p d e n  
S H A R E D  a a m , d s t o t , t o t a l a m t m e t , t o t a l a m t e x c ,  m a x n u m , f  i 1e 1 $ , d i s k i , p a p e r  
S H A R E D  c s o l d # ( ) , w f # ( ) , a a t # ( ) , a a b # ( ) , c s # ( ) , w t # ( ) , t m a x % ( ),m a x c o u n t X ( ) , t i s s u e m a x () 
S H A R E D  w p v , a p v , a p a , a p i , a p p , a p l , a p f , b a b s , b a b c v , b a p s , b a p c v , c s s , c s c v  
S H A R E D  g r a p h 1 , g r a p h 2 , g r a p h 3 , g r a p h 4 , g r a p h 5 , g r a p h 6  
S H A R E D  l e g a r t , l e g p , l e g f a t , l e g l e a n , 1 e g b r a i n , l e g c v , y s i z e , x s i z e  
S H A R E D  x l X , x 2 % , x 3 % , x 4 % , x 5 % , x 6 % , y 1 % , y 2 % , y 3 % , y 4 % , y 5 % , y 6 % , g $
L O C A L  a a t , a a b , c o n c b l o o d , c o n c t i s s u e , c o n c p l a s m a , 1 , n , y %
■call b l c o n c  to c a l c u l a t e  druq c o n c e n t r a t i o n s :  blood, pla sma .
■ e r y t h r o c y t e  (um ol / 1) .  a q u e o u s  u n i o n i s e d  (umol / Kq w a t er !
■in p e r i p h e r a l  s h u n t  ( ar ter ial  1 .lean. fat, and c e n tr a l  v e n o u s  pool.
■and n o t i o n a l  p e r i p h e r a l  v eno us  b lo od  
C ALL  b l c o n e (c s s ,a a b # ( 2 ) , w f # ( 2 ) , b a b s , b a p s ) ' ar te r i a l  and c en t r a l
C ALL  b 1 c o n e ( c s c v , a p v , w p v , b a b c v , b a p c v ) ‘v e n o u s  p l a s m a  c o n c e n r a t i o n s
IF di ski > 0 T H E N
F 0 R i = 1 T 0 9 ‘d e t e c t  t im e  of m a x i m u m  c o n c e n t r a t i o n
IF c s o l d # ( i )  > c s # ( i ) T H E N  *(ie s t a r t  of f a l l i n g  c o n c e n t r a t i o n )
IF t m a x % ( i )  = 0 T H E N  'for e ac h  t i s s u e  and read i nt o  a r r a y
m a x c o u n t % ( i )  = m a x c o u n t % ( i )  + 1 
ti s s u e m a x ( i , m a x c o u n t % ( i ) ) =  (rtime - d t ) /  60 
IF m a x c o u n t X ( i )  - m a x n u m  THE N 
O PE N  f i 1 el $ FOR A P P E N D  AS #1 
P R I N T  #1,
P R I N T  # 1 , " t i s s u e  c o n c e n t r a t i o n  m a x i m a ( s i m u l a t i o n  t im e  m i n ) "
P R I N T  # 1 , " ”
FOR i = 1 TO 9
FOR n = 1 TO m a x c o u n t X ( i )
P R I N T  #1," # # # # # . # #
i ; t i s s u e m a x ( i ,n)
N EX T  n 
N E X T  i
FOR i = 1 TO 9 
m a x c o u n t X ( i )  = 0
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FOR n = 1 TO m a x n u m  
t 1 s s u e m a x ( i , n )  = 0 
N E X T  n 
N E X T  i 
END IF
t m a x % ( i ) = 1 
EN D  IF 
EN D  IF
IF c s # ( i )  > c s o l d # ( i )  T HE N  t ma xX (i ) = 0 ' res et  m a x  c o n c e n t a r t i o n  I n d i c a t o r  
N E X T  1 
END IF
' pl ot s e l e c t e d  r es u l t s  g r a p h s  on s c r e e n
IF g r a p h !  = 1 T H E N
IF r t i m e  > = 1 AND b ap s > 0 THE N
IF g$ = "1" T H E N  P S E T  (L 0 G 1 0 ( r t i m e ) , L 0 G 1 0 ( b a p s / d f a c )) 'time l o g a r i t h m i c
IF g$ = "2" T H E N  P S E T  (r t i m e ,L 0 G 1 0 ( b a p s / d f a c )) 'time  l i n e a r
IF l e g a r t  = 0 T H E N  ' c a l c u l a t e  c o o r d i n a t e s
'for g r a p h  label
y %  = C I N T ( P M A P ( L 0 G 1 0 ( b a p s / d f a c ) ,  1 ))
IF y %  MOD y s i z e  > y s i z e * 2 / 3  OR y% MOD  y s i z e  < y s i z e / 3  T HE N  
y ! %  = 0 
E LS E
y 1 %  = (y% \ y s i z e )  + 1 
END IF
IF g$ = n 1" T H E N  x1 %  = ( P M A P (L O G 1 0 ( r t i m e ).0 ) \ xsi ze )  + 1 
IF g$ = "2" T H E N  x1 %  = ( P M A P ( r t i m e , 0) \ x siz e)  + 1
IF x 1 %  > 10 T H E N  C AL L 1 e g e n d (x 1 % ,y 1 % , 1 e g a r t , " a ") ' l e g e n d  p r i n t s  label 
END IF 'if c o o r d i n a t e s  s u i t a b l e
END IF 
END IF
IF g r a p h 2  = 1 T HE N
IF r t i m e  > = 1 AND  a a t # ( l )  > 0 THE N
IF g$ = "1" T H E N  P S E T  (L 0 G 1 0 ( r t i m e ) , L 0 G 1 0 ( ( a a t # ( 1 ) / w t # ( 1 ) ) / d f a c ))
IF g$ = " 2 ” T H E N  P S E T  (r t i m e , L 0 G 1 0 ( ( a a t # ( 1 ) / w t # ( 1 ) ) / d f a c ))
IF legp = 0 T H E N
y %  = C I N T ( P M A P { L 0 G 1 0 ( ( a a t # { l ) / w t # ( 1  ) ) / d f a c ) , 1 ))
IF y %  MOD y s i z e  > y s i z e * 2 / 3  OR yX MOD y s i z e  < y s i z e / 3  T HE N  
y 2 %  = 0 
E LS E
y 2 %  = {y% \ y s i z e )  + 1 
END IF
IF g$ = "1" T H E N  x2 X  = (P M A P (L O G ! 0 ( r t i m e ) ,0) \ x s i ze )  + 1 
IF g$ = "2" T H E N  x2%  = ( P M A P ( r t i m e , 0) \ xs i ze )  + 1 
IF x 2 %  > 10 AND y 2 %  > 0 T HEN  CALL 1e g e n d {x 2 % , y 2 % , 1 e g p , " p ")
END IF 
END IF 
END IF
IF g r a p h 3  = 1 T H E N
IF r t i m e  >= 1 AND a a t # ( 8 )  > 0 THEN
IF g$ = "1" T H E N  P S E T  (LOG 1 0 ( r t i m e ), L0G1 0 ( ( a a t # ( 8 ) / w t # ( 8 ) ) / d f a c ) )
IF g$ = "2" T H E N  P S E T  (r t i m e , L 0 G 1 0 ( (a a t # ( 8 ) / w t # ( 8 ) ) / d f a c ) )
IF l e g f a t  = 0 T H E N
y% = C I N T ( P M A P ( L 0 G 1 0 ( ( a a t # ( 8 ) / w t # ( 8 ) ) / d f a c ) ,  1))
IF y %  MOD  y s i z e  > y s i z e * 2 / 3  OR y %  MOD y s i z e  < y s 1 z e / 3  T HEN  
y 3 %  = 0 
E L S E
y 3 %  = (y% \ y s i z e )  + 1 
E ND  IF
IF g$ = "1" T H E N  x 3%  = (P M A P (L 0 G 1 0 ( r t i m e ),0) \ xs i ze )  + 1 
IF g$ = "2" T H E N  x3%  = ( P M A P ( r t i m e , 0) \ xsi ze )  + 1 
IF x 3 %  > 10 T H E N  C AL L 1e g e n d (x 3 % , y 3 % , 1 e g f a t , " f " )
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END IF 
END IF 
END IF
IF g r a p h *  = 1 T HE N
IF r t i m e  >= 1 AND a at #( 7 )  > 0 T H E N
IF g$ = "1" T H E N  P SE T  (L 0 G 1 0 ( r t i m e ) , L 0 G 1 0 ( (a a t # ( 7 ) / w t # ( 7 ) ) / d f a c ) )
IF g$ = "2" T H E N  P SE T (r t i m e , LOG 1 0 ( ( a a t # ( 7 ) / w t # ( 7 ) ) / d f a c ))
IF l e g l e a n  = 0 T HEN
y% = C I N T ( P M A P ( L 0 G 1 0 ( ( a a t # ( 7 ) / w t # ( 7 ) ) / d f a c ) , 1 ) )
IF y% MOD y s i z e  > y s i z e * 2 / 3  OR y %  MOD y s i z e  < y s i z e / 3  T HEN  
y 4 %  = 0 
EL SE
y 4 %  = (y% \ y s i ze )  + 1 
END IF
IF g$ = "1" T H E N  x4% = (P M A P ( LOG1 0 ( r t i m e ), 0) \ xsi ze) + 1 
IF g$ = "2" T H E N  x4% = ( P M A P (r t i m e , 0) \ xsize) + 1 
IF x4% > 10 T H E N  C ALL  1e g e n d (x 4 % ,y 4%,1 eg 1e a n ,"1")
END IF 
END IF 
END IF
IF g r a p h 5  = 1 T HE N
IF r t i m e  >= 1 AND b ap c v  > 0 T H E N
IF g$ = "1" T H E N  P SE T  (L 0 G 1 0 ( r t i m e ) , L 0 G 1 0 ( b a p c v / d f a c ))
IF g$ = "2" T H E N  P SE T  (r t i m e , L O G 1 0 ( b a p c v / d f a c ) )
IF l eg cv = 0 T HEN
y% = C I N T ( P M A P ( L 0 G 1 0 ( b a p c v / d f a c ) , 1))
IF y %  MOD y s i z e  > y s i z e * 2 / 3  OR y %  MO D  y s i z e  < y s i z e / 3  T HE N 
y 5 %  = 0 
E LSE
y 5 %  = (y% \ y s i z e )  + 1 
END IF
IF g$ = "1" T H E N  x5%  = (P M A P (L O G 1 0 ( r t i m e ),0) \ xsize ) + 1 
IF g$ = "2" T H E N  x5%  = ( P M A P (r t i m e , 0) \ xsize) + 1 
IF x 5 %  > 10 T H E N  C AL L 1e g e n d (x 5 % ,y 5%,1 e g c v , " c " )
END IF 
E ND IF 
E ND  IF
IF g r a p h 6  = 1 T HE N
IF r t i m e  >= 1 AND  a at # ( 9 )  > 0 T H E N
IF g$ = "1" T H E N  P SE T  ( L 0 G 1 0 ( r t i m e ) , L 0 G 1 0 ( ( a a t # ( 9 ) / w t # ( 9 ) ) / d f a c ) )
IF g$ = "2" T H E N  P SE T  (r t i m e , LOG 1 0 ( ( a a t # ( 9 ) / w t # ( 9 ) ) / d f a c ))
IF l e g b r a i n  = 0 T HE N
y% = C I N T ( P M A P ( L 0 G 1 0 ( ( a a t # ( 9 ) / w t # ( 9 ) ) / d f a c ) , 1 ) )
IF y %  MOD y s i z e  > y s i z e * 2 / 3  OR y %  MOD  y s i z e  < y s i z e / 3  T HE N 
y 6 %  = 0 
E LSE
y 6 %  = (y% \ y s i z e )  + 1 
END IF
IF g$ = "1" T HE N  x6% = ( P M A P ( L 0 G 1 0 ( r t i m e ),0) \ x siz e)  + 1 
IF g$ = "2" T H E N  x6 %  = ( P M A P ( r t i m e , 0) \ xsi ze) + 1 
IF x 6 %  > 10 T HE N  CAL L 1e g e n d (x 6 % , y 6 % , 1 e g b r a i n , "b " )
END IF 
END IF 
EN D  IF
IF d 1 sk 1 = 1 AND r t i m e  < t t i m e  T H E N  'stor e r ea ds  r e s u l t s  i nt o
IF A & S (60 - pti me) <= (dt/2) T H E N  C ALL  s t o r e  ' arr ay  f or  s t o r a g e
S E L E C T  CASE p ti me
C AS E  <= 3 60 0  ' s t a n d a r d  s a m p l i n g  s c h e m e
IF A B S ( ( p t i m e / 3 0 0  - C I N T ( p t i m e / 3 0 0 ) )*300) <= dt/2 T H E N  CAL L s t o r e  
C AS E  > 3 60 0
IF A B S ( ( p t i m e / 1 800 - C l N T ( p t i m e / 1 8 0 0 ) ) * 1 8 0 0 )  <= dt/2 T HE N  C ALL  s t o r e
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END S E L E C T  
END IF
IF diski = 2 and r t i m e  < t t i m e  T H E N  
IF p t i m e  <= 120 T HE N 
IF dt > 2.0 T HE N
C AL L  s t o r e  ' f r e q u e n t  s a m p l i n g  s c h e m e
E LSE  IF A B S ( ( pti m e/ 2  - Cl N T (p t i m e /2) )*2) <= dt/2 T HE N  
C AL L  s to re  
END IF 
END IF
IF p t i m e  > 120 AND p t i m e  <= 1 2 0 0  T HEN
IF A B S ( ( p t i m e / 3 0  - C I N T ( p t i m e / 3 0 ) )*30) <= dt/2 T H E N  C A L L  s t o r e  
END IF
IF p t i m e  > 1200 AND p t i m e  <= 3 6 0 0  T HEN
IF A B S ( ( p t i m e / 1 2 0  - C I N T ( p t i m e / 1  2 0 ) ) * 1 2 0 )  <= dt/ 2 T HE N  C ALL  s t o r e  
END IF
IF p t i m e  > 3 60 0  AND p t i m e  <= 2 1 6 0 0  T HE N
IF A B S ( ( p t i m e / 6 0 0  - C I N T ( p t i m e / 6 0 0 ) )*600) <= d t/2  T H E N  C AL L  s t o r e  
END IF
IF p t i m e  > 2 1 6 0 0  T HEN
IF A B S ( ( p t i m e / 1 8 0 0  - C I N T ( p t i m e / 1 8 0 0 ) ) * 1 800) <= dt/2 T H E N  C AL L  s t o r e  
END IF 
END IF
IF r t i m e  > = t t i m e  T HE N
aat = 0 ' c a l c u l a t e  t o t a l s
FOR i = 1 TO nc
aat = a a t # ( i ) + aat 
N EX T  i
aab = apa + apv + app + apf  + apl + api 'total a m o u n t  d rug  b l o o d  
IF p a p e r  = 1 T H E N  'final s u m m a r y  to p r i n t e r
L P R I N T  ""
L P R I N T  U S I N G  "ug dru g r e m a i n i n g  in t i s s u e s  # # # # # # . # " ; a a t / d f a c
L P R I N T  U S I N G  "ug d ru g r e m a i n i n g  in b lo od # # # # # # . # " ; a a b / d f a c
L P R I N T  U S I N G  "ug dru g e x c r e t e d  # # # # # # . # " ; t o t a 1a m t e x c / d f a c
L P R I N T  U S I N G  "ug dru g m e t a b o l i s e d  # # # # # # . # " ; t o t a 1a m t m e t / d f a c
L P R I N T  "
L P R I N T  " e r r o r  che ck:  (ug in b o d y  + ug e l i m i n a t e d  - ug a d m i n i s t e r e d )  "; 
(aam + aab + aat + t o t a l a m t e x c  + t o t a l a m t m e t  - d s t o t ) / d f a c  
L P R I N T  ""
L P R I N T  ""
L P R I N T  "END"
END IF
IF di s k 1 > 0 T HEN  
C AL L  s t o r e  
C AL L  dis k
O PE N  f i 1e 1 $ FOR A P P E N D  AS #1 
P R I N T  #1,""
P R I N T  # 1 , " t i s s u e  c o n c e n
P R I N T  #1,""
FOR i = 1 TO 9
'final r e s u l t s  and 
' c o n c e n t r a t i o n  m a x i m a  
'to r e s u i t s  file
t r a t i o n  m a x i m a ( s i m u l a t i o n  t ime  min )
FOR n = 1 TO m a x c o u n t % ( i )
P R I N T  #1, U S I NG "  # ####.##
i ; ti s s u e m a x ( i , n)
N EX T  n 
N E X T  i 
P R I N T  #1,""
e q u i l i b r i u m  t i s s u e / b l o o d  
conc. r a t i o s  to r e s u l t s  f i l e
P R I N T  # 1 , " R a t i o s  at c o n c e n t r a t i o n  e q u i l i b r i u m  (ug /Kg ):  
P R I N T  # 1 , " t i s s u e  t i s s u e / b l o o d  t i s s u e / p 1asma"  
FOR i = 1 TO nc
S E L E C T  CASE i
C AS E  2
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E X I T  S E L E C T  
CAS E 1,3 TO nc 
IF 1 = 5 T H E N
c o n c b 1ood  = a a b # ( 5 )  / ( w f # ( 5 ) + w f # (4 ))
ELS E
c o n c b l o o d  = a a b # ( 1 )  / wf# (i)
END IF
c o n c t i s s u e  = a a t # ( i )  / w t # ( i )
c o n c p l a s m a  = c o n c b l o o d  / (eprat * fr + 1 - fr)
P R I N T  #1, U S I N G  " ## # # . # #  # # . # # " ; _
i ; c o n c t i s s u e / c o n c b 1 o o d ; c o n c t i s s u e / c o n c p l a s m a  
END S E L E C T  
N E X T  i 
P R I N T  #1
P R I N T  #1, U S I N G  "ug dr u g/ 1  e r y t h r o c y t e s  : ug dr u g/ 1  p l a s m a  = # . # # # " ; _  
e p r a t * r d e n / p d e n
P R I N T  #1, U S I N G  "ug dr u g/ 1  b lo od  : ug d r u g/ 1  p l a s m a  = # . # # # " ; b a b s / b a p s  
P R I N T  #1,""
P R I N T  #1,""
P R I N T  #1, " E R R O R  C H E C K  (ug in b od y+ u g  e l i m i n a t e d ) -ug a d m i n i s t e r e d  
(a am  + aab + aa t  + t o t a l a m t e x c  + t o t a l a m t m e t  - d s t o t ) / d f a c  
P R I N T  # 1 , " E N D "
C L O S E  #1 
END IF 
END IF 
END SUB
' c a l c u l a t e  d ru g c o n c e n t r a t i o n s  
'in t h o s e  pool b l o o d s  not 
' a v a i l a b l e  f r o m  SUB r e s u l t s
SUB s t o r e
'sub c a l c u l a t e s  r e s u l t s  not  a v a i l a b l e  f ro m sub  r e s u l t s  
're ads  r e s u l t s  into s t o r a g e  a r r a y  
S H A R E D  r c o u n t , r e s u l t s # ( ) , r t i m e , t o t a l  amtmet, t o t a l a r n t e x c . d s t o t  
S H A R E D  d f a c , c s # ( ) , a a t # ( ) , a a b # ( ) , a a t o l d # ( ) , w t # ( ) , w f # ( ) , n c , e p r a t , f r  
S H A R E D  c s i , a p i , w p i , b a b i , b a p i , c s p , a p p , w p p , b a b p , b a p p  
S H A R E D  c s a , a p a , w p a , b a b a , b a p a , c s c v , a p v , w p v , b a b c v , b a p c v  
S H A R E D  c s s , b a b s , b a p s , c s f , w p f , a p f , b a b f , b a p f , c s l , a p l , w p l , b a b l  
S H A R E D  b a p l , c s p v , a m t p v , w t p v , b a b p v , b a p p v , b d e n , a a m  
L O C A L  i % , x % , a a b , a a t  
C AL L  b l c o n c ( c s i , a p i , w p i , b a b i , b a p i )
C AL L  b l c o n c ( c s p , a p p , w p p , b a b p , b a p p )
C AL L  b l c o n c ( c s a , a p a , w p a , b a b a , b a p a )
C A L L  b l c o n c ( c s f , a p f , w p f , b a b f , b a p f )
C AL L  b l c o n c ( c s l , a p l , w p l , b a b l , b a p l )  
a m t p v  = (babs  + b ab f  + b ab l)  / (3 * bden) 
w t p v  - 1
C AL L  bl c o n c ( c s p v ,  a m t p v , w t p v , b a b p v . b a p p v )  
aat = 0
FOR i% = 1 TO nc _ _ _ _ _ _ _ _ _ _ _ _ _
aat = a a t # ( i % )  + aat 
N E X T  i%
aab = ap a  + apv + app + apf + apl + api 'total a m o u n t  dru g b l o o d  
' re ad r e s u l t s  i nt o  r e s u l t s  s t o r a g e  a r r a y  
' c o n c e n t r a t i o n s  as nq/ml 
r c o u n t  = r c o u n t  + 1
' c a l c u l a t e  total  drug 
'in all b l o o d  and t i s sue
r e s u 1t s # (r c o u n t , 1) 
r e s u 1ts#  (r c o u n t , 2) 
r e s u 1t s # (r c o u n t , 3) 
r e s u 1t s # (r c o u n t , 4) 
r e s u 1t s # (r c o u n t , 5) 
r e s u 1t s # (r c o u n t , 6) 
r e s u 1t s # (r c o u n t , 7)
r t i m e / 6 0  
d s t o t / d f a c  
a a b / d f a c  
a a t / d f a c
t o t a l a m t m e t / d f a c  
t o t a 1a m t e x c / d f a c  
a a t # ( 1 ) / dfac
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r e s u 1t s # (r c o u n t , 8) = a a t # ( 1 ) / ( d f a c * w t # (1)) 
r e s u 1t s # (r c o u n t , 9) = c s # ( 1 ) / d f a c  
i % = 3
FOR xX = 10 TO 34 STEP 3 ' c o n c e n t r a t i o n s  and
r e s u l t s # ( r c o u n t , x X )  = a a t # ( i X ) / d f a c  ' a m o u n t s  in t i s s u e s
r e s u 1t s # (r c o u n t , x X + 1 ) = a a t # ( i X ) / ( d f a c * w t # (1X ) ) 
r e s u 1t s # (r c o u n t , x X + 2 ) = c s # ( i X ) / d f a c  
i X = i X + 1
N E X T  xX ' t i s s u e / b l o o d  and t i s s u e  p l a s m a  c o n c e n t r a t i o n  r a t i o s
IF a a b # (2 ) > 0 T H E N  r e s u 1t s # (r c o u n t , 37) = (a a t o l d # ( 1 ) / ( w t # ( 1 ) ) ) / ( a a b # ( 2 ) / ( w f # ( 2 ) ) )  
IF a a b # (2 ) > 0 T H E N  r e s u 1t s # (r c o u n t , 38) = (a a t o l d # ( 1 ) / ( w t # ( 1 ) ) ) / ( a a b # ( 2 ) / ( w f #(2) _ 
* ( e p r a t  * fr + 1 - f r ))) 
i X = 3
FOR xX = 39 TO 51 STE P 2
IF a a b # ( 2 )  > 0 T H E N  r e s u 1t s # (r c o u n t , x X ) = (a a t o l d # (i X ) / ( w t # ( i X ) ) ) / _  
( a a b # ( 2 ) / ( w f # { 2 ) ))
IF a a b # ( 2 )  > 0 T H E N  r e s u 1t s # (r c o u n t , x X + 1 ) = ( a a t o l d # ( i X ) / ( w t # ( i X ) ) )/_
(a a b # ( 2 ) / ( w f # ( 2 ) * ( e p r a t  * fr + 1 - fr))) 
iX = iX + 1
N EX T  xX ' c o n c e n t r a t i o n s  in b l o o d  and p l a s m a
resu ts# r c o u n t 53) = b a b a / d f a c
resu ts# r c o u n t 54) = b a p a / d f a c
resu ts# r c o u n t 55) = c s a / d f a c
resu ts# r c o u n t 56) = b a b s / d f a c
resu ts# r c o u n t 57) = b a p s / d f a c
resu ts# r c o u n t 58) = c s s / d f a c
resu ts# r c o u n t 59) = b a b c v / d f a c
resu ts# r c o u n t 60) = b a p c v / d f a c
resu ts# r c o u n t 61 ) = c s c v / d f a c
resu ts# r c o u n t 62) = b a b p v / d f a c
resu ts# r c o u n t 63) = b a p p v / d f a c
resu ts# r c o u n t 64) = c s p v / d f a c
resu ts# r c o u n t 65) = b a b p / d f a c
resu ts# r c o u n t 66) = b a p p / d f a c
resu ts# r c o u n t 67) = c s p / d f a c
r esu ts# r c o u n t 68) = b a b l / d f a c
resu ts# r c o u n t 69) = b a p l / d f a c
r esu ts# r c o u n t 70) = cs 1 /dfac
resu ts# r c o u n t 71 ) = b a b f / d f a c
r esu ts# r c o u n t 72) = b a p f / d f a c
r esu ts# r c o u n t 73) = c s f / d f a c
resu ts# r c o u n t 74) = b a b i / d f a c
resu ts# r c o u n t 75) = b a p i / d f a c
resu ts# r c o u n t 76) = cs i/ d fa c
r esu ts# r c o u n t 77) = a a m / d f a c
IF r c o u n t  = 50 T H E N  C ALL  disk ' re s u l t s  to file w h e n  a r r a y  full
END SUB
SUB  d is k
'sub r e a d s  r e s u l t s  s t o r a g e  a r r a y  to r e s u l t s  fil e 
S H A R E D  r e s u 1t s # ( ) , r c o u n t , f i 1e 1 $
L O C A L  x X , y X , i X  
O PE N  f 11 el $ FOR A P P E N D  AS #1 
FOR xX = 1 TO r c o u n t  
P R I N T  #1,""
P R I N T  #1, U S I N G  " t i m e  # # # # . # #  min 
r e s u l t s # ( x X , l ) ; r e s u l t s # ( x X , 2 )
P R I N T  #1, U S I N G  "ug in b l o o d # # # # # . #  
r e s u l t s # ( x X , 3 ) ; r e s u l t s # ( x X , 4 )
P R I N T  #1, U S I N G  "ug m e t a b o l i s e d # # # # # . #
ug a d m i n i s t e r e d # # # # # . # " ;  
ug in ti s s u e # # # # # . # " ; _  
ug e x c r e t e d # # # # # . #
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ug d r u g / K g  t i s s u e  u n i o n i s e d  a q 1
r e s u l t s # ( x X , 5 ) ; r e s u l t s # ( x % , 6 )
P R I N T  # 1 , " t i s s u e  total drug 
i% = 1
P R I N T  # 1 , U S I N G  " ## # # # # # . # #  # # # # # # - # # # #
i % ; r e s u l t s # ( x X , 7 ) ; r e s u 1t s # ( x X , 8 ) ; r e s u l t s # ( x X , 9) 
i % = 3
FOR y X  = 10 TO 34 STE P 3
P R I N T  # 1 . U S I N G  " ## # # # # # . # #  ### ### . ### #
i X ; r e s u l t s # ( x X , y X ) ;r e s u l t s # (x X , y X + 1 ) ; r e s u l t s # (x % , y % + 2 ) 
i % = i % + 1 
N EX T  y%
U S I N G  " m u c o u s  # # # # . # # " ; r e s u l t s # ( x X , 77) 
t i s s u e  r a t i o s  t i s : a r t  b l o o d  t i s : a r t  p l a s m a "
####•####";_
# # # # . # # # # " ; _
P R I N T  #1 
P R I N T  #1 
iX = 1
P R I N T  #1, U S I N G  " ##
i X ; r e s u l t s # ( x X , 3 7 ) ; r e s u l t s # ( x X , 3 8 )
1% = 3
FOR y %  = 39 TO 51 STEP 2 
P R I N T  #1, U S I N G  B ## 
i X ; r e s u l t s # ( x X , y X ) ; r e s u l t s # ( x X , y X + 1 ) 
i% = iX + 1 
N E X T  y%
ug/1 b lo od  
U S I N G  " ca ####
x X , 5 3 ) ; r e s u l t s # ( x X , 5 4 )
U S I N G  "pa ####
x X , 5 6 ) ; r e s u l t s # ( x X , 5 7 )
U S I N G  "cv ####
x X , 5 9 ) ; r e s u l t s # ( x X , 6 0 )
U S I N G  "pv ####
x % , 6 2 ) ; r e s u l t s # ( x % , 6 3 )
U S I N G  " po r  ####
x X , 6 5 ) ; r e s u l t s # ( x X , 6 6 )
U S I N G  " le an  ####
x X , 6 8 ) ; r e s u l t s # ( x X , 6 9 )
U S I N G  "fa t ####
x X , 7 1 ) ; r e s u 1t s # (x X , 72)
U S I N G  "inj ####
x X , 7 4 ) ; r e s u l t s # ( x X , 7 5 )
P R I N T  #1 
P R I N T  #1 
r e s u 1ts# 
P R I N T  #1 
res u 1 ts# 
P R I N T  #1 
r e s u 1ts# 
P R I N T  #1 
r e s u 1ts# 
P R I N T  #1 
r e s u 1ts# 
P R I N T  #1 
r e s u 1ts# 
P R I N T  #1 
r e s u 1ts# 
P R I N T  #1 
r e s u 1ts# 
N E X T  x% 
r c o u n t  = 0 
C L O S E  #1 
END SUB
##.####
##.####
ug/1 p l a s m a
####
r e s u 1t s # (x X , 55)
#### 
r e s u 1t s # (x % , 58)
#### ####.####
r e s u 1t s # (x X , 61)
#### ####.####
r e s u 1t s # (x % # 64)
#### # # # # . # # # #
r e s u 1ts # ( x X ,67)
#### #### . # # # #
r e s u 1t s # (x X , 70)
####
r e s u 1t s # (x X , 73)
####
r e s u 1t s # (x X , 76)
####";_
##.####" ;
u n i o n i s e d  aq'
####
####.####
####.####
####
####
####
####
're set r e s u l t s  a r r a y  c o u n t e r
S UB  g r a p h s c a l e
'sub set s up s c r e e n  for g r a p h i c a l  d i s p l a y  of r e s u l t s  
S H A R E D  g r a p h 1 , g r a p h 2 , g r a p h 3 , g r a p h 4 , g r a p h 5 , g r a p h 6 , l e g l e a n f l e g f a t  
S H A R E D  l e g c v , l e g p , 1 eg a r t , l e g b r a i n , x s i z e , y s i z e , t t i m e , g $
L O C A L
CLS
y.y i -ry 2 , x , x l ,x 2 , e $ , p , n u l $
P R I N T
P R I N T
" S c r e e n  o u t D U t : "  ' i n D u t  r o u t i n e f o r  q r a p h  s e l e c t i o n
P R I N T " t h e p r o g r a m  w i l l  p l o t  d r u g  c o n c e n t r a t i o n in a n y  c o m b i n a t i o n  o f "
P R I N T
P R I N T
" t h e f o l l o w i n g  to a s u i t a b l e  s c r e e n  d u r i n g t h e  s i m u l a t i o n : "
P R I N T "FI a r t e r i a l  p l a s m a  "
P R I N T " F2 c e n t r a l  v e n o u s  p l a s m a "
P R I N T " F3 f a t  t i s s u e "
P R I N T " F4 l e a n  t i s s u e  ( m u s c l e ) "
P R I N T " F5 l u n g  t i s s u e "
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P R I N T  "F6 b r a i n  t i s s u e  
P R I N T  ""
KEY 1, "1" 'la be l s  f u n c t i o n  keys
K EY  2, "2"
KEY  3, "3"
KEY  4, "4"
KEY 5, "5"
KEY  6, "6"
KEY  9, "9"
nul$ = I N K E Y $  ' cl ear s k e y b o a r d  b u f f e r
e$ = ""
P R I N T  " P r e s s  the f u n c t i o n  key (s )  c o r r e s p o n d i n g  to the g r a p h ( s )  y o u  w a n t  to plot" 
P R I N T  " P r e s s  F9 to e r a s e  and r ed o"
P R I N T  " P r e s s  R E T U R N  w h e n  y ou  h a v e  f i n i s h e d "
W H I L E  -1
e$ = I N K E Y $  'reads input
S E L E C T  C ASE  e$
CASE "5" 
g r a p h 2  = 1 
legp = 0 
L O C A T E  10,32  
P R I N T  
C AS E "3" 
g r a p h 3  = 1 
l e g f a t  = 0 
L O C A T E  8,32 
P R I N T  "*"
CAS E "4" 
g r a p h 4  = 1 
l e g l e a n  = 0 
L O C A T E  9,32 
P R I N T  "*"
C AS E  "2" 
g r a p h s  = 1 
l eg cv  = 0 
L O C A T E  7,32 
P R I N T  "*"
C ASE  "6" 
g r a p h 6  = 1 
l e g b r a i n  = 0 
L O C A T E  1 1, 32 
P R I N T  "*"
C AS E "9"
gra ph l  = 0 're set s g r a p h  i n d i c a t o r s
g r a p h 2  = 0
g r a p h 3  = 0
g r a p h 4  = 0
g r a p h 5  = 0
g r a p h 6  = 0
L O C A T E  11,32
P R I N T  " "
L O C A T E  1 0, 32 ' r e mo v es  * f r o m  s c r e e n  d i s p l a y
P R I N T  " "
L O C A T E  9,32 
P R I N T  " ”
L O C A T E  8,32
C AS E "1"
g r a ph l  = 1 
l e g a r t  = 0 
L O C A T E  6,32 
P R I N T  "*"
'sets i n d i c a t o r  for a p p r o p r i a t e  g r a p h  
' i n i t i a l i s e s  i n d i c a t o r  for  g r a p h  l e g e n d
' in d i c a t e s  s e l e c t i o n  on s c r e e n
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P R I N T  " "
L O C A T E  7,32 
P R I N T  " "
L O C A T E  6,32 
P R I N T  " " .
CAS E C H R $ (13)
IF g r a p h l  = 0 AND g r a p h 2  = 0 AND g r a ph 3  = 0 AND g r a p h 4  = 0 AND g r a p h 5  = 0 
AND  g r a p h 6  = 0 T HE N 
n u 1 $ = IN K EY $ 
e $ = ""
DO U N T I L  U C A S E $ (e $) = "Y" OR U C A S E $ ( e $ )  = "N"
L O C A T E  20,1
P R I N T  "No g r a p h s  h ave  been cho sen"
P R I N T  "Do y o u  w a n t  g r a p h s  Y or N?" 
e$ = I NKE YS  
L OO P
IF U C A S E $ ( e $ )  = "N" T HE N 
CLS
L O C A T E  1 2, 30
P R I N T  " S i m u l a t i o n  u n d e r w a y "
E X I T  LOOP 
E LS E
L O C A T E  20,1 
P R I N T  "
P R I N T  " 
e $ = ""
END IF 
E LS E
E X I T  LOOP 
E ND IF 
END S E L E C T  
W END
IF g r a p h l  = 1 OR g r a p h 2  = 1 OR g r a ph 3  = 1 OR g r a p h 4  = 1 OR g r a p h 5  = 1_
OR g r a p h 6  = 1 THE N 
CLS
g$ = ""
n u 1 $ = I N K E Y S
DO U N T I L  g$ = "1" OR gS = "2"
L O C A T E  1,1
P R I N T  " D r u g  c o n c e n t r a t i o n  is p lo t t e d  on a l o g a r i t h m i c  sca le"
P R I N T  ""
P R I N T  " T i m e  m a y  be l o g a r i t h m i c  or lin ear "
P R I N T  ""
P R I N T  " P r e s s  FI f or  l o g a r i t h m i c  time sc a le "
P R I N T  "OR F2 fo r  l i n e a r  time scale"
gS = INK EY S  
LOOP 
CLS
eS = ""
nu 1 $ = I N K E Y S
DO U N T I L  eS = "1" OR eS = "2" OR e$ = "3" OR e$ = "4" OR eS = "5"
L O C A T E  1,1 
P R I N T  ""
P R I N T  " M o n i t o r  t ype :"
P R I N T  ""
P R I N T  "FI M o n o c h r o m e  or C o l o u r
P R I N T  "F2 C o l o u r  EGA  hig h r e s o l u t i o n
P R I N T  "F3 M o n o c h r o m e  hig h r e s o l u t i o n
P R I N T  "F4 C o l o u r  EGA e n h a n c e d  high r e s o l u t i o n  640 * 35 0  p i x e l s "
P R I N T  ""
P R I N T  " P r e s s  the f u n c t i o n  b u t t o n  c o r r e s p o n d i n g  to y o u r  m o n i t o r "
640 * 200 p i x e l s "  
640  * 200 p i x e l s "  
720 * 34 8  p i x e l s "
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d i s a b l e s  the s c r e e n  d i s p l a y  and  e n a b l e s  the progr am'  
to p r o c e e d  w i t h o u t  s c r e e n  o u t p u t "
S i m u l a t i o n  u n d e r w a y "
' d e f i n e  a r e a  of s c r e e n  to be use d for 
'gr aph: a s s u m e s  640 * 200 p i x e l s  
' s c a l i n g  f a c t o r s  to c o n v e r t  pixel to
P R I N T  "If y o u  i n a d v e r t a n t l y  m a k e  an i n c o m p a t i b l e  c h o i c e  the p r o g r a m "  
P R I N T  " ma y  c r a s h  and yo u  will h ave  to s t a r t  a g a in "
P R I N T  ""
P R I N T  " F5 
P R I N T  " 
e$ = INK EYS  
LOOP
S E L E C T  C AS E e$
C AS E  "5" 
g r a p h l  
g r a p  h2 
g r a p h 3  
g r a p h 4  
g r a p h 5  
g r a p h 6  
CLS
L O C A T E  1 2,3 0 
P R I N T  
E X I T  IF 
C AS E  "1"
S C R E E N  2 
KEY  OFF
V I E W  (48 ,12) - ( 6 3 9 , 1 7 9 )  
y s i z e  = 8 
x s i z e  = 8 
C AS E  "2"
S C R E E N  8 
KEY  OFF
V I E W  (48 ,12) - ( 63 9, 1 7 9 )  
y s i z e  = 8 
x s i z e  = 8 
C AS E  "3"
S C R E E N  2 
KE Y  OFF
V I E W  (54 ,21 ) - ( 7 1 9 , 3 1 4 )  
y s i z e  = 14 
x s i z e  = 9 
C AS E  "4"
S C R E E N  9 
KE Y  OFF
V I E W  (48 .21 ) - ( 6 3 9 , 3 1 4 )  
y s i z e  = 14 
x s i z e  = 8 
END S E L E C T  
yl = L 0 G 1 0(0.1)
y2 = L 0 G 1 0 (1 0 0 0 )  'for axe s
S E L E C T  C ASE  g$
C A S E  "1"
xl = L O G 10(1) 
x2 = L 0 G 1 0 ( 3 6 0 0  * 24.0)
C AS E  "2"
' a s s u m e s 640 * 200 p i x el s
' a s s u m e s 720  * 34 8 p i x e l s
'a s s u m e s 640 * 350 pi xels
' de f i n e c o o r d  i n at e s y s t e m
x1 = 0 
tti 
tti 
tti 
tti 
tti
me <= 120 T H E N  x2 = 120
me > 120 AND t t i m e  <= 30 0  T H E N  x2 = 3 0 0  
m e  > 300 AND t t i m e  <= 3 60 0  T HE N  x2 = 3 6 0 0  
m e  > 3 60 0  AND t t i m e  <= 2 1 6 0 0  T H E N  x2 = 2 1 6 0 0  
m e  > 2 1 6 0 0  AND  t t i m e  <= 8 6 4 0 0  T H E N  x2 = 8 6 4 0 0  
> 8 6 4 0 0  T H E N  x2 = t ti met t i m e  
E ND  S E L E C T
W I N D O W  (x1 ,y1 ) - (x 2 , y 2)
'draw d o t t e d  h o r i z o n t a l  lines
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FOR y = -1 TO 3
FOR x = P M A P ( x 1 , 0) TO P M A P ( x 2 , 0 )  STEP 3 
P S E T (P M A P (x , 2 ) , y )
N E X T  x 
NE XT  y
'label axes and d r a w  v e r t i c a l  l in es
L O C A T E  1,7
IF g r a p h 6  = 0 AN D  g r a p h 3  = 0 AND  g r a p h 4  = 0 THEN 
P R I N T  " P l a s m a  c o n c e n t r a t i o n  ( n a n o g r a m  / ml)";
ELSE IF ( g r a p h 6  = 1 OR g r a p h 3  = 1 OR g r a p h 4  = 1) AND g r a p h 5  = 0 A N D _  
g rap hl  = 0 AND g r a p h 2  = 0 T H E N
P R I N T  " T i s s u e  c o n c e n t r a t i o n  ( n a n o g r a m  / g)";
ELSE
P R I N T  " P l a s m a  c on e  ( n a n o g r a m  / ml) T i s s u e  con e ( n a n o g r a m  / g ) M ; 
END IF 
L O C A T E  2 3,4  
P R I N T  "0.1";
L O C AT E  18,4 
P R I N T  "1 .0";
LO C A T E  12,3 
P R I N T  " 10 .0" ;
LO C A T E  7,2 
P R I N T  " 10 0. 0 ";
L O C AT E  2,1 
P R I N T  " 1 0 0 0 . 0 " ;
L O C AT E  2 5 , 7 6  
P R I N T  "Ti me" ;
S E L E C T  CAS E g$
CAS E "1"
LINE 
LINE 
LINE 
LINE 
LINE 
LINE 
LINE
LOG 10(1), -4) - (LOG  1 0 ( 1 ) , 3 )
1,-4) - (1,3)
L 0 G 1 0 ( 6 0 . 0 ) ,-4) - (LOG 1 0 ( 6 0 . 0 ) , 3 )
LOG 1 0 ( 6 0 0 . 0 ) , - 4 )  - (LOG 1 0 ( 6 0 0 . 0 ) , 3 )
L 0 G 1 0 ( 3 6 0 0 . 0 ) , -4 )  - (LOG 1 0(3 600 . 0),3 )
L O G 1 0 ( 3 6 0 0 . 0  * 6 . 0 ) , - 4 )  - (LOG 1 0 ( 3 6 0 0 . 0  * 6 . 0 ), 3 )  
LOG 1 0 ( 3 6 0 0 . 0  * 2 4 . 0 ) , - 4 )  - (LOG 1 0 ( 3 6 0 0 . 0  * 24.0), 3) 
L O C A T E  24,7 
P R I N T  "1 s";
L O C A T E  2 4 , 2 0  
P R I N T  "10 s";
L O C A T E  24,31 
P R I N T  "1 min";
L O C A T E  2 4, 45  
P R I N T  "10 m i n " ;
L O C A T E  2 4 , 5 9  
P R I N T  "1 h";
LO C A T E  2 4 , 7 0  
P R I N T  "6 h";
L O C A T E  2 4, 77  
P R I N T  "24 h";
CASE "2"
LINE (0,-4) - (0,3)
L O C A T E  24,7 
P R I N T  "0";
S E L E C T  CAS E x2 
CAS E 120
LINE (20,- 4)  - (20,3)
LINE (40 ,-4 ) - (40,3)
LINE (60,- 4)  - (60,3)
LINE (80 ,-4 ) - (80,3)
LINE (1 0 0, - 4)  - (10 0, 3 )
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LINE ( 12 0, - 4)  - 
LO C A T E  2 4, 17  
P R I N T  "20 s"; 
L O C A T E  2 4 , 2 9  
P R I N T  "40 s"; 
L O C A T E  24,41 
P R I N T  "60 s"; 
L O C A T E  2 4 , 5 4  
P R I N T  "80 s"; 
L O C A T E  2 4, 6 6  
P R I N T  "100 s"; 
L O C A T E  2 4, 7 6  
P R I N T  "120 s";
C ASE  300
LINE (60,-4) - 
LINE (12 0,- 4) - 
LINE (18 0,- 4) - 
LINE ( 24 0, -4 ) - 
LINE ( 30 0, -4 ) - 
L O C A T E  2 4 , 2 0  
P R I N T  "1 D IS ­
LO C A T E  2 4, 35  
P R I N T  "2 m"; 
L O C A T E  2 4 , 4 9  
P R I N T  "3 m"; 
L O C A T E  2 4 , 6 4  
P R I N T  "4 m"; 
L O C A T E  2 4 , 7 8  
P R I N T  "5 m";
C ASE 3 60 0
LINE (60 0,- 4) - 
LINE ( 1 2 00 , -4 )  
LINE ( 18 00 , - 4 )  
LINE ( 24 00 , - 4 )  
LINE ( 30 00 , - 4 )  
LINE ( 36 00 , - 4 )  
L O C A T E  2 4, 17  
P R I N T  "10 m" 
L O C A T E  2 4 , 2 9  
P R I N T  "20 m" 
L O C A T E  24,41 
P R I N T  "30 m" 
L O C A T E  2 4 , 5 4  
P R I N T  "40 m" 
L O C A T E  2 4 , 6 6  
P R I N T  "50 m" 
L O C A T E  2 4, 77  
P R I N T  "60 m"
CAS E 2 1 6 0 0
LINE ( 36 00 , -4 ) 
LINE ( 72 00 , -4 ) 
LINE ( 1 0 8 0 0 , - 4 )  
LINE ( 14 4 0 0 , - 4 )  
LINE ( 1 8 0 0 0 , - 4 )  
LINE ( 2 1 6 0 0 , - 4 )  
L O C A T E  2 4, 17  
P R I N T  "1 h"; 
L O C A T E  2 4, 29  
P R I N T  "2 h"; 
L O C A T E  24,41 
P R I N T  "3 h";
( 120 , 3 )
(60,3)
(12 0.3 )
(18 0.3 )
(24 0. 3 )
(30 0.3 )
(600, 3)
- (1 2 00 , 3)
- (1 8 00 , 3)
- ( 2 4 00 , 3)
- (3 0 00 , 3)
- (3 6 00 , 3)
( 36 00. 3)
( 72 00. 3)
- ( 1 0 8 0 0 ,3 )
- ( 1 4 4 0 0 ,3 )
- ( 18 00 0 , 3 )
- ( 21 60 0 , 3 )
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L O C A T E  2 4, 54  
P R I N T  "4 h" 
L O C A T E  2 4, 66  
P R I N T  "5 h" 
L O C A T E  2 4, 78  
P R I N T  "6 h" 
CAS E 8 64 00  
LIN E (14400 -4)
-4)
-4)
-4)
-4)
-4)
LIN E (28800 
LIN E (43 200  
L IN E (57600 
L IN E (72000 
L IN E (86400 
L O C A T E  24,17  
P R I N T  "4 h"
L O C A T E  2 4, 29  
P R I N T  "8 h"
L O C A T E  24,41 
P R I N T  "12 h 
L O C A T E  2 4,5 4 
P R I N T  "16 h" 
L O C A T E  2 4, 66  
P R I N T  "20 h" 
L O C A T E  24,77  
P R I N T  "24 h"
C ASE  > 8 6 4 0 0
L INE  ( t t i m e , -4) 
L O C A T E  2 4, 73  
P R I N T  U SI NG  
END S E L E C T
END S E L E C T
p = 0
IF g r a p h 2  = 1 T HEN  
L O C A T E  2,66 
P R I N T  "p p u l m o n a r y "  
P = 1
END IF
IF g r a p h 5  = 1 THE N 
L O C A T E  (2 + p ),66 
P R I N T  "c cen v e n o u s
p = p +  1
END IF
IF g r a p h l  = 1 T HEN  
L O C A T E  (2 + p ),70 
P R I N T  "a a r t e r i a l " ;
p = p + 1
END  IF
IF g r a p h 3  = 1 T HE N  
L O C A T E  (2 + p ),73 
P R I N T  "f fat";
p = p + 1
END IF
IF g r a p h 4  = 1 T HEN  
L O C A T E  (2 + p },73 
P R I N T  "1 lean";
p = p + 1
END IF
IF g r a p h 6  = 1 THE N 
L O C A T E  (p + 2),73  
P R I N T  "b brain";
END  IF
( 14 40 0 .3 )
( 28 80 0 .3 )
(43 20 0 .3 )
(57 60 0 .3 )
( 72 00 0 .3 )
( 86 40 0 .3 )
(tti m e ,3)
I h " ;tti m e / 3 6 0 0 ;
'pr int  l e g e n d  fo r  i n d i v i d u a l  
'grap h l a b e l s
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END  IF 
END SUB
SUB  1e g e n d (x X , y X , 1 e g , 1 e g $ )
' l a b e l s  i n d i v i d u a l  g r a p h s
' p l a c e s  label n e a r  the s t a r t  of e ach  g r a p h  w h e r e v e r  it o c c u r s  on s c r e e n  
' e n s u r e s  l abe ls  do not o v e r p r i n t  eac h o t h e r
S H A R E D  l e g a r t , l e g p , l e g f a t , l e g 1 e a n , l e g b r a i n , l e g c v  
S H A R E D  x 1 X , x 2 X , x 3 % , x 4 X , x 5 X , x 6 % , y ! X , y 2 X , y 3 % , y 4 X , y 5 % , y 6 X
IF yX; > 0 AND  y% < 23I T HE N
IF y% <= y 1%+1 AND y% >= y 1 % -1 AND l e g a r t  = 1 AND xX < xlX  + 4 T HE N  E X I T  SUB
IF y% <= y2%+1 AND y% >= y 2% -1 AND legp = 1 AND xX < x2X  + 4 T H E N  E X I T  SUB
IF y% <= y3%+1 AND y% >= y 3 % - 1 AND l e g fa t  = 1 AND xX < x3X  + 4 T HE N  E X I T  SUB
IF y% <= y4%+1 AND y% >= y 4 % - 1 AND l e g l e a n  = 1 AND xX < x4X + 4 T HE N  E X I T  SUB
IF y% <= y5X+1 AND y% >= y 5 % - 1 AND l eg cv = 1 AND xX < x 5X  + 4 T HE N  E X I T  SUB
IF y% <= y6%+1 AND y% >= y 6 % - 1 AND 1e g b r a  i n = 1 AND xX < x6X + 4 T H E N  E X I T  SUB
L O C A T E  y % , x %
P R I N T  1e g $;
1 eg = 1 
END IF 
END SUB
$ S E G M E N T  ' c o m p i l i n g  i n s t r u c t i o n
SUB s c r ( r o u t e $ )
'sub  s e t s  d o s e  e n t r y  d i s p l a y  up on s c r e e n  
' i n i t i a l i s e s  v a r i a b l e s  f o r  t i m e  an d  d u r a t i o n  
'of d o s e  a d m i n i s t r a t i o n  
S H A R E D  t i m e , l a s t t i m e , v d u r n , l d u r n , n d u r n , m d u r n  
L O C A L  n u 1 $
L O C A T E  1 5 , 4 0
P R I N T  " P r e s s  any key  to c o n t i n u e . . . "
W H I L E  N OT  I N S T A T : W E N D
n u 1 $ = I N K E Y S
CLS
L O C A T E  1 ,58  
P R I N T  "time";
L O C A T E  1,65 
P R I N T  " do s e " ;
IF routeS = "iv" OR routeS = "ip" OR routeS = "in" T HE N  
L O C A T E  1,72 
P R I N T  "duration";
END IF
time = 0 'time of start of dose administration
last time = -1 'sets time of previous dose < time
IF routeS = "iv" T H E N  vdurn = 0
IF routeS = "ip" T H E N  ldurn = 0
IF routeS = "in" T H E N  ndurn = 0
IF routeS = "im" T H E N  mdurn = 0
END SUB
S UB  d s e n t r y ( n % , d u r n , c o u n t , r o u t e S , t e m p i # ( 2 ) , t e m p 2 # ( 2)) 
'sub is e n t r y  r o u t i n e  for  dos e d e t a i l s  
' f o r c e s  d os e e n t r y  in t em po r al  o r d e r  
' p r e v e n t s  o v e r l a p p i n g  doses  
S H A R E D  p % , 1 a s t t i m e , t t i m e , t i m e , d f a c  
L O C A L  d e n t r y S , n u l $ , x %
S T A T I C  vX
p% = 0 ' i n i t i a l i s e  i n d i c a t o r
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L O C A T E  12,1
P R I N T  " E n t e r  d ose  in M I C R O G R A M  f en tan yl base";
L O C A T E  13,1
INPUT; "Or  p re ss  p l a i n  R E T U R N  to fin ish  " . d e n t r y S  
IF d e n t r y $  = "" T HE N
p% = n% ' in di c a t e s  no dose e n t e r e d  and
'l o c a t i o n  of l e a v i n g  i n p u t  r o u t i n e
E X I T  SUB 
END IF 
DO
L O C A T E  15,1
INPUT; " E n t e r  t im e d ose  c o m m e n c e s ;  M IN U T E S  f ro m s t a r t  " , t i m e  
IF NO T  r o u t e $  = "im" T HEN  
DO
L O C A T E  17,1
INPUT ; " E n t e r  tim e o v e r  w h i c h  dose given; S E C O N D S  " , d ur n  
IF N O T  durn > 0 T HEN  
L O C A T E  17,1 
P R I N T  "
L O C A T E  23,1
P R I N T  " D u r a t i o n  m u s t  be g r e a t e r  than 0. P l e a s e  r e - e n t e r " ;  
END IF 
LOOP U N T I L  d urn  > 0 
END IF
IF ( t i m e * 6 0  + durn) > (tt im e  + 0.1) OR ( ti me* 60)  <= l a s t t i m e  T HE N  
L O C A T E  23,1
P R I N T  " t i m e ( s )  i n c o r r e c t  p l e a s e  r e - e n t e r  ";
L O C A T E  15,1 
P R I N T  "
L O C A T E  17,1 
P R I N T  "
END IF
LOOP U N T I L  ( t i m e * 6 0  + durn) < (t t im e  + 0.1) AND t i m e * 6 0  > l a s t t i m e  
l a s t t i m e  = t i m e * 6 0  + durn 'set time of dose e n d i n g  
LO C A T E  12,1 
P R I N T  "
L O C A T E  13,1 
P R I N T  "
L O C A T E  15,1 
P R I N T  "
L O C A T E  17,1 
P R I N T  "
L O C A T E  23,1 
P R I N T  "
IF c o u n t  > 1 T HE N
FOR x% = 1 TO ( cou nt  - 1)
t e m p 1 # ( x % , 1 )  = t e m p 2 # ( x % , 1 )  ' t r an s fe r s  d e t a i l s  b e t w e e n
t e m p i # ( x % , 2) = t e m p 2 # ( x % , 2 )  ' t e m p o r a r y  a r r a y s
t e m p 1 # ( x % , 3 )  = t e m p 2 # ( x % , 3 )
N E X T  xX 
END IF
t e m p i # ( c o u n t , 1) = V A L { d e n t r y $ )* d f a c
tem p 1 # ( c o u n t , 2) = t i m e * 6 0  'adds new  d o s e  d e t a i l s
t e m p i § ( c o u n t , 3 ) = durn 
v% = 2
FOR x% = 1 TO c o u n t
L O C A T E  v % , 5 8  'prints d os e  d e t a i l s  on
P R I N T  t e m p 1 # ( x % , 2 ) / 6 0 ;  'screen d i s p l a y
L O C A T E  V % ,65
P R I N T  t e m p i # ( x % , 1 ) /dfac;
IF N O T  r o u t e S  = "im" THEN
'clear 
'screen
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L O C A T E  v X ,72 
P R I N T  t e m p i # ( x X , 3);
END IF 
vX = vX + 1
IF vX > 22 t he n vX = (vX MOD  22) + 1 
N EX T  xX
IF l a s t t i m e  > = t t i m e  T H E N  
L O C A T E  13,1
P R I N T  " D o s e  a c c e p t e d ;  but  no m ore  s i m u l a t i o n  t ime  left"
P R I N T  " f o r  f u r t h e r  d ru g a d m i n i s t r a t i o n  by this rou te "
P R I N T  " P r e s s  R E T U R N  to c o n t i n u e "  ' p r e v e n t s  p r o g r a m  s t i c k i n g  
IF nX = 1 T H E N  pX = 2 'when p r e v i o u s
IF nX = 2 T H E N  pX = 1 'dose doe s not f i n i s h  b e f o r e
c o u n t  = c o u n t  + 1 'ttime and u s e r  has a t t e m p t e d
W H I L E  NO T  I N S T A T : W E N D  'to e n t e r  a f u r t h e r  dos e
n u 1 $ = I N K EY $
END IF 
END SUB
SUB  p e n d ( h o l d # ( 2 ) , v a r , c o u n t , v a r $ , u n i t $ )
'sub c h a n g e s  c u r r e n t  v a r i a b l e  v al ue to t hat  s t o r e d  in a r r a y  w he n  run tim e 
' eq ua l s  a d m i n i s t r a t i o n  t i m e  or. if a d m i n i s t r a t i o n  t ime  not d i v i s i b l e  e x a c t l y  
'by c y c l e  time, at th e  f i r s t  run time w h i c h  e x c e e d s  a d m i n i s t r a t i o n  tim e 
'ca lls  s ub s to r e c a l c u l a t e  d e p e n d a n t  i n t e r m e d i a t e  v a r i a b l e s  
S H A R E D  r t i m e , d i s k 1 , f i l e 1 $ , d t , p a p e r , p t i m e
IF ( r t im e  + dt) > ho 1d # (c o u n t ,2) OR A B S ( r t i m e  - ho 1d # (c o u n t ,2)) < E X P 1 0 ( - 9 . 0 )  T H E N  
var  = h o l d # ( c o u n t , 1)
p t i m e  = 0 'reset c o u n t e r  for r e s u l t s  f r e q u e n c y
c o u n t  = c o u n t  + 1 'ad van ce p e n d i n g  a r r a y  p o s i t i o n  i n d i c a t o r
IF v ar$  = " p l a s m a  pH" T H E N  C ALL  p hca lc  
IF var $ = " u r i n e  pH" T H E N  C AL L ucalc
IF var $ = " c a r d i a c  o u t p u t "  OR var$ = " c y c l e  t im e"  0 R _  
var $ = " u r i n e  w a t e r  o u t p u t "  T H E N  CALL q d t c a l c  
IF r t i m e  > 0 T HE N
IF p a p e r  = 1 T H E N  'sends d e t a i l s  to p r i n e r
L P R I N T  ""
L P R I N T  U S I N G  "& c h a n g e d  to # # # # . # # # # #  & at # # # # # . #  min 
v a r $ ;v a r ;u n i t $ ;r t i m e / 6 0  
END IF
IF d i s k 1 > 0 T H E N  'sends d e t a i l s  to r e s u l t s  file
C AL L  d isk  'sends m ai n  r e s u l t s  so far  to r e s u l t s  f il e
O P E N  f i 1e 1 $ FOR  A P P E N D  AS #1 
P RIN  T #1, ""
P R I N T  #1, U S I N G  "& c h a n g e d  to # # # # . # # # # #  & at # # # # # . #  m i n " ; _  
v a r $ ;v a r ;uni t $ ;r t i m e / 6 0  
C L O S E  #1 
END IF 
END IF 
END IF 
END SUB
SUB  d o s p e n d { d u r n , d o s e , d o s e $ , d l e f t , c o u n t , d o s e h o l d # ( 2 ) )
'sub c h a n g e s  c u r r e n t  d o s e  to t ha t sto re d  in a r r a y  w h e n  run t im e e q u a l s
' a d m i n i s t r a t i o n t ime  or , if a d m i n i s t r a t i o n  t i m e  not d i v i s i b l e  e x a c t l y
'bv c y c l e  time, at the f i r s t  run time w h i c h  e x c e e d s a d m i n i s t r a t i o n  t ime
S H A R E D  r t i m e , p t i m e , d f a c , d i s k i , p a p e r , f i l e 1 $ , d t  
IF ( r t i m e  + dt) > d o s e h o l d # (c o u n t , 2) 0R_
A B S (rt ime - d o s e h o 1d # ( c o u n t ,2)) < E X P 1 0 ( - 9 . 0 )  T H E N  
d os e  = d o s e h o l d # (c o u n t , 1)
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d ur n  = d o s e h o 1d # (c o u n t ,3) 
d l e f t  = dose 
c o u n t  = c o u n t  + 1 
p t i m e  = 0
'set d os e r e m a i n d e r  = dose 
' a d va n ce  a r r a y  p o s i t i o n  i n d i c a t o r  
'reset r e s u l t s M  f r e q u e n c y  c o u n t e r
IF p a p e r  = 1 T H E N  
L P R I N T  ""
IF d o s e $  = " i n t r a m u s c u l a r l y "  T HE N
L P R I N T  U S I N G  " # # # # . #  ug g iv en  & at # # # # . #  m i n " ;d o s e / d f a c ;d o s e $ ;r t i m e / 60 
E LS E
L P R I N T  U S I N G  " # # # # . #  ug g i v e n  & o v e r  # # # # # #  s s t a r t i n g  # # # # # . #  m i n " ;d o s e / d f a c ;  
d o s e $ ; d u r n ; r t i m e / 6 0  
END IF
L P R I N T  "" ‘r e c o r d  d os e  d e t a i l s  on p r i n t o u t
END IF
IF d is kl  > 0 T HEN
Call d is k  'sends m a i n  r e s u l t s  so far to r e s u l t s  fil e
O P E N  f i 1e 1 $ FOR A P P E N D  AS #1 
P R I N T  #1,""
IF d o s e $  = " i n t r a m u s c u l a r l y "  THE N
P R I N T  #1, U S I N G  " # # # # . #  ug g i v e n  & at # # # # # # . #  m i n " ;d o s e / d f a c ; d o s e $ ;r t i m e / 60 
ELS E
P R I N T  #1, U S I N G  " # # # # . #  ug g i v e n  & o v e r  # # # # # # . #  s s t a r t i n g  # # # # # . #  m 1 n " ; _  
d o s e / d f a c ; d o s e $ ; d u r n ; r t i m e / 6 0  
END IF 
C L O S E  #1
END IF 
E ND IF 
END SUB
S UB  d o s e ( d l e f t , d o s e , d u r n , d i n c )
'sub c a l c u l a t e s  dose i n c r e m e n t  to be a d m i n i s t e r e d  e ach  cycle  
S H A R E D  dt 
L O C A L  a liq
a l i q  = d os e  * (dt / durn)
IF a liq  > d os e T HE N  a li q = dose 
IF a li q  > d l e f t  T H E N  a liq  = d lef t
d l e f t  = d l e f t  - aliq ' d e c r e m e n t  r e m a i n i n g  p o r t i o n  of dos e
d i n c = a 1 i q 
END SUB
S U B  v s c r ( v a r $ , v a r )
'sub s et s v a r i a b l e - c h a n q e  e n t r y  d i s p l a y  up on s c r ee n 
' i n i t i a l i s e s  v a r i a b l e s  for  times  of c h a n g e s  
S H A R E D  t i m e , 1 a s t t i m e  
L O C A L  n u 1 $
KE Y  OFF 
CLS
P R I N T  "Yo u m a y  e n t e r  as m a n y  d i f f e r e n t  " ; v a r $ ; " s  as y o u  like" 
P R I N T  "Th e n e w  v a l u e s  m u s t  be e n t e r e d  in th e  o r d e r  t he y  o ccu r"  
P R I N T  " f r o m  the  s t a r t  of the s i m u l a t i o n "
P R I N T  "If y o u  d o n ' t  g i v e  a new  v al ue  f or  t i m e  0 the d e f au l t"  
P R I N T  "will be used up to the time of the f i r s t  c h a ng e "
L O C A T E  1 5 , 4 0
P R I N T  " P r e s s  any  key to c o n t i n u e . . . "
W H I L E  N O T  I N S T A T :W EN D  
nu 1 $ = IN K E Y $
CLS
L O C A T E  1,65
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P R I N T  "ti me" ; 
L O C A T E  1,72 
P R I N T  " v a r i a b l e "  
L O C A T E  2,6 5 
P R I N T  "0";
L O C A T E  2,72 
P R I N T  var; 
t im e  = 0 
l a s t t i m e  = -1 
END SUB
S U B  v a r e n t r y ( n % , c o u n t , v a r $ , u n i t $ , v a r , h o l d 1 # ( 2 ) , h o 1 d 2 # ( 2 ) )
'sub Is e n t r y  r o u t i n e  for c h a n g e s  of v a r i a b l e  v a l ue s  
' fo r c e s  e nt r y  of c h a n g e s  in t e m p o r a l  o r d e r  
S H A R E D  t t i m e , t i m e , 1 a s t t i m e , p %
L O C A L  e n t r y $ , x %
S T A T I C  v%
IF n% = 1 and c o u n t  = 2 T HE N  'if f i r s t  pas s t h r o u g h  loop
h o 1d 1 #( 1, 1 )  = var  ' e n t e r s  d e f a u l t  v a l u e s  into
ho 1d 1 #( 1 , 2 )  = 0 ' t e m p o r a r y  a r r a y
END IF
p% = 0 ' i n i t i a l i s e s  i n d i c a t o r
00
L O C A T E  11,1
P R I N T  " E n t e r  new  " ; v a r $ ;u n i t $ ;
L O C A T E  12,1
INPUT; "Or p re ss p l a i n  R E T U R N  to f i n i s h  c h a n g e s  " , e n t r y $
IF e n t r y S  = "" T HE N
IF n% = 1 AND c o u n t  = 2 T H E N  c o u n t  = 1 ' ad j u s t  c o u n t e r  to p r e v e n t
' c o u n t i n g  d e f a u l t  as c h a n g e  
p% = n% ' i n d i c a t e s  e n t r y  c o m p l e t e  and p o s i t i o n  of l e a v i n g  r o u t i n e
E X I T  SUB
ELS E IF (NOT V A L ( e n t r y $ )  > 0 ) AND (NO T var$ = " u r i n e  w a t e r  o u t p u t " )  T H E N  
L O C A T E  12,1 
P R I N T  "
L O C A T E  22,1
P R I N T  var$; " m u s t  be g r e a t e r  t han  0 P l e a s e  r e - e n t e r " ;
END IF
LOOP U N T I L  e n t ry $  = "" OR V A L ( e n t r y S )  > 0 OR var$ = " u r i n e  w a t e r  o u t p u t "
L O C A T E  22,1 
P R I N T  "
DO
L O C A T E  14,1
P R I N T  " E n t e r  tim e of new  v a l u e  t a k i n g  e f f e c t : " ;
L O C A T E  15,1
INPUT; " M I N U T E S  f ro m  s ta rt  " . t i m e  
IF t i m e * 6 0  >= t ti m e  OR t i m e * 6 0  <= l a s t t i m e  T HE N  
L O C A T E  15,1 
P R I N T  "
L O C A T E  22,1
P R I N T  " tim e i n c o r r e c t  p l e a s e  r e - e n t e r " ;
ELSE
L O C A T E  11,1 
P R I N T  "
L O C A T E  12,1
P R I N T  " ' c l e a r
L O C A T E  14,1 ' t e x t
P R I N T  "
L O C A T E  15,1 
P R I N T  "
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L O C A T E  22,1 
P R I N T  "
END IF
LOOP U N T I L  t i m e * 6  0 < t t i m e  AND t i m e * 6 0  > l a s t t i m e
l a s t t i m e  = t i m e * 6 0  'sets l a s t t i m e  fo r  n e x t  e n t r y
IF t im e  = 0 T H E N  c o u n t  = 1
IF c o u n t  > 2 OR ( c o u n t  = 2 AND n% = 2) T HEN
FOR xX = 1 TO ( c o u n t  - 1) 
ho 1d 1 # ( x % , 1) = ho 1d 2 # (x % , 1) 
h o i d 1 # ( x % , 2) = ho 1d 2 # (x X , 2)
N E X T  x%
END IF
h o i d 1 # ( c o u n t , 1) = V A L ( e n t r y $ )  
h o i d 1 # ( c o u n t ,2) = t i m e * 6 0  
vX = 2 
L O C A T E  2 ,6 4  
P R I N T  "
FOR x% = 1 TO c o u n t  
L O C A T E  v X ,65 
P R I N T  h o l d 1 # ( x X , 2 ) / 6 0 ;
L O C A T E  v % , 72 
P R I N T  h o i d l # ( x % , 1); 
v% = vX + 1
IF vX > 23 t hen  vX = (vX MOD  23) + 
N E X T  xX 
END SUB
' u n l e s s  f i r s t  t im e  t h r o u g h  sub 
' t r a n s f e r s  d e t a i l s  b e t w e e n  
' t e m p o r a r y  a r r a y s
'adds n e w  d e t a i l s
' c l e a r s  d e f a u l t  v a l u e s  
' f r o m  d i s p l a y
' d i s p l a y s  d e t a i l s  on s c r e e n
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APPENDIX 2 
Running the Program
Instructions For Using The Programs
The programs should run on any IBM compatible micro-computer 
under MS-DOS or PC-DOS 2.0 or above. A Printer is optional.
1. To run the fentanyl simulation insert the program disk into 
the computer and type FENTSIM followed by the RETURN key.
2. To run the pethidine simulation insert the program disk 
into the computer and type PETHSIM followed by the RETURN 
key.
A star * in the bottom left hand corner of the display screen 
indicates the simulation has finished. The display will remain 
in the screen until pressing any key restarts the program for a 
new simulation. Pressing SHIFT-PrtScr at this stage will not 
remove the display, thereby allowing a "Screen Dump" to a 
suitable printer.
There is no provision for interrupting the program once a 
simulation is underway.
E r r o r s : The following errors may crash the program without 
warning:
- printer not turned on after "printer available" option chosen.
- inaccessible results file e.g. filename of wrong form,
non-existent diskdrive specified, "write protect" on floppy 
disk, disk full (beware when using frequent results scheme) 
etc.
- wrong screen specification selected for graphical display, 
(may also cause a distorted display)
284
Summary
This thesis concerns two investigations into the opioid 
analgesic fentanyl. The first is a clinical investigation into 
the safety and efficacy of fentanyl administered by 
inhalation. The second is a theoretical assessment of the 
feasibility and merits of applying an alternative form of 
pharmacokinetic model to the drug. The thesis is in two 
related but essentially self-contained parts preceded by a 
review of fentanyl pharmacology.
The first part describes a study oj- nebulised inhaled 
fentanyl for post-operative pain relief. One of three 
concentrations of fentanyl citrate solution (318 pg ml-1, 159
pg ml-1, or 64 pg ml-1) was administered to each of 30 
patients from Lifecare Micro-Neb disposable jet nebulisers. 
There were no major side effects. Within the limits of the 
trial design the study suggests possible efficacy of nebulised 
inhaled fentanyl for postoperative pain relief. The 
disadvantages and limitations of the drug delivery regimen 
employed in the trial are described and improvements in trial 
design discussed. Aspects of nebulisation and aerosol delivery 
and the measurement of pain by linear visual analogue are 
reviewed.
The second part describes the extension of an existing 
physiological model of intravenously and intramuscularly 
administered pethidine to allow intranasal and intrapulmonary 
administration and adaptation of the model to describe 
fentanyl.
The original pethidine model exists as a computer program in 
several different versions. During the present modifications,
with help from the original author, several errors were 
identified in these programs. Some of these are present in 
published versions.
A preliminary evaluation of the fentanyl model against 
published data suggests that simulated arterial and venous 
plasma concentrations are similar to those obtained 
experimentally.
Elements of the model are examined individually and its future 
development discussed.
The model proved only of limited use for simulating the 
transient concentration changes which occur in the few seconds 
following drug administration, the examination of which was 
suggested by work reported the first part of this thesis, 
nevertheless, the model is a useful conceptual tool in the 
examination of questions arising from the development of new 
routes of drug delivery.
A lack of agreement between published studies of aspects of 
fentanyl pharmacology is noted.
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